FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Jos Beijnen

Research Profile

Chemicals & Drugs

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Nalini N E Radhakishun; Mariska van Vliet; Ines A Von Rosenstiel; Jos H Beijnen; Michaela Diamant
Limited value of routine microalbuminuria assessment in multi-ethnic obese children.
Serena Marchetti; Roberto Mazzanti; Dick Pluim; Monique van Eijndhoven; Olaf van Tellingen; Jos H Beijnen; Jan H M Schellens
Erratum to: Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.
Suman Rijal; Rupa Singh; Surendra Uranw; Manu Vanaerschot; Prahlad Karki; Bart Ostyn; Keshav Rai; Jos H Beijnen; Narayan Raj Bhattarai; Marleen Boelaert; Murari L Das; Saskia Decuypere; Subodh S Dhakal; Thomas P C Dorlo; Jean-Claude Dujardin
Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Jos Beijnen (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Nalini N E Radhakishun; Mariska van Vliet; Ines A Von Rosenstiel; Jos H Beijnen; Michaela Diamant
Limited value of routine microalbuminuria assessment in multi-ethnic obese children.
Pediatric nephrology (Berlin, Germany) 2013;28(7):1145-9.
2013: Serena Marchetti; Roberto Mazzanti; Dick Pluim; Monique van Eijndhoven; Olaf van Tellingen; Jos H Beijnen; Jan H M Schellens
Erratum to: Effect of the drug transporters ABCG2, Abcg2, ABCB1 and ABCC2 on the disposition, brain accumulation and myelotoxicity of the aurora kinase B inhibitor barasertib and its more active form barasertib-hydroxy-QPA.
Investigational new drugs 2013;31(3):800.
2013: Suman Rijal; Rupa Singh; Surendra Uranw; Manu Vanaerschot; Prahlad Karki; Bart Ostyn; Keshav Rai; Jos H Beijnen; Narayan Raj Bhattarai; Marleen Boelaert; Murari L Das; Saskia Decuypere; Subodh S Dhakal; Thomas P C Dorlo; Jean-Claude Dujardin
Increasing failure of miltefosine in the treatment of kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2013;56(11):1530-8.
2013: C M Nijenhuis; J H M Schellens; J B A G Haanen; Jos H Beijnen
Is combination therapy the next step to overcome resistance and reduce toxicities in melanoma?
Cancer treatment reviews 2013;39(4):305-12.
2013: Jeroen J M A Hendrikx; Jurjen S Lagas; Hilde Rosing; Jan H M Schellens; Jos H Beijnen; Alfred H Schinkel
P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
International journal of cancer. Journal international du cancer 2013;132(10):2439-47.
2013: Jolanda M van den Hoven; Jos H Beijnen; Josbert M Metselaar; Reka Nemes; Bastiaan Nuijen; Gert Storm; Janos Szebeni
Complement activation by PEGylated liposomes containing prednisolone.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2013;49(2):265-71.
2013: W Kromdijk; M A Sikma; M P H van den Broek; Jos H Beijnen; A D R Huitema; Dylan W de Lange
Pharmacokinetics of oseltamivir carboxylate in critically ill patients: each patient is unique.
Intensive care medicine 2013;39(5):977-8.
2013: Fan Lin; Jos H Beijnen; Levi Buil; Lisette Hoogendijk; Olaf van Tellingen
Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
European journal of cancer (Oxford, England : 1990) 2013;49(8):2059-64.
2013: A Kort; Hilde Rosing; J H M Schellens; Alfred H Schinkel; E E Voest; G A Cirkel; M J X Hillebrand; Jos H Beijnen
Quantification of cabazitaxel, its metabolite docetaxel and the determination of the demethylated metabolites RPR112698 and RPR123142 as docetaxel equivalents in human plasma by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2013;925():117-23.
2013: Rolf W Sparidans; Selvi Durmus; Jan H M Schellens; Alfred H Schinkel; Jos H Beijnen
Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor dabrafenib in mouse plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2013;925():124-8.
2013: Maarten J Deenen; Luc Dewit; Jan H M Schellens; Jos H Beijnen; Henk Boot; Annemieke Cats
Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study.
International journal of radiation oncology, biology, physics 2013;85(5):e201-7.
2013: Nienke A G Lankheet; H Rosing; J H M Schellens; N Steeghs; Jos H Beijnen; A D R Huitema
Quantification of sunitinib and N-desethyl sunitinib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry: validation and application in routine therapeutic drug monitoring.
Therapeutic drug monitoring 2013;35(2):168-76.
2013: N A G Lankheet; Hilde Rosing; J H M Schellens; Jos H Beijnen; M J X Hillebrand; A D R Huitema
Method development and validation for the quantification of dasatinib, erlotinib, gefitinib, imatinib, lapatinib, nilotinib, sorafenib and sunitinib in human plasma by liquid chromatography coupled with tandem mass spectrometry.
Biomedical chromatography : BMC 2013;27(4):466-76.
2013: L A Devriese; G Edwards; A Jenner; S Marchetti; M Mergui-Roelvink; F Peng; Larisa Reyderman; Jos H Beijnen; William Copalu; J Wanders; J H M Schellens
Eribulin mesylate pharmacokinetics in patients with solid tumors receiving repeated oral ketoconazole.
Investigational new drugs 2013;31(2):381-9.
2013: W Kromdijk; J W Mulder; S A Pereira; Hilde Rosing; Jos H Beijnen; A D R Huitema
Development and validation of an assay for the simultaneous determination of zidovudine, abacavir, emtricitabine, lamivudine, tenofovir and ribavirin in human plasma using liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2013;919-920():43-51.
2013: Anne-Charlotte Dubbelman; Edward Hellriegel; Philmore Robertson; Hilde Rosing; Jos H Beijnen; Mary Bond; Denise D'Andrea; Mona Darwish; Jan H M Schellens
Pharmacokinetics and excretion of (14)C-bendamustine in patients with relapsed or refractory malignancy.
Drugs in R&D 2013;13(1):17-28.
2013: Dick Pluim; Anna E M Ruijter; Jos H Beijnen; Bart A W Jacobs; Martin D Krähenbühl; Jan H M Schellens
Correction of peripheral blood mononuclear cell cytosolic protein for hemoglobin contamination.
Analytical and bioanalytical chemistry 2013;405(7):2391-5.
2013: Dick Pluim; Jos H Beijnen; Bart A W Jacobs; Kim A A Schilders; Daniëlle Vaartjes; Jan H M Schellens
Pharmacodynamic assay of thymidylate synthase activity in peripheral blood mononuclear cells.
Analytical and bioanalytical chemistry 2013;405(8):2495-503.
2013: Patrick M Smit; Paul H M Smits; Olivier Weijer; Jos H Beijnen; Eric C J Claas; Jos C Kaandorp; Fanny N Lauw; Jan W Mulder; Suzanne M Pronk; Dees P M Brandjes
RT-PCR detection of respiratory pathogens in newborn children admitted to a neonatal medium care unit.
Pediatric research 2013;73(3):355-61.
2013: Lot A Devriese; Geoff Edwards; Alwin D R Huitema; Kenneth Law; Serena Marchetti; Fuping Peng; Larisa Reyderman; Jos H Beijnen; William Copalu; Emile E Voest; Jantien Wanders; Petronella Els O Witteveen; Jan H M Schellens
Pharmacokinetics of eribulin mesylate in patients with solid tumours receiving repeated oral rifampicin.
British journal of clinical pharmacology 2013;75(2):507-15.
2013: Jelte Meulenaar; Jos H Beijnen; Jan H M Schellens; Bastiaan Nuijen
Slow dissolution behaviour of amorphous capecitabine.
International journal of pharmaceutics 2013;441(1-2):213-7.
2013: Serge A L Zander; Jos H Beijnen; Olaf van Tellingen
Sensitive method for plasma and tumor Ko143 quantification using reversed-phase high-performance liquid chromatography and fluorescence detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2013;913-914():129-36.
2013: Maarten J Deenen; Michel J Hillebrand; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Quantitative determination of capecitabine and its six metabolites in human plasma using liquid chromatography coupled to electrospray tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2013;913-914():30-40.
2013: Ellen J B Derissen; Jos H Beijnen; Jan H M Schellens
Concise drug review: azacitidine and decitabine.
The oncologist 2013;18(5):619-24.
2013: T P C Dorlo; N G L Jager; Jos H Beijnen; J H M Schellens
[Concomitant use of proton pump inhibitors and systemic corticosteroids].
Nederlands tijdschrift voor geneeskunde 2013;157(19):A5540.
2013: Nalini N E Radhakishun; Mariska van Vliet; Ines A Von Rosenstiel; Olivier Weijer; Jos H Beijnen; Dees P M Brandjes; Michaela Diamant
Increasing thyroid-stimulating hormone is associated with impaired glucose metabolism in euthyroid obese children and adolescents.
Journal of pediatric endocrinology & metabolism : JPEM 2013;26(5-6):531-7.
2013: Maarten J Deenen; Jos H Beijnen; Annemieke Cats; Jan H M Schellens
Standard-dose tegafur-uracil (UFT) is not a safe alternative in partial dihydropyrimidine dehydrogenase-deficient patients.
Therapeutic advances in medical oncology 2013;5(1):91-2.
2013: Bojana Milojkovic Kerklaan; Jos H Beijnen; Veronique Diéras; Anne-Sophie Govaerts; Alwin D R Huitema; Bojana Milojkovic Kerklaan; Christophe Le Tourneau; Sandrine Marreaud; Marja Mergui-Roelvink; Martine J Piccart-Gebhart; Hilde Rosing; Jan H M Schellens; Ahmad Awada
Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2/neu overexpressing breast cancer: EORTC study 16023.
Cancer chemotherapy and pharmacology 2013;71(1):53-62.
2012: L A Devriese; G Edwards; A Jenner; S Marchetti; M Mergui-Roelvink; Larisa Reyderman; E E Voest; J Wanders; Petronella O Witteveen; Jos H Beijnen; J H M Schellens
Pharmacokinetics of eribulin mesylate in patients with solid tumors and hepatic impairment.
Cancer chemotherapy and pharmacology 2012;70(6):823-32.
2012: J.G. Coen van Hasselt; Jos H Beijnen; Melvin R Mac Gillavry; Jan H M Schellens; Alwin D R Huitema
Model-based evaluation and optimization of cardiac monitoring protocols for adjuvant treatment of breast cancer with trastuzumab.
Pharmaceutical research 2012;29(12):3499-511.
2012: Jolanda M van den Hoven; Gert Storm; Jos H Beijnen; Josbert M Metselaar; Bastiaan Nuijen
Cyclodextrin as membrane protectant in spray-drying and freeze-drying of PEGylated liposomes.
International journal of pharmaceutics 2012;438(1-2):209-16.
2012: Selvi Durmus; Rolf W Sparidans; Els Wagenaar; Jos H Beijnen; Alfred H Schinkel
Oral availability and brain penetration of the B-RAFV600E inhibitor vemurafenib can be enhanced by the P-GLYCOprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
Molecular pharmaceutics 2012;9(11):3236-45.
2012: Thomas P C Dorlo; Jos H Beijnen; Marleen Boelaert; Raffaella Ravinetto
Universal access to quality medicines: prioritisation of a-priori solutions.
The Lancet infectious diseases 2012;12(11):829-30.
2012: Anne-Charlotte Dubbelman; Kimberly Krone; Serena Marchetti; Suraj Anand; Jos H Beijnen; Eugene Tan; Alana Upthagrove; Jan H M Schellens
Disposition and metabolism of 14C-dovitinib (TKI258), an inhibitor of FGFR and VEGFR, after oral administration in patients with advanced solid tumors.
Cancer chemotherapy and pharmacology 2012;70(5):653-63.
2012: Thomas P C Dorlo; Manica Balasegaram; Jos H Beijnen; Peter de Vries
Miltefosine: a review of its pharmacology and therapeutic efficacy in the treatment of leishmaniasis.
The Journal of antimicrobial chemotherapy 2012;67(11):2576-97.
2012: Jurjen S Lagas; Jos H Beijnen; Carola W N Damen; Dilek Iusuf; Robert A B van Waterschoot; Alfred H Schinkel
P-glycoprotein, multidrug-resistance associated protein 2, Cyp3a, and carboxylesterase affect the oral availability and metabolism of vinorelbine.
Molecular pharmacology 2012;82(4):636-44.
2012: Joost S Vermaat; Jos H Beijnen; Epie Boven; Frank L Gerritse; Jourik A Gietema; John B Haanen; Tatjana M Niers; Sjoukje F Oosting; Dick J Richel; Wijnand M Roessingh; Jeanine M Roodhart; Jan H Schellens; Stefan Sleijfer; Astrid A van der Veldt; Emile E Voest
Validation of serum amyloid α as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients.
European urology 2012;62(4):685-95.
2012: Rolf W Sparidans; Seng Chuan Tang; Luan N Nguyen; Jan H M Schellens; Alfred H Schinkel; Jos H Beijnen
Liquid chromatography-tandem mass spectrometric assay for the ALK inhibitor crizotinib in mouse plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2012;905():150-4.
2012: Rolf W Sparidans; Marieke E B Welzen; Tahani T A Ahmed; Eline W Muilwijk; Jan H M Schellens; Jos H Beijnen
Liquid chromatography-tandem mass spectrometric assay for therapeutic drug monitoring of the tyrosine kinase inhibitor pazopanib in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2012;905():137-40.
2012: Dilek Iusuf; Kathryn E Kenworthy; Jos H Beijnen; Mike Hobbs; Rolf W Sparidans; Evita van de Steeg; Anita van Esch; Els Wagenaar; Alfred H Schinkel
Organic anion-transporting polypeptides 1a/1b control the hepatic uptake of pravastatin in mice.
Molecular pharmaceutics 2012;9(9):2497-504.
2012: Markus Joerger; Stefanie Kraff; Berta Moritz; Jan H M Schellens; Jos H Beijnen; Gary Feiss; Alwin D R Huitema; Ulrich Jaehde
Evaluation of a pharmacology-driven dosing algorithm of 3-weekly paclitaxel using therapeutic drug monitoring: a pharmacokinetic-pharmacodynamic simulation study.
Clinical pharmacokinetics 2012;51(9):607-17.
2012: Ron J Keizer; Jan H M Schellens; Anthe S Zandvliet; Jos H Beijnen; Alwin D R Huitema
Performance of methods for handling missing categorical covariate data in population pharmacokinetic analyses.
The AAPS journal 2012;14(3):601-11.
2012: Andrew K L Goey; Irma Meijerman; Hilde Rosing; Jan H M Schellens; Rolf W Sparidans; Jos H Beijnen
The bioanalysis of the major Echinacea purpurea constituents dodeca-2E,4E,8Z,10E/Z-tetraenoic acid isobutylamides in human plasma using LC-MS/MS.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2012;902():151-6.
2012: Thomas P C Dorlo; Manica Balasegaram; Jos H Beijnen; Peter de Vries; María Angeles Lima; Alwin D R Huitema
Translational pharmacokinetic modelling and simulation for the assessment of duration of contraceptive use after treatment with miltefosine.
The Journal of antimicrobial chemotherapy 2012;67(8):1996-2004.
2012: Dick Pluim; Jos H Beijnen; Lot A Devriese; Jan H M Schellens
Validation of a multiparameter flow cytometry method for the determination of phosphorylated extracellular-signal-regulated kinase and DNA in circulating tumor cells.
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2012;81(8):664-71.
2012: Ron J Keizer; Jan H M Schellens; Robert Shumaker; Jos H Beijnen; Anubha Gupta; Alwin D R Huitema
Model-based treatment optimization of a novel VEGFR inhibitor.
British journal of clinical pharmacology 2012;74(2):315-26.
2012: Maarten J Deenen; Heinz-Josef Klümpen; Dick J Richel; Jan H M Schellens; Rolf W Sparidans; Mariette J Weterman; Jos H Beijnen; Johanna W Wilmink
Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.
Investigational new drugs 2012;30(4):1557-65.
2012: Ron J Keizer; Jan H M Schellens; Anthe S Zandvliet; Jos H Beijnen; Alwin D R Huitema
Two-stage model-based design of cancer phase I dose escalation trials: evaluation using the phase I program of barasertib (AZD1152).
Investigational new drugs 2012;30(4):1519-30.
2012: Fan Lin; Jos H Beijnen; Gayathri Chandrasekaran; Mark C de Gooijer; Olaf van Tellingen
Determination of NVP-BEZ235, a dual PI3K and mTOR inhibitor, in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2012;901():9-17.
2012: Thomas P C Dorlo; Alwin D R Huitema; Jos H Beijnen; Peter de Vries
Optimal dosing of miltefosine in children and adults with visceral leishmaniasis.
Antimicrobial agents and chemotherapy 2012;56(7):3864-72.
2012: Anne-Charlotte Dubbelman; Edward Hellriegel; Robert S Jansen; Philmore Robertson; Hilde Rosing; Jan H M Schellens; Mona Darwish; Jos H Beijnen
Metabolite profiling of bendamustine in urine of cancer patients after administration of [14C]bendamustine.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(7):1297-307.
2012: Annemieke W J Opstal-van Winden; Petra H M Peeters; Jos H Beijnen; Roel C H Vermeulen; Carla H van Gils
Early diagnostic protein biomarkers for breast cancer: how far have we come?
Breast cancer research and treatment 2012;134(1):1-12.
2012: N G L Jager; Sabine C Linn; H Rosing; J H M Schellens; Jos H Beijnen
Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen.
Breast cancer research and treatment 2012;133(2):793-8.
2012: Robert S Jansen; Ron J Keizer; Hilde Rosing; Jan H M Schellens; Pierre W Wijermans; Jos H Beijnen
Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: a pilot study.
Cancer chemotherapy and pharmacology 2012;69(6):1457-66.
2012: D S Boss; William Copalu; Jos H Beijnen; H Glen; M Keesen; A Mazur; R Morrison; J P O'Brien; J H M Schellens; B Tait; J Wanders; T R J Evans
A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours.
British journal of cancer 2012;106(10):1598-604.
2012: Rolf W Sparidans; Ning Xu; Selvi Durmus; Jan H M Schellens; Alfred H Schinkel; Jos H Beijnen
Liquid chromatography-tandem mass spectrometric assay for the VEGFR inhibitor cediranib and its primary human metabolite cediranib-N⁺-glucuronide in plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2012;895-896():169-73.
2012: Rolf W Sparidans; Ning Xu; Selvi Durmus; Jan H M Schellens; Alfred H Schinkel; Jos H Beijnen
Liquid chromatography-tandem mass spectrometric assay for the JAK2 inhibitor CYT387 in plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2012;895-896():174-7.
2012: Wiete Kromdijk; Jan W Mulder; Hilde Rosing; Patrick M Smit; Jos H Beijnen; Alwin D R Huitema
Use of dried blood spots for the determination of plasma concentrations of nevirapine and efavirenz.
The Journal of antimicrobial chemotherapy 2012;67(5):1211-6.
2012: Markus Joerger; Egbert F Smit; Paul H M Smits; Andrew Vincent; Paul Baas; Martin P L Bard; Jos H Beijnen; Sjaak A Burgers; Valerie D Doodeman; Tjeerd J Haitjema; Alwin D R Huitema; Jan H M Schellens
Germline polymorphisms in patients with advanced nonsmall cell lung cancer receiving first-line platinum-gemcitabine chemotherapy: a prospective clinical study.
Cancer 2012;118(9):2466-75.
2012: A C Dubbelman; A Gebretensae; S H Gorman; L Nan; P Robertson; Hilde Rosing; J H M Schellens; M Tibben; Jos H Beijnen
Development and validation of LC-MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2012;893-894():92-100.
2012: W Kromdijk; Hilde Rosing; M P H van den Broek; Jos H Beijnen; A D R Huitema
Quantitative determination of oseltamivir and oseltamivir carboxylate in human fluoride EDTA plasma including the ex vivo stability using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2012;891-892():57-63.
2012: Seng Chuan Tang; Els Wagenaar; Jos H Beijnen; Nienke A G Lankheet; Birk Poller; Alfred H Schinkel
P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.
The Journal of pharmacology and experimental therapeutics 2012;341(1):164-73.
2012: Nienke A de Vries; Jan H M Schellens; Jos H Beijnen; Tessa Buckle; Jin Zhao; Olaf van Tellingen
Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.
Investigational new drugs 2012;30(2):443-9.
2012: Rolf W Sparidans; Selvi Durmus; Jan H M Schellens; Alfred H Schinkel; Jos H Beijnen
Liquid chromatography-tandem mass spectrometric assay for the mutated BRAF inhibitor vemurafenib in human and mouse plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2012;889-890():144-7.
2012: Thomas P C Dorlo; Teunis A Eggelte; Peter de Vries; Jos H Beijnen
Characterization and identification of suspected counterfeit miltefosine capsules.
The Analyst 2012;137(5):1265-74.
2012: A C Dubbelman; A Gebretensae; L Lucas; Hilde Rosing; J H M Schellens; R Shumaker; Bas Thijssen; H Chen; Jos H Beijnen
Development and validation of LC-MS/MS assays for the quantification of E7080 and metabolites in various human biological matrices.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2012;887-888():25-34.
2012: Mariska van Vliet; Inès A von Rosenstiel; Henk J Aanstoot; Jos H Beijnen; Desiderius P M Brandjes; Michaela Diamant; Martijn W Heymans; Roger K Schindhelm; Josine C van der Heyden; Henk J Veeze
Overweight children with type 1 diabetes have a more favourable lipid profile than overweight non-diabetic children.
European journal of pediatrics 2012;171(3):493-8.
2012: Anne-Charlotte Dubbelman; Alwin D R Huitema; Robert S Jansen; Barbara Koetz; Arturo Lopez-Anaya; Margarita Lymboura; Marja Mergui-Roelvink; Larisa Reyderman; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Mass balance study of [¹⁴C]eribulin in patients with advanced solid tumors.
Drug metabolism and disposition: the biological fate of chemicals 2012;40(2):313-21.
2012: Hendrik van den Berg; John N van den Anker; Jos H Beijnen
Cytostatic drugs in infants: a review on pharmacokinetic data in infants.
Cancer treatment reviews 2012;38(1):3-26.
2012: Annemieke W J Opstal-van Winden; Petra H M Peeters; Jeroen L A Pennings; Wendy Rodenburg; Carla H van Gils; Conny Th M van Oostrom; Jos H Beijnen; Annemieke de Vries
A bead-based multiplexed immunoassay to evaluate breast cancer biomarkers for early detection in pre-diagnostic serum.
International journal of molecular sciences 2012;13(10):13587-604.
2012: Maarten J Deenen; C M P W Mandigers; Jos H Beijnen; Annemieke Cats; Marcel Soesan; Wim E Terpstra; J H M Schellens
[Prevention of severe toxicity from capecitabine, 5-fluorouracil and tegafur by screening for DPD-deficiency].
Nederlands tijdschrift voor geneeskunde 2012;156(48):A4934.
2012: Thomas P C Dorlo; Raffaella M Ravinetto; Jos H Beijnen; Marleen Boelaert
Commentary: Substandard medicines are the priority for neglected tropical diseases.
BMJ (Clinical research ed.) 2012;345():e7518.
2012: Maarten Swartjes; Koen van de Wetering; Amanda R Waxman; Caroline Arout; Jos H Beijnen; Jan den Hartigh; Benjamin Kest; René A G Mooren; Albert Dahan
Morphine induces hyperalgesia without involvement of μ-opioid receptor or morphine-3-glucuronide.
Molecular medicine (Cambridge, Mass.) 2012;18():1320-6.
2012: Robin M J M van Geel; Jos H Beijnen; Jan H M Schellens
Concise drug review: pazopanib and axitinib.
The oncologist 2012;17(8):1081-9.
2012: Thomas P C Dorlo; Teunis A Eggelte; Gerard J Schoone; Peter de Vries; Jos H Beijnen
A poor-quality generic drug for the treatment of visceral leishmaniasis: a case report and appeal.
PLoS neglected tropical diseases 2012;6(5):e1544.
2012: J G Coen van Hasselt; Jos H Beijnen; Dieta Brandsma; Jan H M Schellens; Michel M van den Heuvel; Alwin D R Huitema
Severe cannabinoid intoxication in a patient with non-small-cell lung cancer.
Journal of palliative care 2012;28(1):60-1.
2012: Kim D Mooiman; Jos H Beijnen; Andrew K L Goey; Irma Meijerman; Jan H M Schellens
Letter to the editor regarding "A prospective, controlled study of the botanical compound mixture LCS101 for chemotherapy-induced hematological complications in breast cancer" by Yaal-Hahoshen et al. (The Oncologist 2011;16:1197-1202).
The oncologist 2012;17(5):740-1; author reply 742-3.
2012: Frans L Opdam; Jos H Beijnen; Henk-Jan Guchelaar; Jan H M Schellens
Lapatinib for advanced or metastatic breast cancer.
The oncologist 2012;17(4):536-42.
2012: Martijn L Manson; J H M Schellens; Pierre W Wijermans; Ellen J B Derissen; Jos H Beijnen
[Demethylating medication in myelodysplastic syndrome].
Nederlands tijdschrift voor geneeskunde 2012;156(4):A3167.
2012: Seng Chuan Tang; Jos H Beijnen; Michel J X Hillebrand; Jurjen S Lagas; Nienke A G Lankheet; Birk Poller; Hilde Rosing; Alfred H Schinkel
Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.
International journal of cancer. Journal international du cancer 2012;130(1):223-33.
2011: Fan Lin; David Sherris; Jos H Beijnen; Olaf van Tellingen
High-performance liquid chromatography analysis of a novel small-molecule, anti-cancer drug, Palomid 529, in human and mouse plasma and in mouse tissue homogenates.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2011;879(32):3823-31.
2011: Anne-Charlotte Dubbelman; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Bioanalytical aspects of clinical mass balance studies in oncology.
Bioanalysis 2011;3(23):2637-55.
2011: Marie-Christine W Gast; Connie R Jimenez; Jaco C Knol; Jan H M Schellens; Paul N Span; Vivianne C G Tjan-Heijnen; Harm van Tinteren; Marc Zapatka; Marijke Bontenbal; Jos H Beijnen
Postoperative serum proteomic profiles may predict recurrence-free survival in high-risk primary breast cancer.
Journal of cancer research and clinical oncology 2011;137(12):1773-83.
2011: Lot A Devriese; Jos H Beijnen; Emile E Voest; Jan H M Schellens
Circulating tumor cells as pharmacodynamic biomarker in early clinical oncological trials.
Cancer treatment reviews 2011;37(8):579-89.
2011: J J Moes; Jos H Beijnen; A D R Huitema; S L W Koolen; J H M Schellens; B Nuijen
Pharmaceutical development and preliminary clinical testing of an oral solid dispersion formulation of docetaxel (ModraDoc001).
International journal of pharmaceutics 2011;420(2):244-50.
2011: Jeroen J M A Hendrikx; Michel J X Hillebrand; Hilde Rosing; Jan H M Schellens; Alfred H Schinkel; Bas Thijssen; Jos H Beijnen
A sensitive combined assay for the quantification of paclitaxel, docetaxel and ritonavir in human plasma using liquid chromatography coupled with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2011;879(28):2984-90.
2011: Annelies H Boekhout; Otilia B Dalesio; Joke H Foekema-Töns; Bastiaan Nuijen; Sandra Adriaansz; Jos H Beijnen; Sylvia Sprangers; Joan van den Bosch; Andrew D Vincent; Jan H M Schellens
Management of hot flashes in patients who have breast cancer with venlafaxine and clonidine: a randomized, double-blind, placebo-controlled trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(29):3862-8.
2011: Nienke A G Lankheet; Henk Mallo; Hilde Rosing; Jan H M Schellens; Sandra Adriaansz; Christian U Blank; Alwin D R Huitema; Jos H Beijnen
Determination of sunitinib and its active metabolite N-desethylsunitinib in sweat of a patient.
Journal of analytical toxicology 2011;35(8):558-65.
2011: Whitney P Caron; Harvey Clewell; Whitney L Davis; Robert Dedrick; Ramesh K Ramanathan; Jan H Schellens; Margaret Tonda; Ning Yu; Jos H Beijnen; William C Zamboni
Allometric scaling of pegylated liposomal anticancer drugs.
Journal of pharmacokinetics and pharmacodynamics 2011;38(5):653-69.
2011: Elena Soto; Iñaki F Trocóniz; Jantien Wanders; Jos H Beijnen; Josep María Cendrós; Lena E Friberg; Alwin D R Huitema; Ron J Keizer; Rosendo Obach; Concepción Peraire; Jan H M Schellens; Mats O Karlsson
Predictive ability of a semi-mechanistic model for neutropenia in the development of novel anti-cancer agents: two case studies.
Investigational new drugs 2011;29(5):984-95.
2011: Jolanda M van den Hoven; Josee Wagenaar-Hilbers; Marca H M Wauben; Jos H Beijnen; Wouter Hofkens; Josbert M Metselaar; Bastiaan Nuijen; Gert Storm
Optimizing the therapeutic index of liposomal glucocorticoids in experimental arthritis.
International journal of pharmaceutics 2011;416(2):471-7.
2011: Stijn L W Koolen; Roelien H Kronemeijer; Marlies H G Langenberg; Annemarie Nol; Jos H Beijnen; Karim Benhadji; Sophie Callies; Ignacio Garcia-Ribas; Robert Jansen; Christopher A Slapak; Emile E Voest; Petronella O Witteveen; Jan H M Schellens
Phase I study of Oral gemcitabine prodrug (LY2334737) alone and in combination with erlotinib in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(18):6071-82.
2011: Jeanine M L Roodhart; Henk S Schipper; Edwin C A Stigter; Miranda van Amersfoort; Joost S P Vermaat; Marieke J G Backer; Jos H Beijnen; Arjan B Brenkman; Laura G M Daenen; Patrick W B Derksen; Johan Gerrits; Marije G Gerritsen; Julia M Houthuijzen; Kenji Ishihara; Eric Kalkhoven; Anton C Martens; René H Medema; Petra Moerer; Henk-Jan Prins; Emile E Voest
Mesenchymal stem cells induce resistance to chemotherapy through the release of platinum-induced fatty acids.
Cancer cell 2011;20(3):370-83.
2011: Karin Holweger; Hans-Peter Lipp; Jos H Beijnen; Carsten Bokemeyer; Joerg Thomas Hartmann
Evaluation of a non cystatin-C-based novel algorithm to calculate individual glomerular filtration rate in cancer patients receiving carboplatin.
Cancer chemotherapy and pharmacology 2011;68(3):693-701.
2011: Jurjen S Lagas; Jiri F P Wagenaar; Desiderius P M Brandjes; Victor E A Gerdes; Michel J X Hillebrand; Alwin D R Huitema; Cornelis H W Koks; Jos H Beijnen
Lethal morphine intoxication in a patient with a sickle cell crisis and renal impairment: case report and a review of the literature.
Human & experimental toxicology 2011;30(9):1399-403.
2011: Ron J Keizer; Jos H Beijnen; Paul Baas
'Flooding' of the lungs and severe dyspnea in a patient with bronchoalveolar carcinoma.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2011;17(3):270-3.
2011: Anne-Joy M de Graan; Felix E de Jongh; AI de Vos; Filip Y F L de Vos; Walter J Loos; Caroline Seynaeve; Sebastiaan F Teunissen; RJ van Alphen; Bronno van der Holt; Ron H N van Schaik; Jaap Verweij; Jos H Beijnen; Ron H J Mathijssen
Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(24):3240-6.
2011: Rolf W Sparidans; Liselot B J Valkenburg-van Iersel; Jan den Hartigh; Irene Martens; Jan H M Schellens; Jos H Beijnen
Liquid chromatography-tandem mass spectrometric assay for the PARP-1 inhibitor olaparib in combination with the nitrogen mustard melphalan in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2011;879(21):1851-6.
2011: S F Teunissen; N G L Jager; Hilde Rosing; Alfred H Schinkel; J H M Schellens; Jos H Beijnen
Development and validation of a quantitative assay for the determination of tamoxifen and its five main phase I metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2011;879(19):1677-85.
2011: Rob ter Heine; Robert A B van Waterschoot; Ron J Keizer; Jos H Beijnen; Alfred H Schinkel; Alwin D R Huitema
An integrated pharmacokinetic model for the influence of CYP3A4 expression on the in vivo disposition of lopinavir and its modulation by ritonavir.
Journal of pharmaceutical sciences 2011;100(6):2508-15.
2011: Bas Teunissen; Hilde Rosing; M Dominguez Seoane; L Brunsveld; J H M Schellens; Alfred H Schinkel; Jos H Beijnen
Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques.
Journal of pharmaceutical and biomedical analysis 2011;55(3):518-26.
2011: Dilek Iusuf; Sebastiaan F Teunissen; Els Wagenaar; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel
P-glycoprotein (ABCB1) transports the primary active tamoxifen metabolites endoxifen and 4-hydroxytamoxifen and restricts their brain penetration.
The Journal of pharmacology and experimental therapeutics 2011;337(3):710-7.
2011: Maarten J Deenen; Valerie D Doodeman; Henk-Jan Guchelaar; Cornelis J A Punt; Jan H M Schellens; Paul H M Smits; Jolien Tol; Andrew Vincent; Jos H Beijnen; Artur M Burylo; Anthonius de Boer; Annemieke Cats
Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2011;17(10):3455-68.
2011: Rob ter Heine; Jan W Mulder; Eric C M van Gorp; Jiri Fp Wagenaar; Jos H Beijnen; Alwin D R Huitema
Clinical evaluation of the determination of plasma concentrations of darunavir, etravirine, raltegravir and ritonavir in dried blood spot samples.
Bioanalysis 2011;3(10):1093-7.
2011: A C Dubbelman; Hilde Rosing; Bas Thijssen; L Lucas; William Copalu; J Wanders; J H M Schellens; Jos H Beijnen
Validation of high-performance liquid chromatography-tandem mass spectrometry assays for the quantification of eribulin (E7389) in various biological matrices.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2011;879(15-16):1149-55.
2011: Patrick M Smit; Maarten Limper; Eric C M van Gorp; Paul H M Smits; Jos H Beijnen; Dees P M Brandjes; Jan W Mulder
Adult outpatient experience of the 2009 H1N1 pandemic: clinical course, pathogens, and evaluation of case definitions.
The Journal of infection 2011;62(5):371-8.
2011: Birk Poller; Dilek Iusuf; Rolf W Sparidans; Els Wagenaar; Jos H Beijnen; Alfred H Schinkel
Differential impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on axitinib brain accumulation and oral plasma pharmacokinetics.
Drug metabolism and disposition: the biological fate of chemicals 2011;39(5):729-35.
2011: mariska van vliet; Roel P Gazendam; Inès A von Rosenstiel; Anton P van Zanten; Desiderius P M Brandjes; Jos H Beijnen; Joost Rotteveel; Michaela Diamant
Differential impact of impaired fasting glucose versus impaired glucose tolerance on cardiometabolic risk factors in multi-ethnic overweight/obese children.
European journal of pediatrics 2011;170(5):589-97.
2011: Tine Janssens; Elke E M Brouwers; Johan P de Vos; Jan H M Schellens; Jos H Beijnen
Determination of platinum originating from carboplatin in human urine and canine excretion products by inductively coupled plasma mass spectrometry.
Journal of analytical toxicology 2011;35(3):153-61.
2011: Robert S Jansen; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites?
Fundamental & clinical pharmacology 2011;25(2):172-85.
2011: Robert S Jansen; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Mass spectrometry in the quantitative analysis of therapeutic intracellular nucleotide analogs.
Mass spectrometry reviews 2011;30(2):321-43.
2011: Nienke A G Lankheet; Roos D Padberg; Evelyne M de Kluiver; Abraham J Wilhelm; Job B M van Woensel; Jos H Beijnen; Alwin D R Huitema
Relatively mild symptoms after an olanzapine intoxication in a 2-year-old girl with excessively high serum levels.
Journal of child and adolescent psychopharmacology 2011;21(1):93-5.
2011: Ron J Keizer; J H M Schellens; Jos H Beijnen; Alwin D R Huitema
Pharmacodynamic biomarkers in model-based drug development in oncology.
Current clinical pharmacology 2011;6(1):30-40.
2011: Tine Janssens; Elke E M Brouwers; Johan P de Vos; Jan H M Schellens; Jos H Beijnen
Determination of platinum originating from carboplatin in canine sebum and cerumen by inductively coupled plasma mass spectrometry.
Journal of pharmaceutical and biomedical analysis 2011;54(2):395-400.
2011: Mariska van Vliet; Inès A von Rosenstiel; Jos H Beijnen; Desiderius P M Brandjes; Martijn W Heymans; Michaela Diamant
Cardiometabolic risk variables in overweight and obese children: a worldwide comparison.
Cardiovascular diabetology 2011;10():106.
2011: Annemieke W J Opstal-van Winden; Petra H M Peeters; Carla H van Gils; Jos H Beijnen; Marie-Christine W Gast; Diederick E Grobbee; Marina C Jeppsson; Bo A G Jönsson; Monica H Kåredal; Esmeralda J M Krop; Christian H Lindh; Roel C H Vermeulen
Searching for early breast cancer biomarkers by serum protein profiling of pre-diagnostic serum; a nested case-control study.
BMC cancer 2011;11():381.
2011: Maarten J Deenen; Jos H Beijnen; Annemieke Cats; Jan H M Schellens
Part 2: pharmacogenetic variability in drug transport and phase I anticancer drug metabolism.
The oncologist 2011;16(6):820-34.
2011: Annelies H Boekhout; Jos H Beijnen; Jan H M Schellens
Trastuzumab.
The oncologist 2011;16(6):800-10.
2011: Maarten J Deenen; Jos H Beijnen; Annemieke Cats; Jan H M Schellens
Part 1: background, methodology, and clinical adoption of pharmacogenetics.
The oncologist 2011;16(6):811-9.
2011: L Tran; Joke W Baars; Jan Paul de Boer; Cornelis A Hoefnagel; Jos H Beijnen; Alwin D R Huitema
The pharmacokinetics of ¹³¹I-rituximab in a patient with CD20 positive non-Hodgkin Lymphoma: evaluation of the effect of radioiodination on the biological properties of rituximab.
Human antibodies 2011;20(1-2):37-40.
2011: L Tran; Alwin D R Huitema; M H van Rijswijk; H J Dinant; Joke W Baars; Jos H Beijnen; Wouter V Vogel
CD20 antigen imaging with ¹²⁴I-rituximab PET/CT in patients with rheumatoid arthritis.
Human antibodies 2011;20(1-2):29-35.
2011: L Tran; Wouter V Vogel; M Sinaasappel; S Muller; Joke W Baars; M van Rijswijk; H J Dinant; Jos H Beijnen; Alwin D R Huitema
The pharmacokinetics of ¹²⁴I-rituximab in patients with rheumatoid arthritis.
Human antibodies 2011;20(1-2):7-14.
2011: David Boss; Hilary Glen; Jos H Beijnen; Daphne de Jong; Jantien Wanders; T R Jeffry Evans; Jan H M Schellens
Serum beta-HCG and CA-125 as tumor markers in a patient with osteosarcoma: case report.
Tumori 2011;97(1):109-14.
2011: Andrew K L Goey; Rolf W Sparidans; Irma Meijerman; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
A sensitive LC-MS/MS method for the quantitative analysis of the Echinacea purpurea constituent undeca-2-ene-8,10-diynoic acid isobutylamide in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2011;879(1):41-8.
2011: Ron J Keizer; Michel van Benten; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM.
Computer methods and programs in biomedicine 2011;101(1):72-9.
2011: Jurjen S Lagas; Abraham J Wilhelm; René M Vos; Erik-Jan van den Dool; Yvonne van der Heide; Sandra Huissoon; Jos H Beijnen; Desiderius P M Brandjes
Toxicokinetics of a dipyridamole (Persantin) intoxication: case report.
Human & experimental toxicology 2011;30(1):74-8.
2011: Natalie M G M Appels; Maria J Bolijn; Monique van Eijndhoven; Trevor C Stephens; Jos H Beijnen; Jan H M Schellens
Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor.
Cancer chemotherapy and pharmacology 2011;67(1):137-45.
2010: Bas Teunissen; Hilde Rosing; Alfred H Schinkel; J H M Schellens; Jos H Beijnen
Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review.
Analytica chimica acta 2010;683(1):21-37.
2010: Robert A B van Waterschoot; Jurjen S Lagas; Els Wagenaar; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel
Individual and combined roles of CYP3A, P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) in the pharmacokinetics of docetaxel.
International journal of cancer. Journal international du cancer 2010;127(12):2959-64.
2010: Rob ter Heine; James C Fanggiday; Nienke A G Lankheet; Jos H Beijnen; Monique M L Van Der Westerlaken; Gerald H A Staaks; Mirte M Malingré
Erlotinib and pantoprazole: a relevant interaction or not?
British journal of clinical pharmacology 2010;70(6):908-11.
2010: Irene van den Broek; Rolf W Sparidans; Annemieke W J van Winden; Marie-Christine W Gast; Eric J van Dulken; Jan H M Schellens; Jos H Beijnen
The absolute quantification of eight inter-α-trypsin inhibitor heavy chain 4 (ITIH4)-derived peptides in serum from breast cancer patients.
Proteomics. Clinical applications 2010;4(12):931-9.
2010: Bas Teunissen; Hilde Rosing; Alfred H Schinkel; J H M Schellens; Jos H Beijnen
Review on the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine and its phase I and phase II metabolites in biological matrices, foodstuff and beverages.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2010;878(31):3199-216.
2010: Dieta Brandsma; Thomas Dorlo; John H Haanen; Jos H Beijnen; Willem Boogerd
Severe encephalopathy and polyneuropathy induced by dichloroacetate.
Journal of neurology 2010;257(12):2099-100.
2010: Rolf W Sparidans; Dilek Iusuf; Alfred H Schinkel; Jan H M Schellens; Jos H Beijnen
Liquid chromatography-tandem mass spectrometric assay for pravastatin and two isomeric metabolites in mouse plasma and tissue homogenates.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2010;878(28):2751-9.
2010: Linda R Tulner; Jos P C M van Campen; Suzanne V Frankfort; Cornelis H W Koks; Jos H Beijnen; D P M Brandjes; Paul A F Jansen
Changes in under-treatment after comprehensive geriatric assessment: an observational study.
Drugs & aging 2010;27(10):831-43.
2010: Wieneke A Buikhuisen; Jacobus A Burgers; Andrew D Vincent; Jan H M Schellens; Jos H Beijnen; Egbert F Smit; Markus Joerger
Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(27):e482-3; author reply e484.
2010: Bas Teunissen; Maria L H Vlaming; Hilde Rosing; J H M Schellens; Alfred H Schinkel; Jos H Beijnen
Development and validation of a liquid chromatography-tandem mass spectrometry assay for the analysis of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and its metabolite 2-hydroxyamino-1-methyl-6-phenylimidazo[4,5-b]pyridine (N-OH-PhIP) in plasma, urine, bile, intestinal contents, faeces and eight selected tissues from mice.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2010;878(25):2353-62.
2010: Stefan Harmsen; Irma Meijerman; C L Febus; R F Maas-Bakker; Jos H Beijnen; J H M Schellens
PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line.
Cancer chemotherapy and pharmacology 2010;66(4):765-71.
2010: Annemieke W J van Winden; Irene van den Broek; Marie-Christine W Gast; Judith Y M N Engwegen; Rolf W Sparidans; Eric J van Dulken; Annekatrien C T M Depla; Annemieke Cats; Jan H M Schellens; Petra H M Peeters; Jos H Beijnen; Carla H van Gils
Serum degradome markers for the detection of breast cancer.
Journal of proteome research 2010;9(8):3781-8.
2010: Ron J Keizer; Anubha Gupta; Melvin R Mac Gillavry; Mendel Jansen; Jantien Wanders; Jos H Beijnen; Jan H M Schellens; Mats O Karlsson; Alwin D R Huitema
A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080.
Journal of pharmacokinetics and pharmacodynamics 2010;37(4):347-63.
2010: Rolf W Sparidans; Pim N J Langendijk; Eric Boers; Erik van Kan; Hanno L Tan; Jos H Beijnen
Liquid chromatographic assay with fluorescence detection to determine ajmaline in serum from patients with suspected Brugada syndrome.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2010;878(23):2168-72.
2010: Ron J Keizer; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Clinical pharmacokinetics of therapeutic monoclonal antibodies.
Clinical pharmacokinetics 2010;49(8):493-507.
2010: Rolf W Sparidans; Sara G A van Velsen; Marlise P de Roos; Jan H M Schellens; Carla A F M Bruijnzeel-Koomen; Jos H Beijnen
Liquid chromatography-tandem mass spectrometric assay for clobetasol propionate in human serum from patients with atopic dermatitis.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2010;878(23):2150-4.
2010: Rob ter Heine; Hilde Rosing; Jos H Beijnen; Alwin D R Huitema
A less sensitive detector does not necessarily result in a less sensitive method: fast quantification of 13 antiretroviral analytes in plasma with liquid chromatography coupled with tandem mass spectrometry.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2010;48(8):1153-5.
2010: Jos H Beijnen; Jan H M Schellens
Selected new developments in oncology.
Current clinical pharmacology 2010;5(3):140.
2010: Jos H Beijnen; Jan H M Schellens
Personalized medicine in oncology: a personal view with myths and facts.
Current clinical pharmacology 2010;5(3):141-7.
2010: Suzanne Leijen; Jos H Beijnen; Jan H M Schellens
Abrogation of the G2 checkpoint by inhibition of Wee-1 kinase results in sensitization of p53-deficient tumor cells to DNA-damaging agents.
Current clinical pharmacology 2010;5(3):186-91.
2010: David Boss; Jos H Beijnen; Jan H M Schellens
Inducing synthetic lethality using PARP inhibitors.
Current clinical pharmacology 2010;5(3):192-5.
2010: Joost H van den Berg; Koen Oosterhuis; Jos H Beijnen; Bastiaan Nuijen; John B A G Haanen
DNA vaccination in oncology: current status, opportunities and perspectives.
Current clinical pharmacology 2010;5(3):218-25.
2010: Irene van den Broek; Rolf W Sparidans; Jan H M Schellens; Jos H Beijnen
Sensitive liquid chromatography/tandem mass spectrometry assay for absolute quantification of ITIH4-derived putative biomarker peptides in clinical serum samples.
Rapid communications in mass spectrometry : RCM 2010;24(13):1842-50.
2010: Linda R Tulner; Ingeborg M J A Kuper; Jos P C M van Campen; Melvin R Mac Gillavry; Vincent I H Kwa; Cornelis H W Koks; Jos H Beijnen; D P M Brandjes
Contraindications for anticoagulation in older patients with atrial fibrillation; a narrative review.
Current drug safety 2010;5(3):223-33.
2010: Robert A B van Waterschoot; Rob ter Heine; Els Wagenaar; C M M van der Kruijssen; R W Rooswinkel; Alwin D R Huitema; Jos H Beijnen; Alfred H Schinkel
Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.
British journal of pharmacology 2010;160(5):1224-33.
2010: Helgi H Helgason; Judith Y M Engwegen; Marc Zapatka; Andrew Vincent; Annemieke Cats; Henk Boot; Jos H Beijnen; Jan H M Schellens
Identification of serum proteins as prognostic and predictive markers of colorectal cancer using surface enhanced laser desorption ionization-time of flight mass spectrometry.
Oncology reports 2010;24(1):57-64.
2010: Nienke A de Vries; Sophia W Bruggeman; Danielle Hulsman; Hilda I de Vries; John Zevenhoven; Tessa Buckle; Bob C Hamans; William P Leenders; Jos H Beijnen; Maarten van Lohuizen; Anton J M Berns; Olaf van Tellingen
Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(13):3431-41.
2010: Trijn Israels; Carola W N Damen; Michael Cole; Nan van Geloven; Alan V Boddy; Huib N Caron; Jos H Beijnen; Elizabeth M Molyneux; Gareth J Veal
Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate.
European journal of cancer (Oxford, England : 1990) 2010;46(10):1841-7.
2010: Joost H van den Berg; Susanne G L Quaak; Jos H Beijnen; Wim E Hennink; Gert Storm; Ton N Schumacher; John B A G Haanen; Bastiaan Nuijen
Lipopolysaccharide contamination in intradermal DNA vaccination: toxic impurity or adjuvant?
International journal of pharmaceutics 2010;390(1):32-6.
2010: Rob ter Heine; Jan W Mulder; Eric C M van Gorp; Jiri F P Wagenaar; Jos H Beijnen; Alwin D R Huitema
Intracellular and plasma steady-state pharmacokinetics of raltegravir, darunavir, etravirine and ritonavir in heavily pre-treated HIV-infected patients.
British journal of clinical pharmacology 2010;69(5):475-83.
2010: Stijn L W Koolen; Roos L Oostendorp; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Population pharmacokinetics of intravenously and orally administered docetaxel with or without co-administration of ritonavir in patients with advanced cancer.
British journal of clinical pharmacology 2010;69(5):465-74.
2010: Peter Blanken; Wim van den Brink; Vincent M Hendriks; Ineke A Huijsman; Marjolein G Klous; Elisabeth J Rook; Jennifer S Wakelin; Cas Barendrecht; Jos H Beijnen; Jan M van Ree
Heroin-assisted treatment in the Netherlands: History, findings, and international context.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2010;20 Suppl 2():S105-58.
2010: Jurjen S Lagas; Rolf W Sparidans; Els Wagenaar; Jos H Beijnen; Alfred H Schinkel
Hepatic clearance of reactive glucuronide metabolites of diclofenac in the mouse is dependent on multiple ATP-binding cassette efflux transporters.
Molecular pharmacology 2010;77(4):687-94.
2010: Liia D Vainchtein; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
A new, validated HPLC-MS/MS method for the simultaneous determination of the anti-cancer agent capecitabine and its metabolites: 5'-deoxy-5-fluorocytidine, 5'-deoxy-5-fluorouridine, 5-fluorouracil and 5-fluorodihydrouracil, in human plasma.
Biomedical chromatography : BMC 2010;24(4):374-86.
2010: Roos L Oostendorp; Petronella O Witteveen; B Schwartz; L D Vainchtein; Margaret Schot; A Nol; Hilde Rosing; Jos H Beijnen; Emile E Voest; J H M Schellens
Dose-finding and pharmacokinetic study of orally administered indibulin (D-24851) to patients with advanced solid tumors.
Investigational new drugs 2010;28(2):163-70.
2010: Jan-Hendrik Beumer; N E Franke; R Tolboom; Tessa Buckle; Hilde Rosing; Luis Lopez-Lazaro; J H M Schellens; Jos H Beijnen; Olaf van Tellingen
Disposition and toxicity of trabectedin (ET-743) in wild-type and mdr1 gene (P-gp) knock-out mice.
Investigational new drugs 2010;28(2):145-55.
2010: Susanne G L Quaak; John B A G Haanen; Jos H Beijnen; Bastiaan Nuijen
Naked plasmid DNA formulation: effect of different disaccharides on stability after lyophilisation.
AAPS PharmSciTech 2010;11(1):344-50.
2010: Robert S Jansen; Hilde Rosing; Wiete Kromdijk; Rob ter Heine; Jan Hm Schellens; Jos H Beijnen
Simultaneous quantification of emtricitabine and tenofovir nucleotides in peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2010;878(7-8):621-7.
2010: Irene van den Broek; Rolf W Sparidans; Jan H M Schellens; Jos H Beijnen
Quantitative assay for six potential breast cancer biomarker peptides in human serum by liquid chromatography coupled to tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2010;878(5-6):590-602.
2010: Marlies H G Langenberg; Petronella O Witteveen; Nienke A G Lankheet; Jeanine Ml Roodhart; Hilde Rosing; Ingeborg J G M van den Heuvel; Jos H Beijnen; Emile E Voest
Phase 1 study of combination treatment with PTK 787/ZK 222584 and cetuximab for patients with advanced solid tumors: safety, pharmacokinetics, pharmacodynamics analysis.
Neoplasia (New York, N.Y.) 2010;12(2):206-13.
2010: Jurjen S Lagas; Robert A B van Waterschoot; Rolf W Sparidans; Els Wagenaar; Jos H Beijnen; Alfred H Schinkel
Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation.
Molecular cancer therapeutics 2010;9(2):319-26.
2010: Anthe S Zandvliet; Mats O Karlsson; Jan H M Schellens; William Copalu; Jos H Beijnen; Alwin D R Huitema
Two-stage model-based clinical trial design to optimize phase I development of novel anticancer agents.
Investigational new drugs 2010;28(1):61-75.
2010: Joost H van den Berg; Koen Oosterhuis; Wim E Hennink; Gert Storm; Hans van der Aa; Johan F J Engbersen; John B A G Haanen; Jos H Beijnen; Ton N Schumacher; Bastiaan Nuijen
Shielding the cationic charge of nanoparticle-formulated dermal DNA vaccines is essential for antigen expression and immunogenicity.
Journal of controlled release : official journal of the Controlled Release Society 2010;141(2):234-40.
2010: Irene van den Broek; Rolf W Sparidans; Judith Y M N Engwegen; Annemieke Cats; Annekatrien C T M Depla; Jan H M Schellens; Jos H Beijnen
Evaluation of human neutrophil peptide-1, -2 and -3 as serum markers for colorectal cancer.
Cancer biomarkers : section A of Disease markers 2010;7(2):109-15.
2010: Heinz-Josef Klümpen; Jos H Beijnen; Howard Gurney; Jan H M Schellens
Inhibitors of mTOR.
The oncologist 2010;15(12):1262-9.
2010: Filis Kazazi-Hyseni; Jos H Beijnen; Jan H M Schellens
Bevacizumab.
The oncologist 2010;15(8):819-25.
2010: Andrew K L Goey; J H M Schellens; Jos H Beijnen; Alwin D R Huitema
[Dexrazoxane in anthracycline induced cardiotoxicity and extravasation].
Nederlands tijdschrift voor geneeskunde 2010;154():A1155.
2010: L Tran; J W Baars; L Aarden; Jos H Beijnen; Alwin D R Huitema
Pharmacokinetics of rituximab in patients with CD20 positive B-cell malignancies.
Human antibodies 2010;19(1):7-13.
2010: Robert Jansen; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Facile small scale synthesis of nucleoside 5'-phosphate mixtures.
Nucleosides, nucleotides & nucleic acids 2010;29(1):14-26.
2010: Linda R Tulner; Jos P C M van Campen; Ingeborg M J A Kuper; George J P T Gijsen; Cornelis H W Koks; Melvin R Mac Gillavry; Harm van Tinteren; Jos H Beijnen; D P M Brandjes
Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study.
Drugs & aging 2010;27(1):39-50.
2010: Jurjen S Lagas; Lin Fan; Els Wagenaar; Maria L H Vlaming; Olaf van Tellingen; Jos H Beijnen; Alfred H Schinkel
P-glycoprotein (P-gp/Abcb1), Abcc2, and Abcc3 determine the pharmacokinetics of etoposide.
Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(1):130-40.
2010: S L W Koolen; Jos H Beijnen; J H M Schellens
Intravenous-to-oral switch in anticancer chemotherapy: a focus on docetaxel and paclitaxel.
Clinical pharmacology and therapeutics 2010;87(1):126-9.
2010: Joost H van den Berg; Bastiaan Nuijen; Ton N Schumacher; John B A G Haanen; Gert Storm; Jos H Beijnen; Wim E Hennink
Synthetic vehicles for DNA vaccination.
Journal of drug targeting 2010;18(1):1-14.
2010: Carola W N Damen; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
High-performance liquid chromatography coupled with mass spectrometry for the quantitative analysis of vinca-alkaloids in biological matrices: a concise survey from the literature.
Biomedical chromatography : BMC 2010;24(1):83-90.
2009: Rolf W Sparidans; Dilek Iusuf; Alfred H Schinkel; Jan H M Schellens; Jos H Beijnen
Liquid chromatography-tandem mass spectrometric assay for the light sensitive tyrosine kinase inhibitor axitinib in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(32):4090-6.
2009: Carola W N Damen; Ellen J B Derissen; Jan H M Schellens; Hilde Rosing; Jos H Beijnen
The bioanalysis of the monoclonal antibody trastuzumab by high-performance liquid chromatography with fluorescence detection after immuno-affinity purification from human serum.
Journal of pharmaceutical and biomedical analysis 2009;50(5):861-6.
2009: Robert A B van Waterschoot; Jurjen S Lagas; Els Wagenaar; Cornelia M M van der Kruijssen; Antonius E van Herwaarden; Ji-Ying Song; Rogier W Rooswinkel; Olaf van Tellingen; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel
Absence of both cytochrome P450 3A and P-glycoprotein dramatically increases docetaxel oral bioavailability and risk of intestinal toxicity.
Cancer research 2009;69(23):8996-9002.
2009: Nienke A de Vries; Jos H Beijnen; Olaf van Tellingen
High-grade glioma mouse models and their applicability for preclinical testing.
Cancer treatment reviews 2009;35(8):714-23.
2009: Robert A B van Waterschoot; Rogier W Rooswinkel; Rolf W Sparidans; Antonius E van Herwaarden; Jos H Beijnen; Alfred H Schinkel
Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(12):2305-13.
2009: Carola W N Damen; Jurjen S Lagas; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
The bioanalysis of vinorelbine and 4-O-deacetylvinorelbine in human and mouse plasma using high-performance liquid chromatography coupled with heated electrospray ionization tandem mass-spectrometry.
Biomedical chromatography : BMC 2009;23(12):1316-25.
2009: A G Lankheet; Michel J X Hillebrand; M H G Langenberg; Hilde Rosing; A D R Huitema; E E Voest; J H M Schellens; Jos H Beijnen
A validated assay for the quantitative analysis of vatalanib in human EDTA plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(29):3625-30.
2009: Dick Pluim; Jos H Beijnen; Jan H M Schellens; Olaf van Tellingen
Simultaneous determination of AZD1152 (prodrug) and AZD1152-hydroxyquinazoline pyrazol anilide by reversed phase liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(29):3549-55.
2009: Carola W N Damen; Weibin Chen; Asish B Chakraborty; Mike van Oosterhout; Jeffrey R Mazzeo; John C Gebler; Jan H M Schellens; Hilde Rosing; Jos H Beijnen
Electrospray ionization quadrupole ion-mobility time-of-flight mass spectrometry as a tool to distinguish the lot-to-lot heterogeneity in N-glycosylation profile of the therapeutic monoclonal antibody trastuzumab.
Journal of the American Society for Mass Spectrometry 2009;20(11):2021-33.
2009: S G L Quaak; J H van den Berg; K Oosterhuis; Jos H Beijnen; John B A G Haanen; Bastiaan Nuijen
DNA tattoo vaccination: effect on plasmid purity and transfection efficiency of different topoisoforms.
Journal of controlled release : official journal of the Controlled Release Society 2009;139(2):153-9.
2009: Robert Jansen; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Simultaneous quantification of 2',2'-difluorodeoxycytidine and 2',2'-difluorodeoxyuridine nucleosides and nucleotides in white blood cells using porous graphitic carbon chromatography coupled with tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2009;23(19):3040-50.
2009: Robert S Jansen; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Protein versus DNA as a marker for peripheral blood mononuclear cell counting.
Analytical and bioanalytical chemistry 2009;395(3):863-7.
2009: Carola W N Damen; Han Speijer; Wim T Hermens; Jan H M Schellens; Hilde Rosing; Jos H Beijnen
The bioanalysis of trastuzumab in human serum using precipitate-enhanced ellipsometry.
Analytical biochemistry 2009;393(1):73-9.
2009: Linda R Tulner; Hanna C van der Jagt-Willlems; Jos H Beijnen
Intoxication with trazodone caused by dirty facsimile machine.
Journal of the American Geriatrics Society 2009;57(9):1718-9.
2009: Stijn L W Koolen; Alwin D R Huitema; Robert S Jansen; Theo van Voorthuizen; Jos H Beijnen; Willem M Smit; Jan H M Schellens
Pharmacokinetics of gemcitabine and metabolites in a patient with double-sided nephrectomy: a case report and review of the literature.
The oncologist 2009;14(9):944-8.
2009: R ter Heine; M J X Hillebrand; H Rosing; Eric C M van Gorp; Jan W Mulder; Jos H Beijnen; Alwin D R Huitema
Identification and profiling of circulating metabolites of atazanavir, a HIV protease inhibitor.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(9):1826-40.
2009: Mariska van Vliet; Inès A von Rosenstiel; Roger K Schindhelm; D P M Brandjes; Jos H Beijnen; Michaela Diamant
Identifying the metabolic syndrome in obese children and adolescents: do age and definition matter?
Current clinical pharmacology 2009;4(3):233-8.
2009: Bas Teunissen; Hilde Rosing; R H T Koornstra; Sabine C Linn; J H M Schellens; Alfred H Schinkel; Jos H Beijnen
Development and validation of a quantitative assay for the analysis of tamoxifen with its four main metabolites and the flavonoids daidzein, genistein and glycitein in human serum using liquid chromatography coupled with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(24):2519-29.
2009: Carola W N Damen; Els R de Groot; Marianne Heij; David Boss; Jan H M Schellens; Hilde Rosing; Jos H Beijnen; Lucien A Aarden
Development and validation of an enzyme-linked immunosorbent assay for the quantification of trastuzumab in human serum and plasma.
Analytical biochemistry 2009;391(2):114-20.
2009: Linda R Tulner; Ingeborg M J A Kuper; Jos P C M van Campen; Cornelis H W Koks; Melvin R Mac Gillavry; Jos H Beijnen; D P M Brandjes
Treatment of hypertension in an elderly outpatient population in the Netherlands.
The American journal of geriatric pharmacotherapy 2009;7(4):204-9.
2009: David Boss; Jos H Beijnen; Jan H M Schellens
Clinical experience with aurora kinase inhibitors: a review.
The oncologist 2009;14(8):780-93.
2009: Judith Y M N Engwegen; Niven Mehra; John B A G Haanen; Jan H M Schellens; Emile E Voest; Jos H Beijnen
Identification of two new serum protein profiles for renal cell carcinoma.
Oncology reports 2009;22(2):401-8.
2009: Marie-Christine W Gast; Eric J van Dulken; Thea K G van Loenen; Florine Kingma-Vegter; Johan Westerga; Claudie C Flohil; Jaco C Knol; Connie R Jimenez; Carla H van Gils; Lodewyk F A Wessels; Jan H N Schellens; Jos H Beijnen
Detection of breast cancer by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry tissue and serum protein profiling.
The International journal of biological markers 2009;24(3):130-41.
2009: Jeroen J M A Hendrikx; Jos H Beijnen; Jan H M Schellens
Methylnaltrexone.
The oncologist 2009;14(7):679-82.
2009: David Boss; Wandena S Siegel-Lakhai; Nadja E van Egmond-Schoemaker; Dick Pluim; Hilde Rosing; Wim W ten Bokkel Huinink; Jos H Beijnen; Jan H M Schellens
Phase I pharmacokinetic and pharmacodynamic study of Carboplatin and topotecan administered intravenously every 28 days to patients with malignant solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(13):4475-83.
2009: Marie-Christine W Gast; Carla H van Gils; Lodewyk Wessels; Nathan Harris; Johannes M G Bonfrer; Emiel J Th Rutgers; Jan H M Schellens; Jos H Beijnen
Serum protein profiling for diagnosis of breast cancer using SELDI-TOF MS.
Oncology reports 2009;22(1):205-13.
2009: Marie-Christine W Gast; Jan H M Schellens; Jos H Beijnen
Clinical proteomics in breast cancer: a review.
Breast cancer research and treatment 2009;116(1):17-29.
2009: Roos L Oostendorp; Alwin D R Huitema; Hilde Rosing; Robert Jansen; Rob ter Heine; Marianne Keessen; Jos H Beijnen; Jan H M Schellens
Coadministration of ritonavir strongly enhances the apparent oral bioavailability of docetaxel in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(12):4228-33.
2009: Carola W N Damen; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Application of dried blood spots combined with high-performance liquid chromatography coupled with electrospray ionisation tandem mass spectrometry for simultaneous quantification of vincristine and actinomycin-D.
Analytical and bioanalytical chemistry 2009;394(4):1171-82.
2009: Corine Ekhart; Sjoerd Rodenhuis; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Carboplatin dosing in overweight and obese patients with normal renal function, does weight matter?
Cancer chemotherapy and pharmacology 2009;64(1):115-22.
2009: S Harmsen; Irma Meijerman; Jos H Beijnen; J H M Schellens
Nuclear receptor mediated induction of cytochrome P450 3A4 by anticancer drugs: a key role for the pregnane X receptor.
Cancer chemotherapy and pharmacology 2009;64(1):35-43.
2009: Linda R Tulner; Suzanne V Frankfort; Floor Wesselius; Jos P C M van Campen; Cornelis H W Koks; Jos H Beijnen
Do geriatric outpatients adhere to medication changes advised after assessment? An exploratory pilot study.
Current clinical pharmacology 2009;4(2):154-8.
2009: mariska van vliet; Inès A von Rosenstiel; Roger K Schindhelm; Desiderius P M Brandjes; Jos H Beijnen; Michaela Diamant
The association of elevated alanine aminotransferase and the metabolic syndrome in an overweight and obese pediatric population of multi-ethnic origin.
European journal of pediatrics 2009;168(5):585-91.
2009: Robert S Jansen; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Retention studies of 2'-2'-difluorodeoxycytidine and 2'-2'-difluorodeoxyuridine nucleosides and nucleotides on porous graphitic carbon: development of a liquid chromatography-tandem mass spectrometry method.
Journal of chromatography. A 2009;1216(15):3168-74.
2009: Linda R Tulner; Ingeborg M J A Kuper; Suzanne V Frankfort; Jos P C M van Campen; Cornelis H W Koks; Desiderius P M Brandjes; Jos H Beijnen
Discrepancies in reported drug use in geriatric outpatients: relevance to adverse events and drug-drug interactions.
The American journal of geriatric pharmacotherapy 2009;7(2):93-104.
2009: Jurjen S Lagas; Robert A B van Waterschoot; Vicky A C J van Tilburg; Michel J X Hillebrand; Nienke Lankheet; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel
Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(7):2344-51.
2009: Roos L Oostendorp; Evita van de Steeg; Cornelia M M van der Kruijssen; Jos H Beijnen; Kathryn E Kenworthy; Alfred H Schinkel; Jan H M Schellens
Organic anion-transporting polypeptide 1B1 mediates transport of Gimatecan and BNP1350 and can be inhibited by several classic ATP-binding cassette (ABC) B1 and/or ABCG2 inhibitors.
Drug metabolism and disposition: the biological fate of chemicals 2009;37(4):917-23.
2009: Roos L Oostendorp; Jos H Beijnen; Jan H M Schellens
The biological and clinical role of drug transporters at the intestinal barrier.
Cancer treatment reviews 2009;35(2):137-47.
2009: Ron J Keizer; Miren K Zamacona; Mendel Jansen; David Critchley; Jantien Wanders; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Application of population pharmacokinetic modeling in early clinical development of the anticancer agent E7820.
Investigational new drugs 2009;27(2):140-52.
2009: Joost H van den Berg; Bastiaan Nujien; Jos H Beijnen; Andrew Vincent; Harm van Tinteren; Jörn Kluge; Leonie A E Woerdeman; Wim E Hennink; Gert Storm; Schumacher Ton; John B A G Haanen
Optimization of intradermal vaccination by DNA tattooing in human skin.
Human gene therapy 2009;20(3):181-9.
2009: Roos L Oostendorp; J Loftiss; SANJAY GOEL; D A Smith; M M Dar; Petronella O Witteveen; R B Cohen; L D Lewis; S Kurian; A Patnaik; Hilde Rosing; Jos H Beijnen; Emile E Voest; H Burris
Bioequivalence study of a new oral topotecan formulation, relative to the current topotecan formulation, in patients with advanced solid tumors.
International journal of clinical pharmacology and therapeutics 2009;47(3):195-206.
2009: Carola W N Damen; Trijn Israëls; Huib N Caron; Jan H M Schellens; Hilde Rosing; Jos H Beijnen
Validated assay for the simultaneous quantification of total vincristine and actinomycin-D concentrations in human EDTA plasma and of vincristine concentrations in human plasma ultrafiltrate by high-performance liquid chromatography coupled with tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2009;23(6):763-74.
2009: S G L Quaak; Bastiaan Nuijen; John B A G Haanen; Jos H Beijnen
Development and validation of an anion-exchange LC-UV method for the quantification and purity determination of the DNA plasmid pDERMATT.
Journal of pharmaceutical and biomedical analysis 2009;49(2):282-8.
2009: R Ter Heine; Hilde Rosing; Eric C M van Gorp; Jan W Mulder; Jos H Beijnen; Alwin D R Huitema
Quantification of etravirine (TMC125) in plasma, dried blood spots and peripheral blood mononuclear cell lysate by liquid chromatography tandem mass spectrometry.
Journal of pharmaceutical and biomedical analysis 2009;49(2):393-400.
2009: R ter Heine; M Davids; Hilde Rosing; Eric C M van Gorp; Jan W Mulder; Y T van der Heide; Jos H Beijnen; Alwin D R Huitema
Quantification of HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in peripheral blood mononuclear cell lysate using liquid chromatography coupled with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(5-6):575-80.
2009: Ly Tran; Joke W Baars; Harry J Maessen; Cornelis A Hoefnagel; Jos H Beijnen; Alwin D R Huitema
A simple and safe method for 131I radiolabeling of rituximab for myeloablative high-dose radioimmunotherapy.
Cancer biotherapy & radiopharmaceuticals 2009;24(1):103-10.
2009: Anthe S Zandvliet; Jan H M Schellens; William Copalu; Jos H Beijnen; Alwin D R Huitema
Covariate-based dose individualization of the cytotoxic drug indisulam to reduce the risk of severe myelosuppression.
Journal of pharmacokinetics and pharmacodynamics 2009;36(1):39-62.
2009: Corine Ekhart; Sjoerd Rodenhuis; Jos H Beijnen; Alwin D R Huitema
Pharmacokinetics of cyclophosphamide and thiotepa in a conventional fractionated high-dose regimen compared with a novel simplified unfractionated regimen.
Therapeutic drug monitoring 2009;31(1):95-103.
2009: Corine Ekhart; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment.
Cancer treatment reviews 2009;35(1):18-31.
2009: Rolf W Sparidans; Maria L H Vlaming; Jurjen S Lagas; Alfred H Schinkel; Jan H M Schellens; Jos H Beijnen
Liquid chromatography-tandem mass spectrometric assay for sorafenib and sorafenib-glucuronide in mouse plasma and liver homogenate and identification of the glucuronide metabolite.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2009;877(3):269-76.
2009: S Nilgün Cömezoğlu; Van T Ly; Donglu Zhang; W Griffith Humphreys; Samuel J Bonacorsi; Donald W Everett; Marvin B Cohen; Jinping Gan; Jan H Beumer; Jos H Beijnen; H M Schellens; Graham Lappin
Biotransformation profiling of [(14)C]ixabepilone in human plasma, urine and feces samples using accelerator mass spectrometry (AMS).
Drug metabolism and pharmacokinetics 2009;24(6):511-22.
2009: Ly Tran; Jos H Beijnen; Alwin D R Huitema
The preparation of radiolabeled monoclonal antibodies for human use.
Human antibodies 2009;18(4):145-56.
2009: Carola W N Damen; Jan H M Schellens; Jos H Beijnen
Bioanalytical methods for the quantification of therapeutic monoclonal antibodies and their application in clinical pharmacokinetic studies.
Human antibodies 2009;18(3):47-73.
2009: Rob ter Heine; Alwin D R Huitema; Robert S Jansen; Paul Hm Smits; Eric C M van Gorp; Jiri Fp Wagenaar; Jos H Beijnen; Jan W Mulder
Prolonged exposure to tenofovir monotherapy 1 month after treatment discontinuation because of tenofovir-related renal failure.
Antiviral therapy 2009;14(2):299-301.
2009: Marie-Christine W Gast; Carla H van Gils; Lodewyk F A Wessels; Nathan Harris; Johannes M G Bonfrer; Emiel J Th Rutgers; Jan H M Schellens; Jos H Beijnen
Influence of sample storage duration on serum protein profiles assessed by surface-enhanced laser desorption/ionisation time-of-flight mass spectrometry (SELDI-TOF MS).
Clinical chemistry and laboratory medicine : CCLM / FESCC 2009;47(6):694-705.
2009: E E M Brouwers; Alwin D R Huitema; Willem Boogerd; Jos H Beijnen; Jan H M Schellens
Persistent neuropathy after treatment with cisplatin and oxaliplatin.
Acta oncologica (Stockholm, Sweden) 2009;48(6):832-41.
2009: mariska van vliet; Inès A von Rosenstiel; Roger K Schindhelm; Desiderius P M Brandjes; Jos H Beijnen; Michaela Diamant
Ethnic differences in cardiometabolic risk profile in an overweight/obese paediatric cohort in the Netherlands: a cross-sectional study.
Cardiovascular diabetology 2009;8():2.
2009: Annemieke W J van Winden; Marie-Christine W Gast; Jos H Beijnen; Emiel J Th Rutgers; Diederick Grobbee; Petra Peeters; Carla H van Gils
Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study.
BMC medical genomics 2009;2():4.
2009: Jan Handrick Beumer; L Lopez-Lazaro; Jan H M Schellens; Jos H Beijnen; Olaf van Tellingen
Evaluation of human plasma protein binding of trabectedin (Yondelis, ET-743).
Current clinical pharmacology 2009;4(1):38-42.
2009: Corine Ekhart; Valerie D Doodeman; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
British journal of clinical pharmacology 2009;67(1):50-60.
2009: E E M Brouwers; M Söhne; S Kuipers; Eric C M van Gorp; J H M Schellens; Cornelis H W Koks; Jos H Beijnen; Alwin D R Huitema
Ciprofloxacin strongly inhibits clozapine metabolism: two case reports.
Clinical drug investigation 2009;29(1):59-63.
2009: Corine Ekhart; J Martijn Kerst; Sjoerd Rodenhuis; Jos H Beijnen; Alwin D R Huitema
Altered cyclophosphamide and thiotepa pharmacokinetics in a patient with moderate renal insufficiency.
Cancer chemotherapy and pharmacology 2009;63(2):375-9.
2008: Stephan A Veltkamp; Els O Witteveen; Angela Capriati; Attilio Crea; Fabio Animati; Marja Voogel-Fuchs; Ingeborg J G M van den Heuvel; Jos H Beijnen; Emile E Voest; Jan H M Schellens
Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(22):7535-44.
2008: Corine Ekhart; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Relations between polymorphisms in drug-metabolising enzymes and toxicity of chemotherapy with cyclophosphamide, thiotepa and carboplatin.
Pharmacogenetics and genomics 2008;18(11):1009-15.
2008: Maarten J Deenen; Jos H Beijnen; Jan H M Schellens
Is fluorouracil-induced severe toxicity in DPYD*2A individuals related to sex or to treatment regimen?
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(30):4997-8; author reply 4998-9.
2008: Jos H Beijnen; Sabien C van der Schoot; Bastiaan Nuijen; Frits M Flesch; A Gore; Dorla Mirejovsky; Luigi Lenaz
Complexation study of the anticancer agent EO-9 with 2-hydroxypropyl-beta-cyclodextrin.
Drug development and industrial pharmacy 2008;34(10):1130-9.
2008: Anthe S Zandvliet; Jan H M Schellens; Christian Dittrich; Jantien Wanders; Jos H Beijnen; Alwin D R Huitema
Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin.
British journal of clinical pharmacology 2008;66(4):485-97.
2008: S G L Quaak; J H van den Berg; Mireille Toebes; Schumacher Ton; John B A G Haanen; Jos H Beijnen; Bastiaan Nuijen
GMP production of pDERMATT for vaccination against melanoma in a phase I clinical trial.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft für Pharmazeutische Verfahrenstechnik e.V 2008;70(2):429-38.
2008: Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer.
Cancer treatment reviews 2008;34(6):505-20.
2008: Suzanne V Frankfort; Jos P C M van Campen; Linda R Tulner; Jos H Beijnen
Serum amyloid beta peptides in patients with dementia and age-matched non-demented controls as detected by surface-enhanced laser desorption ionisation-time of flight mass spectrometry (SELDI-TOF MS).
Current clinical pharmacology 2008;3(3):144-54.
2008: Irene van den Broek; Rolf W Sparidans; Jan H M Schellens; Jos H Beijnen
Liquid chromatography/tandem mass spectrometric method for the quantification of eight proteolytic fragments of ITIH4 with biomarker potential in human plasma and serum.
Rapid communications in mass spectrometry : RCM 2008;22(18):2915-28.
2008: Irene van den Broek; Rolf W Sparidans; Jan H M Schellens; Jos H Beijnen
Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;872(1-2):1-22.
2008: Rolf W Sparidans; Jurjen S Lagas; Alfred H Schinkel; Jan H M Schellens; Jos H Beijnen
Liquid chromatography-tandem mass spectrometric assay for diclofenac and three primary metabolites in mouse plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;872(1-2):77-82.
2008: Stephan A Veltkamp; Dick Pluim; Monique van Eijndhoven; Maria J Bolijn; Felix H G Ong; Rajgopal Govindarajan; Jashvant D Unadkat; Jos H Beijnen; Jan H M Schellens
New insights into the pharmacology and cytotoxicity of gemcitabine and 2',2'-difluorodeoxyuridine.
Molecular cancer therapeutics 2008;7(8):2415-25.
2008: Serena Marchetti; Nienke A de Vries; Tessa Buckle; Maria J Bolijn; Monique van Eijndhoven; Jos H Beijnen; Roberto Mazzanti; Olaf van Tellingen; Jan H M Schellens
Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice.
Molecular cancer therapeutics 2008;7(8):2280-7.
2008: Thomas Dorlo; Pieter P A M van Thiel; Alwin D R Huitema; Ron J Keizer; Henry J C de Vries; Jos H Beijnen; Peter de Vries
Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.
Antimicrobial agents and chemotherapy 2008;52(8):2855-60.
2008: Stephan A Veltkamp; Dick Pluim; Olaf van Tellingen; Jos H Beijnen; Jan H M Schellens
Extensive metabolism and hepatic accumulation of gemcitabine after multiple oral and intravenous administration in mice.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(8):1606-15.
2008: E E M Brouwers; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
The effects of sulfur-containing compounds and gemcitabine on the binding of cisplatin to plasma proteins and DNA determined by inductively coupled plasma mass spectrometry and high performance liquid chromatography-inductively coupled plasma mass spectrometry.
Anti-cancer drugs 2008;19(6):621-30.
2008: Natalie M G M Appels; M J Bolijn; K Chan; T C Stephens; G Hoctin-Boes; M Middleton; Jos H Beijnen; J S de Bono; A L Harris; J H M Schellens
Phase I pharmacokinetic and pharmacodynamic study of the prenyl transferase inhibitor AZD3409 in patients with advanced cancer.
British journal of cancer 2008;98(12):1951-8.
2008: Judith Y M N Engwegen; Marieke Alberts; Jaco C Knol; Connie R Jimenez; Annekatrien C T M Depla; Henriëtte Tuynman; Henk A van Heukelem; Pleun Snel; Marianne E Smits; Annemieke Cats; Jan H M Schellens; Jos H Beijnen
Influence of variations in sample handling on SELDI-TOF MS serum protein profiles for colorectal cancer.
Proteomics. Clinical applications 2008;2(6):936-45.
2008: Judith Ymn Derijks-Engwegen; Annemieke Cats; Marianne E Smits; Jan Hm Schellens; Jos H Beijnen
Improving colorectal cancer management: the potential of proteomics.
Biomarkers in medicine 2008;2(3):253-89.
2008: Gert Jan Timmers; Lonneke W Kessels; Abraham Wilhelm; Agnes I Veldkamp; Tessa M Bosch; Jos H Beijnen; Peter C Huijgens
Effects of cyclosporine a on single-dose pharmacokinetics of intravenous itraconazole in patients with hematologic malignancies.
Therapeutic drug monitoring 2008;30(3):301-5.
2008: Stephan A Veltkamp; Robert Jansen; Sophie Callies; Dick Pluim; Carla M Visseren-Grul; Hilde Rosing; Susanne Kloeker-Rhoades; Valerie A M Andre; Jos H Beijnen; Christopher A Slapak; Jan H M Schellens
Oral administration of gemcitabine in patients with refractory tumors: a clinical and pharmacologic study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(11):3477-86.
2008: Carola W N Damen; Hilde Rosing; Matthijs M Tibben; Maria J van Maanen; Jurjen S Lagas; Alfred H Schinkel; Jan H M Schellens; Jos H Beijnen
A sensitive assay for the quantitative analysis of vinorelbine in mouse and human EDTA plasma by high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;868(1-2):102-9.
2008: Corine Ekhart; Valerie D Doodeman; Sjoerd Rodenhuis; Paul H M Smits; Jos H Beijnen; Alwin D R Huitema
Influence of polymorphisms of drug metabolizing enzymes (CYP2B6, CYP2C9, CYP2C19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide.
Pharmacogenetics and genomics 2008;18(6):515-23.
2008: S Harmsen; Andries Koster; Jos H Beijnen; J H M Schellens; Irma Meijerman
Comparison of two immortalized human cell lines to study nuclear receptor-mediated CYP3A4 induction.
Drug metabolism and disposition: the biological fate of chemicals 2008;36(6):1166-71.
2008: Anthe S Zandvliet; Wandena S Siegel-Lakhai; Jos H Beijnen; William Copalu; M-C Etienne-Grimaldi; G Milano; J H M Schellens; Alwin D R Huitema
PK/PD model of indisulam and capecitabine: interaction causes excessive myelosuppression.
Clinical pharmacology and therapeutics 2008;83(6):829-39.
2008: Rob ter Heine; Hilde Rosing; Eric C M van Gorp; Jan W Mulder; W A van der Steeg; Jos H Beijnen; Alwin D R Huitema
Quantification of protease inhibitors and non-nucleoside reverse transcriptase inhibitors in dried blood spots by liquid chromatography-triple quadrupole mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;867(2):205-12.
2008: Suzanne V Frankfort; Linda R Tulner; Jos P C M van Campen; Marcel M Verbeek; René W M M Jansen; Jos H Beijnen
Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.
Current clinical pharmacology 2008;3(2):123-31.
2008: E E M Brouwers; Matthijs M Tibben; Dick Pluim; Hilde Rosing; H Boot; A Cats; J H M Schellens; Jos H Beijnen
Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin.
Analytical and bioanalytical chemistry 2008;391(2):577-85.
2008: Wandena S Siegel-Lakhai; Anthe S Zandvliet; Alwin D R Huitema; Matthijs M Tibben; G Milano; V Girre; V Diéras; A King; E Richmond; Jantien Wanders; Jos H Beijnen; J H M Schellens
A dose-escalation study of indisulam in combination with capecitabine (Xeloda) in patients with solid tumours.
British journal of cancer 2008;98(8):1320-6.
2008: Thomas Dorlo; Michel J X Hillebrand; Hilde Rosing; Teunis A Eggelte; Peter de Vries; Jos H Beijnen
Development and validation of a quantitative assay for the measurement of miltefosine in human plasma by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2008;865(1-2):55-62.
2008: Eelco de Bree; Hilde Rosing; Dimitris Filis; John Romanos; Maria Melisssourgaki; Markos Daskalakis; Maria Pilatou; Elias Sanidas; Panagiotis Taflampas; Konstantinos Kalbakis; Jos H Beijnen; Dimitris D Tsiftsis
Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study.
Annals of surgical oncology 2008;15(4):1183-92.
2008: Stephan A Veltkamp; Jos H Beijnen; Jan H M Schellens
Prolonged versus standard gemcitabine infusion: translation of molecular pharmacology to new treatment strategy.
The oncologist 2008;13(3):261-76.
2008: Elke E M Brouwers; Matthijs Tibben; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
The application of inductively coupled plasma mass spectrometry in clinical pharmacological oncology research.
Mass spectrometry reviews 2008;27(2):67-100.
2008: Jurjen S Lagas; Rolf W Sparidans; Robert A B van Waterschoot; Els Wagenaar; Jos H Beijnen; Alfred H Schinkel
P-glycoprotein limits oral availability, brain penetration, and toxicity of an anionic drug, the antibiotic salinomycin.
Antimicrobial agents and chemotherapy 2008;52(3):1034-9.
2008: Robert A B van Waterschoot; Antonius E van Herwaarden; Jurjen S Lagas; Rolf W Sparidans; Els Wagenaar; Cornelia M M van der Kruijssen; Joyce A Goldstein; Darryl C Zeldin; Jos H Beijnen; Alfred H Schinkel
Midazolam metabolism in cytochrome P450 3A knockout mice can be attributed to up-regulated CYP2C enzymes.
Molecular pharmacology 2008;73(3):1029-36.
2008: Carola W N Damen; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Quantitative aspects of the analysis of the monoclonal antibody trastuzumab using high-performance liquid chromatography coupled with electrospray mass spectrometry.
Journal of pharmaceutical and biomedical analysis 2008;46(3):449-55.
2008: Marie-Christine W Gast; Harm van Tinteren; Marijke Bontenbal; René Q G C M van Hoesel; Marianne A Nooij; Sjoerd Rodenhuis; Paul N Span; Vivianne C G Tjan-Heijnen; Elisabeth G E de Vries; Nathan Harris; Jos W R Twisk; Jan H M Schellens; Jos H Beijnen
Haptoglobin phenotype is not a predictor of recurrence free survival in high-risk primary breast cancer patients.
BMC cancer 2008;8():389.
2008: Rob ter Heine; Henriette J Scherpbier; Kristel M L Crommentuyn; Vincent Bekker; Jos H Beijnen; Taco W Kuijpers; Alwin D R Huitema
A pharmacokinetic and pharmacogenetic study of efavirenz in children: dosing guidelines can result in subtherapeutic concentrations.
Antiviral therapy 2008;13(6):779-87.
2008: E E M Brouwers; Alwin D R Huitema; Jos H Beijnen; Jan H M Schellens
Long-term platinum retention after treatment with cisplatin and oxaliplatin.
BMC clinical pharmacology 2008;8():7.
2008: Anthe S Zandvliet; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Population pharmacokinetics and pharmacodynamics for treatment optimization in clinical oncology.
Clinical pharmacokinetics 2008;47(8):487-513.
2008: Dorien W Voskuil; Alina Vrieling; Catharina M Korse; Jos H Beijnen; Johannes M G Bonfrer; Jaap van Doorn; Reinie Kaas; Hester S A Oldenburg; Nicola S Russell; E J Th Rutgers; Senno Verhoef; Flora E van Leeuwen; Laura J van't Veer; Matti A Rookus
Effects of lycopene on the insulin-like growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk.
Nutrition and cancer 2008;60(3):342-53.
2008: Linda R Tulner; Suzanne V Frankfort; George J P T Gijsen; Jos P C M van Campen; Cornelis H W Koks; Jos H Beijnen
Drug-drug interactions in a geriatric outpatient cohort: prevalence and relevance.
Drugs & aging 2008;25(4):343-55.
2008: Wouter Meuleman; Judith Y M N Engwegen; Marie-Christine W Gast; Jos H Beijnen; Marcel J T Reinders; Lodewyk F A Wessels
Comparison of normalisation methods for surface-enhanced laser desorption and ionisation (SELDI) time-of-flight (TOF) mass spectrometry data.
BMC bioinformatics 2008;9():88.
2008: David Boss; Renato Valdes Olmos; Michiel Sinaasappel; Jos H Beijnen; Jan H M Schellens
Application of PET/CT in the development of novel anticancer drugs.
The oncologist 2008;13(1):25-38.
2008: Marie-Christine W Gast; Judith Y M N Engwegen; Jan Hm Schellens; Jos H Beijnen
Comparing the old and new generation SELDI-TOF MS: implications for serum protein profiling.
BMC medical genomics 2008;1():4.
2008: Liia D Vainchtein; Hilde Rosing; Dorla Mirejovsky; Van Huynh; Luigi Lenaz; Jan H M Schellens; Jos H Beijnen
Enhanced resolution triple-quadrupole mass spectrometry for ultra-sensitive and quantitative analysis of the investigational anticancer agent EO9 (apaziquone) and its metabolite EO5a in human and dog plasma to support (pre)-clinical studies of EOquin given intravesically.
Rapid communications in mass spectrometry : RCM 2008;22(4):462-70.
2007: Serena Marchetti; Roos L Oostendorp; Dick Pluim; Monique van Eijndhoven; Olaf van Tellingen; Alfred H Schinkel; Richard Versace; Jos H Beijnen; Roberto Mazzanti; Jan H Schellens
In vitro transport of gimatecan (7-t-butoxyiminomethylcamptothecin) by breast cancer resistance protein, P-glycoprotein, and multidrug resistance protein 2.
Molecular cancer therapeutics 2007;6(12 Pt 1):3307-13.
2007: Antonius E van Herwaarden; Els Wagenaar; Cornelia M M van der Kruijssen; Robert A B van Waterschoot; Johan W Smit; Ji-Ying Song; Martin van der Valk; Olaf van Tellingen; José W A van der Hoorn; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel
Knockout of cytochrome P450 3A yields new mouse models for understanding xenobiotic metabolism.
The Journal of clinical investigation 2007;117(11):3583-92.
2007: Nienke A de Vries; Jin Zhao; Emily Kroon; Tessa Buckle; Jos H Beijnen; Olaf van Tellingen
P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6440-9.
2007: Markus Joerger; Alwin D R Huitema; Dick J Richel; Christian Dittrich; Nicholas Pavlidis; Evangelos Briasoulis; Jan B Vermorken; Elena Strocchi; Andrea Martoni; Roberto Sorio; Henk P Sleeboom; Miguel A Izquierdo; Duncan I Jodrell; Hilary Calvert; Alan V Boddy; Harry Hollema; Regine Féty; Wjf J F Van der Vijgh; Georg Hempel; Etienne Chatelut; Mats Karlsson; Justin Wilkins; Brigitte Tranchand; Ad H G J Schrijvers; Chris Twelves; Jos H Beijnen; Jan H M Schellens
Population pharmacokinetics and pharmacodynamics of paclitaxel and carboplatin in ovarian cancer patients: a study by the European organization for research and treatment of cancer-pharmacology and molecular mechanisms group and new drug development group.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(21):6410-8.
2007: Markus Joerger; Alwin D R Huitema; manon huizing; P H B Willemse; A de Graeff; Hilde Rosing; J H M Schellens; Jos H Beijnen; Jan B Vermorken
Safety and pharmacology of paclitaxel in patients with impaired liver function: a population pharmacokinetic-pharmacodynamic study.
British journal of clinical pharmacology 2007;64(5):622-33.
2007: Nienke A de Vries; Mariët Ouwehand; Tessa Buckle; Jos H Beijnen; Olaf van Tellingen
Determination of topotecan in human and mouse plasma and in mouse tissue homogenates by reversed-phase high-performance liquid chromatography.
Biomedical chromatography : BMC 2007;21(11):1191-200.
2007: Stephan A Veltkamp; Hilde Rosing; Alwin D R Huitema; M R Fetell; A Nol; Jos H Beijnen; J H M Schellens
Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours.
Cancer chemotherapy and pharmacology 2007;60(5):635-42.
2007: Liia D Vainchtein; Hilde Rosing; Armin Maier; Heinz-Herbert Fiebig; Jan H M Schellens; Jos H Beijnen
Quantitative and selective assay of 5-methylindirubine, an inhibitor of cyclin-dependent kinases, in murine plasma using coupled liquid chromatography and electrospray tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;856(1-2):261-6.
2007: Mario Campone; Jeany M Rademaker-Lakhai; Jaafar Bennouna; Stephen B Howell; David Nowotnik; Jos H Beijnen; Jan H M Schellens
Phase I and pharmacokinetic trial of AP5346, a DACH-platinum-polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients.
Cancer chemotherapy and pharmacology 2007;60(4):523-33.
2007: Rolf W Sparidans; Jurjen S Lagas; Afred H Schinkel; Jan H M Schellens; Jos H Beijnen
Liquid chromatography-tandem mass spectrometric assays for salinomycin in mouse plasma, liver, brain and small intestinal contents and in OptiMEM cell culture medium.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;855(2):200-10.
2007: Serena Marchetti; Roberto Mazzanti; Jos H Beijnen; Jan H M Schellens
Concise review: Clinical relevance of drug drug and herb drug interactions mediated by the ABC transporter ABCB1 (MDR1, P-glycoprotein).
The oncologist 2007;12(8):927-41.
2007: Wandena S Siegel-Lakhai; Jos H Beijnen; Walter L Vervenne; Henk Boot; Marianne Keessen; Melissa Versola; Kevin M Koch; Deborah A Smith; Lini Pandite; Dick J Richel; Jan H M Schellens
Phase I pharmacokinetic study of the safety and tolerability of lapatinib (GW572016) in combination with oxaliplatin/fluorouracil/leucovorin (FOLFOX4) in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 1):4495-502.
2007: Jeany M Rademaker-Lakhai; Laurens V Beerepoot; Niven Mehra; Sandra A Radema; Rianne van Maanen; Joost S Vermaat; Els O Witteveen; Carla M Visseren-Grul; Luna Musib; Nathan Enas; Gertjan van Hal; Jos H Beijnen; Jan H M Schellens; Emile E Voest
Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 1):4474-81.
2007: Koen van de Wetering; Noam Zelcer; Annemieke Kuil; Wouter Feddema; Michel J X Hillebrand; Maria L H Vlaming; Alfred H Schinkel; Jos H Beijnen; Piet Borst
Multidrug resistance proteins 2 and 3 provide alternative routes for hepatic excretion of morphine-glucuronides.
Molecular pharmacology 2007;72(2):387-94.
2007: E E M Brouwers; Alwin D R Huitema; E N Bakker; J W Douma; K J M Schimmel; G van Weringh; P J de Wolf; J H M Schellens; Jos H Beijnen
Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry.
International archives of occupational and environmental health 2007;80(8):689-99.
2007: Jan-Hendrik Beumer; R C Garner; M B Cohen; S Galbraith; G F Duncan; T Griffin; Jos H Beijnen; J H M Schellens
Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry.
Investigational new drugs 2007;25(4):327-34.
2007: Irene van den Broek; Rolf W Sparidans; Jan H M Schellens; Jos H Beijnen
Enzymatic digestion as a tool for the LC-MS/MS quantification of large peptides in biological matrices: measurement of chymotryptic fragments from the HIV-1 fusion inhibitor enfuvirtide and its metabolite M-20 in human plasma.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;854(1-2):245-59.
2007: Corine Ekhart; Abadi Gebretensae; Hilde Rosing; Sjoerd Rodenhuis; Jos H Beijnen; Alwin D R Huitema
Simultaneous quantification of cyclophosphamide and its active metabolite 4-hydroxycyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry (LC-MS/MS).
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2007;854(1-2):345-9.
2007: Roos L Oostendorp; Jos H Beijnen; Jan H M Schellens; Olaf van Tellingen
Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography.
Biomedical chromatography : BMC 2007;21(7):747-54.
2007: Isa E L M Kuppens; Els O Witteveen; Roxanne C Jewell; Sandra A Radema; Elaine M Paul; Steve G Mangum; Jos H Beijnen; Emile E Voest; Jan H M Schellens
A phase I, randomized, open-label, parallel-cohort, dose-finding study of elacridar (GF120918) and oral topotecan in cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(11):3276-85.
2007: S Harmsen; Irma Meijerman; Jos H Beijnen; J H M Schellens
The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology.
Cancer treatment reviews 2007;33(4):369-80.
2007: Rolf W Sparidans; Jan M Prins; Jan H M Schellens; Jos H Beijnen
Liquid chromatography-tandem mass spectrometric assay for the nucleoside reverse transcriptase inhibitor emtricitabine in human plasma.
Biomedical chromatography : BMC 2007;21(6):621-7.
2007: johan jonker; Sandra Musters; Maria L H Vlaming; Torsten Plösch; Karin E R Gooijert; Michel J X Hillebrand; Hilde Rosing; Jos H Beijnen; Henkjan J Verkade; Alfred H Schinkel
Breast cancer resistance protein (Bcrp1/Abcg2) is expressed in the harderian gland and mediates transport of conjugated protoporphyrin IX.
American journal of physiology. Cell physiology 2007;292(6):C2204-12.
2007: Isa E L M Kuppens; Petronella O Witteveen; Margaret Schot; V M Schuessler; A Daehling; Jos H Beijnen; Emile E Voest; J H M Schellens
Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors.
Investigational new drugs 2007;25(3):227-35.
2007: Anthe S Zandvliet; Alwin D R Huitema; William Copalu; Yasuhide Yamada; Tomohide Tamura; Jos H Beijnen; Jan H M Schellens
CYP2C9 and CYP2C19 polymorphic forms are related to increased indisulam exposure and higher risk of severe hematologic toxicity.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(10):2970-6.
2007: Roos L Oostendorp; Serena Marchetti; Jos H Beijnen; Roberto Mazzanti; Jan H M Schellens
The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate.
Cancer chemotherapy and pharmacology 2007;59(6):855-60.
2007: Suzanne V Frankfort; Bregje A Appels; Anthonius de Boer; Linda R Tulner; Jos P C M van Campen; Cornelis H W Koks; Jos H Beijnen; B A Schmand
Identification of responders and reactive domains to rivastigmine in Alzheimer's disease.
Pharmacoepidemiology and drug safety 2007;16(5):545-51.
2007: Jan-Hendrik Beumer; Jeany M Rademaker-Lakhai; Hilde Rosing; Michel J X Hillebrand; Tessa M Bosch; Luis Lopez-Lazaro; Jan H M Schellens; Jos H Beijnen
Metabolism of trabectedin (ET-743, Yondelis) in patients with advanced cancer.
Cancer chemotherapy and pharmacology 2007;59(6):825-37.
2007: Sabien C van der Schoot; Bastiaan Nuijen; Alwin D R Huitema; Jos H Beijnen
Assessment of performance of manufacturing procedures in a unit for production of investigational anticancer agents, using a mixed effects analysis.
Pharmaceutical research 2007;24(3):605-12.
2007: Tessa M Bosch; Irma Meijerman; Jos H Beijnen; S W van Thiel; L T Vlasveld
Lethal toxicity of uracil/tegafur in the treatment of sigmoid carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(3):607-8.
2007: Judith Y M N Engwegen; Niven Mehra; John B A G Haanen; Johannes M G Bonfrer; Jan H M Schellens; Emile E Voest; Jos H Beijnen
Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations.
Laboratory investigation; a journal of technical methods and pathology 2007;87(2):161-72.
2007: Antonius E van Herwaarden; Els Wagenaar; Gracia Merino; johan jonker; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel
Multidrug transporter ABCG2/breast cancer resistance protein secretes riboflavin (vitamin B2) into milk.
Molecular and cellular biology 2007;27(4):1247-53.
2007: Sabien C van der Schoot; Liia D Vainchtein; Jos H Beijnen; A Gore; Dorla Mirejovsky; Luigi Lenaz; Bastiaan Nuijen
EO-9 bladder instillations: formulation selection based on stability characteristics and in vitro simulation studies.
International journal of pharmaceutics 2007;329(1-2):135-41.
2007: Esther F A Brandon; Rolf W Sparidans; Ronald D van Ooijen; Irma Meijerman; Luis Lopez Lazaro; Ignasio Manzanares; Jos H Beijnen; Jan H M Schellens
In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug.
Investigational new drugs 2007;25(1):9-19.
2007: Jan-Hendrik Beumer; Tessa Buckle; Mariët Ouwehand; Niels E F Franke; Luis Lopez-Lazaro; Jan H M Schellens; Jos H Beijnen; Olaf van Tellingen
Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype.
Investigational new drugs 2007;25(1):1-7.
2007: Liia D Vainchtein; Hilde Rosing; Dorla Mirejovsky; Luigi Lenaz; Jan H M Schellens; Jos H Beijnen
Stability experiments in human urine with EO9 (apaziquone): a novel anticancer agent for the intravesical treatment of bladder cancer.
Journal of pharmaceutical and biomedical analysis 2007;43(1):285-92.
2007: Markus Joerger; Alwin D R Huitema; Dick J Richel; Christian Dittrich; Nikolas Pavlidis; Evangelos Briasoulis; Jan B Vermorken; Elena Strocchi; Andrea Martoni; Roberto Sorio; Henk P Sleeboom; Miguel A Izquierdo; Duncan I Jodrell; Régine Féty; Ernst de Bruijn; Georg Hempel; Mats Karlsson; Brigitte Tranchand; Ad H G J Schrijvers; Chris Twelves; Jos H Beijnen; Jan H M Schellens
Population pharmacokinetics and pharmacodynamics of doxorubicin and cyclophosphamide in breast cancer patients: a study by the EORTC-PAMM-NDDG.
Clinical pharmacokinetics 2007;46(12):1051-68.
2007: Robert Jansen; Hilde Rosing; Cornelia J F De Wolf; Jos H Beijnen
Development and validation of an assay for the quantitative determination of cladribine nucleotides in MDCKII cells and culture medium using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2007;21(24):4049-59.
2007: Sabien C van der Schoot; Bastiaan Nuijen; Frits M Flesch; Ashok Gore; Dorla Mirejovsky; Luigi Lenaz; Jos H Beijnen
Development of a bladder instillation of the indoloquinone anticancer agent EO-9 using tert-butyl alcohol as lyophilization vehicle.
AAPS PharmSciTech 2007;8(3):E61.
2007: Rob ter Heine; Carolien G Alderden-Los; Hilde Rosing; Michel J X Hillebrand; Eric C M van Gorp; Alwin D R Huitema; Jos H Beijnen
Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2007;21(15):2505-14.
2007: Liia D Vainchtein; Hilde Rosing; Bas Thijssen; Jan H M Schellens; Jos H Beijnen
Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2007;21(14):2312-22.
2007: E E M Brouwers; Matthijs M Tibben; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry.
Rapid communications in mass spectrometry : RCM 2007;21(9):1521-30.
2007: Tessa M Bosch; Remco Bakker; Jan H M Schellens; Annemieke Cats; Paul H M Smits; Jos H Beijnen
Rapid detection of the DPYD IVS14+1G>A mutation for screening patients to prevent fluorouracil-related toxicity.
Molecular diagnosis & therapy 2007;11(2):105-8.
2007: Irma Meijerman; Linda M Sanderson; Paul H M Smits; Jos H Beijnen; Jan H M Schellens
Pharmacogenetic screening of the gene deletion and duplications of CYP2D6.
Drug metabolism reviews 2007;39(1):45-60.
2007: Sanjay U C Sankatsing; Marion Cornelissen; Nico Kloosterboer; Kristel M L Crommentuyn; Tessa M Bosch; Frederik P Mul; Suzanne Jurriaans; Alwin D R Huitema; Jos H Beijnen; Joep M A Lange; Jan M Prins; Hanneke Schuitemaker
Antiviral activity of HIV type 1 protease inhibitors nelfinavir and indinavir in vivo is not influenced by P-glycoprotein activity on CD4+ T cells.
AIDS research and human retroviruses 2007;23(1):19-27.
2007: E van Leeuwen; R Ter Heine; F van der Veen; Sjoerd Repping; Jos H Beijnen; Jan M Prins
Penetration of atazanavir in seminal plasma of men infected with human immunodeficiency virus type 1.
Antimicrobial agents and chemotherapy 2007;51(1):335-7.
2007: Pauline Breedveld; Dick Pluim; Greta Cipriani; Femke Dahlhaus; Monique van Eijndhoven; Cornelia J F De Wolf; Annemieke Kuil; Jos H Beijnen; George L Scheffer; Gerrit Jansen; Piet Borst; Jan H M Schellens
The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models.
Molecular pharmacology 2007;71(1):240-9.
2007: Stephan A Veltkamp; C Alderden-Los; A Sharma; Hilde Rosing; Jos H Beijnen; J H M Schellens
A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application.
Cancer chemotherapy and pharmacology 2007;59(1):43-50.
2006: Stephan A Veltkamp; Michel J X Hillebrand; Hilde Rosing; Robert Jansen; E R Wickremsinhe; E J Perkins; J H M Schellens; Jos H Beijnen
Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry.
Journal of mass spectrometry : JMS 2006;41(12):1633-42.
2006: E Marleen Kemper; William P J Leenders; Benno Küsters; Scott Lyons; Tessa Buckle; Arend Heerschap; Willem Boogerd; Jos H Beijnen; Olaf van Tellingen
Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies.
European journal of cancer (Oxford, England : 1990) 2006;42(18):3294-303.
2006: Elisabeth J Rook; A P van Zanten; Wim Van den Brink; Jan M Van Ree; Jos H Beijnen
Mast cell mediator tryptase levels after inhalation or intravenous administration of high doses pharmaceutically prepared heroin.
Drug and alcohol dependence 2006;85(3):185-90.
2006: Corine Ekhart; Milly E De Jonge; Alwin D R Huitema; Jan H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Flat dosing of carboplatin is justified in adult patients with normal renal function.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(21):6502-8.
2006: Jurjen S Lagas; Maria L H Vlaming; Olaf van Tellingen; Els Wagenaar; Robert Jansen; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel
Multidrug resistance protein 2 is an important determinant of paclitaxel pharmacokinetics.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(20 Pt 1):6125-32.
2006: H H Helgason; C M F Kruijtzer; Alwin D R Huitema; S G Marcus; Wim W ten Bokkel Huinink; Margaret Schot; Jan H Schornagel; Jos H Beijnen; J H M Schellens
Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer.
British journal of cancer 2006;95(7):794-800.
2006: Sabien C van der Schoot; Bastiaan Nuijen; P Sood; K B Thurmond; Donald R Stewart; John R Rice; Jos H Beijnen
Pharmaceutical development, quality control, stability and compatibility of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum antineoplastic agent AP5346.
Die Pharmazie 2006;61(10):835-44.
2006: Tessa M Bosch; Alwin D R Huitema; Valerie D Doodeman; Robert Jansen; Els O Witteveen; Wim M Smit; Rob L Jansen; C M L van Herpen; Marcel Soesan; Jos H Beijnen; Jan H M Schellens
Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(19):5786-93.
2006: Wandena S Siegel-Lakhai; Mirjam Crul; Peter De Porre; Steven Zhang; Ilsung Chang; Henk Boot; Jos H Beijnen; Jan H M Schellens
Clinical and pharmacologic study of the farnesyltransferase inhibitor tipifarnib in cancer patients with normal or mildly or moderately impaired hepatic function.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(28):4558-64.
2006: Liia D Vainchtein; Hilde Rosing; Dorla Mirejovsky; Van Huynh; Luigi Lenaz; Michel J X Hillebrand; Jan H M Schellens; Jos H Beijnen
Quantitative analysis of EO9 (apaziquone) and its metabolite EO5a in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray tandem mass spectrometry.
Journal of mass spectrometry : JMS 2006;41(10):1268-76.
2006: Rajiv Puri; Victor Palit; Paul M Loadman; Michael Flannigan; Tariq Shah; Guzanfar A Choudry; Saurajyoti Basu; John A Double; Gino Lenaz; Shanta Chawla; Mario Beer; Coen Van Kalken; Richard de Boer; Jos H Beijnen; Christopher J Twelves; Roger M Phillips
Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer.
The Journal of urology 2006;176(4 Pt 1):1344-8.
2006: Anthe S Zandvliet; Jan H M Schellens; William Copalu; Jos H Beijnen; Alwin D R Huitema
A semi-physiological population pharmacokinetic model describing the non-linear disposition of indisulam.
Journal of pharmacokinetics and pharmacodynamics 2006;33(5):543-70.
2006: Eelco de Bree; Panayiotis A Theodoropoulos; Hilde Rosing; John Michalakis; John Romanos; Jos H Beijnen; Dimitris D Tsiftsis
Treatment of ovarian cancer using intraperitoneal chemotherapy with taxanes: from laboratory bench to bedside.
Cancer treatment reviews 2006;32(6):471-82.
2006: Judith R Kroep; Egbert F Smit; Giuseppe Giaccone; Kasper van der Born; Jos H Beijnen; Cees J van Groeningen; Wim J F van der Vijgh; Pieter E Postmus; HERBERT PINEDO; Godefridus J Peters
Pharmacology of the paclitaxel-cisplatin, gemcitabine-cisplatin, and paclitaxel-gemcitabine combinations in patients with advanced non-small cell lung cancer.
Cancer chemotherapy and pharmacology 2006;58(4):509-16.
2006: Stephan A Veltkamp; Bas Thijssen; J S Garrigue; G Lambert; F Lallemand; F Binlich; Alwin D R Huitema; Bastiaan Nuijen; A Nol; Jos H Beijnen; J H M Schellens
A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer.
British journal of cancer 2006;95(6):729-34.
2006: E E M Brouwers; Matthijs M Tibben; Hilde Rosing; Michel J X Hillebrand; Markus Joerger; J H M Schellens; Jos H Beijnen
Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate.
Journal of mass spectrometry : JMS 2006;41(9):1186-94.
2006: Markus Joerger; Alwin D R Huitema; Willem Boogerd; JJ van der Sande; J H M Schellens; Jos H Beijnen
Interactions of serum albumin, valproic acid and carbamazepine with the pharmacokinetics of phenytoin in cancer patients.
Basic & clinical pharmacology & toxicology 2006;99(2):133-40.
2006: Stefan R Vink; Jan H M Schellens; Jos H Beijnen; Herbert Sindermann; Jürgen Engel; Ria Dubbelman; Gemi Moppi; Michel J X Hillebrand; Harry Bartelink; Marcel Verheij
Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours.
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2006;80(2):207-13.
2006: Nienke A de Vries; Jos H Beijnen; Willem Boogerd; Olaf van Tellingen
Blood-brain barrier and chemotherapeutic treatment of brain tumors.
Expert review of neurotherapeutics 2006;6(8):1199-209.
2006: Rolf W Sparidans; Frits Dost; Kristel M L Crommentuyn; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Liquid chromatographic assay for the non-peptidic protease inhibitor tipranavir in plasma.
Biomedical chromatography : BMC 2006;20(8):671-3.
2006: Markus Joerger; Tessa M Bosch; Valerie D Doodeman; Jos H Beijnen; Paul H M Smits; J H M Schellens
Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers.
European journal of clinical pharmacology 2006;62(8):681-4.
2006: J H van den Berg; Jos H Beijnen; Alfons J M Balm; J H M Schellens
Future opportunities in preventing cisplatin induced ototoxicity.
Cancer treatment reviews 2006;32(5):390-7.
2006: Eelco de Bree; Hilde Rosing; John Michalakis; John Romanos; Kostantinos Relakis; Panayiotis A Theodoropoulos; Jos H Beijnen; Vasilis Georgoulias; Dimitris D Tsiftsis
Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2006;32(6):666-70.
2006: Suzanne V Frankfort; Linda R Tulner; Jos P C M van Campen; Cornelis H W Koks; Jos H Beijnen
The effect of admission to a geriatric ward on medication use: 2002 versus 1985.
Pharmacoepidemiology and drug safety 2006;15(8):602-6.
2006: Rolf W Sparidans; Tessa M Bosch; M Jörger; Jan H M Schellens; Jos H Beijnen
Liquid chromatography-tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and beta-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;839(1-2):45-53.
2006: Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Herb-drug interactions in oncology: focus on mechanisms of induction.
The oncologist 2006;11(7):742-52.
2006: Elisabeth J Rook; Alwin D R Huitema; Wim Van den Brink; Michel J X Hillebrand; Jan M Van Ree; Jos H Beijnen
Screening for illicit heroin use in patients in a heroin-assisted treatment program.
Journal of analytical toxicology 2006;30(6):390-4.
2006: Markus Joerger; Alwin D R Huitema; H J G Desirée van den Bongard; P Baas; Jan H Schornagel; J H M Schellens; Jos H Beijnen
Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients.
British journal of clinical pharmacology 2006;62(1):71-80.
2006: Maria L H Vlaming; K Mohrmann; Els Wagenaar; Dirk R de Waart; Ronald P J Oude Elferink; Jurjen S Lagas; Olaf van Tellingen; Liia D Vainchtein; Hilde Rosing; Jos H Beijnen; J H M Schellens; Alfred H Schinkel
Carcinogen and anticancer drug transport by Mrp2 in vivo: studies using Mrp2 (Abcc2) knockout mice.
The Journal of pharmacology and experimental therapeutics 2006;318(1):319-27.
2006: Isa E L M Kuppens; Eric Dansin; Henk Boot; Celine Feger; Sylvie Assadourian; Marie-Edith Bonneterre; Jos H Beijnen; Jan H M Schellens; Jacques Bonneterre
Dose-finding phase I clinical and pharmacokinetic study of orally administered irinotecan in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(12):3774-81.
2006: I van den Broek; Rolf W Sparidans; Alwin D R Huitema; J H M Schellens; Jos H Beijnen
Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography-tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2006;837(1-2):49-58.
2006: Suzanne V Frankfort; Bregje A Appels; Anthonius de Boer; Linda R Tulner; Jos P C M van Campen; Cornelis H W Koks; Jos H Beijnen
Treatment effects of rivastigmine on cognition, performance of daily living activities and behaviour in Alzheimer's disease in an outpatient geriatric setting.
International journal of clinical practice 2006;60(6):646-54.
2006: Annelies H Boekhout; Jos H Beijnen; Jan H M Schellens
Symptoms and treatment in cancer therapy-induced early menopause.
The oncologist 2006;11(6):641-54.
2006: Kristel M L Crommentuyn; Henriëtte J Scherpbier; Taco W Kuijpers; Ron A A Mathôt; Alwin D R Huitema; Jos H Beijnen
Population pharmacokinetics and pharmacodynamics of nelfinavir and its active metabolite M8 in HIV-1-infected children.
The Pediatric infectious disease journal 2006;25(6):538-43.
2006: Anthe S Zandvliet; William Copalu; Jan H M Schellens; Jos H Beijnen; Alwin D R Huitema
Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes.
Drug metabolism and disposition: the biological fate of chemicals 2006;34(6):1041-6.
2006: Rogier R Press; Tessa Buckle; Jos H Beijnen; Olaf van Tellingen
The effect of P-glycoprotein and cytochrome P450 3a on the oral bioavailability of vinorelbine in mice.
Cancer chemotherapy and pharmacology 2006;57(6):819-25.
2006: Milly E De Jonge; Alwin D R Huitema; Jos H Beijnen; Sjoerd Rodenhuis
High exposures to bioactivated cyclophosphamide are related to the occurrence of veno-occlusive disease of the liver following high-dose chemotherapy.
British journal of cancer 2006;94(9):1226-30.
2006: Marjolein G Klous; W C Lee; Wim Van den Brink; Jan M Van Ree; Jos H Beijnen
Volatilisation of diacetylmorphine: in vitro simulation of 'chasing the dragon'.
Die Pharmazie 2006;61(5):438-45.
2006: Judith Y M N Engwegen; Marie-Christine W Gast; Jan H M Schellens; Jos H Beijnen
Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry.
Trends in pharmacological sciences 2006;27(5):251-9.
2006: Tessa M Bosch; Maarten Deenen; Roelof Pruntel; Paul H M Smits; Jan H M Schellens; Jos H Beijnen; Irma Meijerman
Screening for polymorphisms in the PXR gene in a Dutch population.
European journal of clinical pharmacology 2006;62(5):395-9.
2006: Natalie M G M Appels; Hilde Rosing; Trevor C Stephens; Andrew Hughes; Jan H M Schellens; Jos H Beijnen
Absolute quantification of farnesylated Ras levels in complex samples using liquid chromatography fractionation combined with tryptic digestion and electrospray tandem mass spectrometry.
Analytical biochemistry 2006;352(1):33-40.
2006: Natalie M G M Appels; Hilde Rosing; Trevor C Stephens; Jan H M Schellens; Jos H Beijnen
Quantification of farnesylmethylcysteine in lysates of peripheral blood mononuclear cells using liquid chromatography coupled with electrospray tandem mass spectrometry: pharmacodynamic assay for farnesyl transferase inhibitors.
Analytical chemistry 2006;78(8):2617-22.
2006: Markus Joerger; Alwin D R Huitema; Desiree H J G van den Bongard; Jan H M Schellens; Jos H Beijnen
Quantitative effect of gender, age, liver function, and body size on the population pharmacokinetics of Paclitaxel in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(7 Pt 1):2150-7.
2006: Judith Y M N Engwegen; Helgi H Helgason; Annemieke Cats; Nathan Harris; Johannes M G Bonfrer; Jan H M Schellens; Jos H Beijnen
Identification of serum proteins discriminating colorectal cancer patients and healthy controls using surface-enhanced laser desorption ionisation-time of flight mass spectrometry.
World journal of gastroenterology : WJG 2006;12(10):1536-44.
2006: F Van Leth; Bregt S Kappelhoff; D Johnson; Marcelo H Losso; Anna Boron-Kaczmarska; M S Saag; J-M Livrozet; David B Hall; J Leith; Alwin D R Huitema; Ferdinand W N M Wit; Jos H Beijnen; Joep M A Lange
Pharmacokinetic parameters of nevirapine and efavirenz in relation to antiretroviral efficacy.
AIDS research and human retroviruses 2006;22(3):232-9.
2006: Jeany M Rademaker-Lakhai; Mirjam Crul; Lot Zuur; Paul Baas; Jos H Beijnen; Yvonne J W Simis; nico van zandwijk; Jan H M Schellens
Relationship between cisplatin administration and the development of ototoxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(6):918-24.
2006: Esther F A Brandon; Tessa M Bosch; Maarten J Deenen; Rianne Levink; Everdina van der Wal; Joyce B M van Meerveld; Monique Bijl; Jos H Beijnen; Jan H M Schellens; Irma Meijerman
Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines.
Toxicology and applied pharmacology 2006;211(1):1-10.
2006: Natalie M G M Appels; Kien-On Tung; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
A rapid and simple HPLC-UV method for the determination of inhibition characteristics of farnesyl transferase inhibitors.
Biomedical chromatography : BMC 2006;20(2):161-5.
2006: Elisabeth J Rook; Alwin D R Huitema; Wim van den Brink; Jan M van Ree; Jos H Beijnen
Pharmacokinetics and pharmacokinetic variability of heroin and its metabolites: review of the literature.
Current clinical pharmacology 2006;1(1):109-18.
2006: Suzanne V Frankfort; Linda R Tulner; Jos P C M van Campen; Cornelis H W Koks; Jos H Beijnen
Evaluation of pharmacotherapy in geriatric patients after performing complete geriatric assessment at a diagnostic day clinic.
Clinical drug investigation 2006;26(3):169-74.
2006: Suzanne V Frankfort; Mariët Ouwehand; Maria J van Maanen; Hilde Rosing; Linda R Tulner; Jos H Beijnen
A simple and sensitive assay for the quantitative analysis of rivastigmine and its metabolite NAP 226-90 in human EDTA plasma using coupled liquid chromatography and tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2006;20(22):3330-6.
2006: Suzanne V Frankfort; Valerie D Doodeman; Remco Bakker; Linda R Tulner; Jos P C M van Campen; Paul H M Smits; Jos H Beijnen
ABCB1 genotypes and haplotypes in patients with dementia and age-matched non-demented control patients.
Molecular neurodegeneration 2006;1():13.
2006: Tessa M Bosch; Valerie D Doodeman; Paul H M Smits; Irma Meijerman; J H M Schellens; Jos H Beijnen
Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.
Molecular diagnosis & therapy 2006;10(3):175-85.
2006: Marjolein G Klous; WeiChing Lee; Michel J X Hillebrand; Wim Van den Brink; Jan M Van Ree; Jos H Beijnen
Analysis of diacetylmorphine, caffeine, and degradation products after volatilization of pharmaceutical heroin for inhalation.
Journal of analytical toxicology 2006;30(1):6-13.
2006: Elisabeth J Rook; Alwin D R Huitema; Wim Van den Brink; Jan M Van Ree; Jos H Beijnen
Population pharmacokinetics of heroin and its major metabolites.
Clinical pharmacokinetics 2006;45(4):401-17.
2006: Tessa M Bosch; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Clinical pharmacokinetics 2006;45(3):253-85.
2006: Monique W J den Brok; Bastiaan Nuijen; J L García; Elena Miranda; P Calvo; Consuelo Manada; Jos H Beijnen
Compatibility and stability of the novel anticancer agent ES-285 x HCl formulated with 2-hydroxypropyl-beta-cyclodextrin in infusion devices.
Die Pharmazie 2006;61(1):21-4.
2006: Elisabeth J Rook; Jan M Van Ree; Wim Van den Brink; Michel J X Hillebrand; Alwin D R Huitema; Vincent M Hendriks; Jos H Beijnen
Pharmacokinetics and pharmacodynamics of high doses of pharmaceutically prepared heroin, by intravenous or by inhalation route in opioid-dependent patients.
Basic & clinical pharmacology & toxicology 2006;98(1):86-96.
2006: Jan-Hendrik Beumer; Jos H Beijnen; Jan H M Schellens
Mass balance studies, with a focus on anticancer drugs.
Clinical pharmacokinetics 2006;45(1):33-58.
2006: Esther F A Brandon; Rolf W Sparidans; Kees-Jan Guijt; Sjoerd Löwenthal; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis, Trabectidin), a novel marine anti-cancer drug.
Investigational new drugs 2006;24(1):3-14.
2006: Pauline Breedveld; Jos H Beijnen; Jan H M Schellens
Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs.
Trends in pharmacological sciences 2006;27(1):17-24.
2006: Liia D Vainchtein; Bas Thijssen; Ellen Stokvis; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry.
Biomedical chromatography : BMC 2006;20(1):139-48.
2006: Rolf W Sparidans; Frits Dost; Kristel M L Crommentuyn; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Liquid chromatographic assay for the protease inhibitor atazanavir in plasma.
Biomedical chromatography : BMC 2006;20(1):72-6.
2005: Marjolein G Klous; Wim Van den Brink; Jan M Van Ree; Jos H Beijnen
Development of pharmaceutical heroin preparations for medical co-prescription to opioid dependent patients.
Drug and alcohol dependence 2005;80(3):283-95.
2005: Suzanne V Frankfort; Bregje A Appels; Anthonius de Boer; Linda R Tulner; Jos P C M van Campen; Cornelis H W Koks; Jos H Beijnen
Discontinuation of rivastigmine in routine clinical practice.
International journal of geriatric psychiatry 2005;20(12):1167-71.
2005: Milly E De Jonge; Alwin D R Huitema; Selma M Van Dam; Sjoerd Rodenhuis; Jos H Beijnen
Population pharmacokinetics of cyclophosphamide and its metabolites 4-hydroxycyclophosphamide, 2-dechloroethylcyclophosphamide, and phosphoramide mustard in a high-dose combination with Thiotepa and Carboplatin.
Therapeutic drug monitoring 2005;27(6):756-65.
2005: Wandena S Siegel-Lakhai; Mirjam Crul; Steven Zhang; Rolf W Sparidans; Dick Pluim; A Howes; B Solanki; Jos H Beijnen; J H M Schellens
Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours.
British journal of cancer 2005;93(11):1222-9.
2005: Ellen Stokvis; Hilde Rosing; Jos H Beijnen
Liquid chromatography-mass spectrometry for the quantitative bioanalysis of anticancer drugs.
Mass spectrometry reviews 2005;24(6):887-917.
2005: Marjolein G Klous; Gaby M Bronner; Bastiaan Nuijen; Jan M Van Ree; Jos H Beijnen
Pharmaceutical heroin for inhalation: thermal analysis and recovery experiments after volatilisation.
Journal of pharmaceutical and biomedical analysis 2005;39(5):944-50.
2005: Kristel M L Crommentuyn; Bregt S Kappelhoff; Jan W Mulder; Albert T A Mairuhu; Eric C M van Gorp; Pieter L Meenhorst; Alwin D R Huitema; Jos H Beijnen
Population pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients.
British journal of clinical pharmacology 2005;60(4):378-89.
2005: Jeany M Rademaker-Lakhai; Mirjam Crul; Dick Pluim; Rolf W Sparidans; Paul Baas; Jos H Beijnen; nico van zandwijk; Jan H M Schellens
Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Anti-cancer drugs 2005;16(9):1029-36.
2005: Esther F A Brandon; Irma Meijerman; Joyce S Klijn; Dineke den Arend; Rolf W Sparidans; Louis López Lázaro; Jos H Beijnen; Jan H M Schellens
In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction.
Anti-cancer drugs 2005;16(9):935-43.
2005: Jan-Hendrik Beumer; Jeany M Rademaker-Lakhai; Hilde Rosing; Luis Lopez-Lazaro; Jos H Beijnen; J H M Schellens
Trabectedin (Yondelis, formerly ET-743), a mass balance study in patients with advanced cancer.
Investigational new drugs 2005;23(5):429-36.
2005: Milly E De Jonge; Alwin D R Huitema; Marjo J Holtkamp; Selma M Van Dam; Jos H Beijnen; Sjoerd Rodenhuis
Aprepitant inhibits cyclophosphamide bioactivation and thiotepa metabolism.
Cancer chemotherapy and pharmacology 2005;56(4):370-8.
2005: Elisabeth J Rook; Michel J X Hillebrand; Hilde Rosing; Jan M Van Ree; Jos H Beijnen
The quantitative analysis of heroin, methadone and their metabolites and the simultaneous detection of cocaine, acetylcodeine and their metabolites in human plasma by high-performance liquid chromatography coupled with tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2005;824(1-2):213-21.
2005: Maarten Huisman; Aniska A Chhatta; Olaf van Tellingen; Jos H Beijnen; Alfred H Schinkel
MRP2 (ABCC2) transports taxanes and confers paclitaxel resistance and both processes are stimulated by probenecid.
International journal of cancer. Journal international du cancer 2005;116(5):824-9.
2005: Monique W J den Brok; Bastiaan Nuijen; J Jantina Kettenes-van den Bosch; Mies J van Steenbergen; Josie N Buluran; Michael D Harvey; Charles K Grieshaber; Jos H Beijnen
Pharmaceutical development of a parenteral lyophilised dosage form for the novel anticancer agent C1311.
PDA journal of pharmaceutical science and technology / PDA 2005;59(5):285-97.
2005: Bregt S Kappelhoff; Alwin D R Huitema; Frank van Leth; Patrick A Robinson; Thomas R MacGregor; Joep M A Lange; Jos H Beijnen
Pharmacokinetics of nevirapine: once-daily versus twice-daily dosing in the 2NN study.
HIV clinical trials 2005;6(5):254-61.
2005: Wandena S Siegel-Lakhai; Jos H Beijnen; Jan H M Schellens
Current knowledge and future directions of the selective epidermal growth factor receptor inhibitors erlotinib (Tarceva) and gefitinib (Iressa).
The oncologist 2005;10(8):579-89.
2005: Natalie M G M Appels; Jos H Beijnen; Jan H M Schellens
Development of farnesyl transferase inhibitors: a review.
The oncologist 2005;10(8):565-78.
2005: Marjolein G Klous; Elisabeth J Rook; Michel J X Hillebrand; Wim Van den Brink; Jan M Van Ree; Jos H Beijnen
Deuterodiacetylmorphine as a marker for use of illicit heroin by addicts in a heroin-assisted treatment program.
Journal of analytical toxicology 2005;29(6):564-9.
2005: Bregt S Kappelhoff; Alwin D R Huitema; Sanjay U C Sankatsing; Pieter L Meenhorst; Eric C M van Gorp; Jan W Mulder; Jan M Prins; Jos H Beijnen
Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients.
British journal of clinical pharmacology 2005;60(3):276-86.
2005: Monique W J den Brok; Bastiaan Nuijen; Michel J X Hillebrand; Charles K Grieshaber; Michael D Harvey; Jos H Beijnen
Development and validation of an LC-UV method for the quantification and purity determination of the novel anticancer agent C1311 and its pharmaceutical dosage form.
Journal of pharmaceutical and biomedical analysis 2005;39(1-2):46-53.
2005: Heleen A Bardelmeijer; Arjan B G H Roelofs; Michel J X Hillebrand; Jos H Beijnen; Jan H M Schellens; Olaf van Tellingen
Metabolism of docetaxel in mice.
Cancer chemotherapy and pharmacology 2005;56(3):299-306.
2005: Monique W J den Brok; Bastiaan Nuijen; Eric E Challa; Christian Lutz; Hans-Georg Opitz; Jos H Beijnen
Compatibility and stability of Imexon in infusion devices and its in vitro biocompatibility.
Anti-cancer drugs 2005;16(7):727-32.
2005: Jan-Hendrik Beumer; Michel J X Hillebrand; Dick Pluim; Hilde Rosing; Karen Foley; S Murray Yule; Jan H M Schellens; Jos H Beijnen
Human metabolism of [(14)C]indisulam following i.v. infusion in cancer patients.
Investigational new drugs 2005;23(4):317-30.
2005: E E M Brouwers; Matthijs M Tibben; Markus Joerger; Olaf van Tellingen; Hilde Rosing; J H M Schellens; Jos H Beijnen
Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry.
Analytical and bioanalytical chemistry 2005;382(7):1484-90.
2005: Monique W J den Brok; Bastiaan Nuijen; Michel J X Hillebrand; Christian Lutz; Hans-Georg Opitz; Jos H Beijnen
LC-UV method development and validation for the investigational anticancer agent imexon and identification of its degradation products.
Journal of pharmaceutical and biomedical analysis 2005;38(4):686-94.
2005: Monique W J den Brok; Bastiaan Nuijen; Dieuwke M Meijer; Elena Millán; Consuelo Manada; Jos H Beijnen
Pharmaceutical development of a parenteral lyophilised formulation of the investigational anticancer agent ES-285.HCl.
PDA journal of pharmaceutical science and technology / PDA 2005;59(4):246-57.
2005: Bregt S Kappelhoff; Alwin D R Huitema; Albert T A Mairuhu; Jan H M Schellens; Jos H Beijnen
No pharmacokinetic drug-drug interaction between nevirapine and paclitaxel.
Anti-cancer drugs 2005;16(6):627-30.
2005: Antonius E van Herwaarden; Johan W Smit; Rolf W Sparidans; Els Wagenaar; Cornelia M M van der Kruijssen; Jan H M Schellens; Jos H Beijnen; Alfred H Schinkel
Midazolam and cyclosporin a metabolism in transgenic mice with liver-specific expression of human CYP3A4.
Drug metabolism and disposition: the biological fate of chemicals 2005;33(7):892-5.
2005: Kristel M L Crommentuyn; Alwin D R Huitema; Jos H Beijnen
Bioanalysis of HIV protease inhibitors in samples from sanctuary sites.
Journal of pharmaceutical and biomedical analysis 2005;38(1):139-47.
2005: Milly E De Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Sparse sampling design for therapeutic drug monitoring of sequentially administered cyclophosphamide, thiotepa, and carboplatin (CTC).
Therapeutic drug monitoring 2005;27(3):393-402.
2005: Kristel M Crommentuyn; Alwin D Huitema; Kees Brinkman; Marchina E Van Der Ende; Frank de Wolf; Jos H Beijnen
Therapeutic drug monitoring of nevirapine reduces pharmacokinetic variability but does not affect toxicity or virologic success in the ATHENA study.
Journal of acquired immune deficiency syndromes (1999) 2005;39(2):249-50.
2005: Esther F A Brandon; Ronald D van Ooijen; Rolf W Sparidans; Luis López Lázaro; albert heck; Jos H Beijnen; Jan H M Schellens
Structure elucidation of aplidine metabolites formed in vitro by human liver microsomes using triple quadrupole mass spectrometry.
Journal of mass spectrometry : JMS 2005;40(6):821-31.
2005: Charlotte van Kesteren; Anthe S Zandvliet; Mats O Karlsson; Ron A A Mathôt; Cornelis J A Punt; Jean-Pierre Armand; Eric Raymond; Alwin D R Huitema; Christian Dittrich; Herlinde Dumez; Henri Roché; Jean Pierre Droz; Miroslav Ravic; S Murray Yule; Jantien Wanders; Jos H Beijnen; Pierre Fumoleau; Jan H M Schellens
Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam.
Investigational new drugs 2005;23(3):225-34.
2005: Isa E L M Kuppens; Maria J van Maanen; Hilde Rosing; J H M Schellens; Jos H Beijnen
Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry.
Biomedical chromatography : BMC 2005;19(5):355-61.
2005: Noam Zelcer; Koen van de Wetering; Michel J X Hillebrand; Elise Sarton; Annemieke Kuil; peter wielinga; Thomas Tephly; Albert Dahan; Jos H Beijnen; Piet Borst
Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(20):7274-9.
2005: Marjolein G Klous; Alwin D R Huitema; Elisabeth J Rook; Michel J X Hillebrand; Vincent M Hendriks; Wim Van den Brink; Jos H Beijnen; Jan M Van Ree
Pharmacokinetic comparison of two methods of heroin smoking: 'chasing the dragon' versus the use of a heating device.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2005;15(3):263-9.
2005: Monique W J den Brok; Bastiaan Nuijen; Christian Lutz; Hans-Georg Opitz; Jos H Beijnen
Pharmaceutical development of a lyophilised dosage form for the investigational anticancer agent Imexon using dimethyl sulfoxide as solubilising and stabilising agent.
Journal of pharmaceutical sciences 2005;94(5):1101-14.
2005: Jan-Hendrik Beumer; J H M Schellens; Jos H Beijnen
Hepatotoxicity and metabolism of trabectedin: a literature review.
Pharmacological research : the official journal of the Italian Pharmacological Society 2005;51(5):391-8.
2005: Markus Joerger; Alwin D R Huitema; Pieter L Meenhorst; J H M Schellens; Jos H Beijnen
Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma.
Cancer chemotherapy and pharmacology 2005;55(5):488-96.
2005: Milly E De Jonge; Alwin D R Huitema; Selma M Van Dam; Jos H Beijnen; Sjoerd Rodenhuis
Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin.
Cancer chemotherapy and pharmacology 2005;55(5):507-10.
2005: Monique M R de Maat; Jos H Beijnen; Jan H M Schellens; Jan W Mulder
Chronic hepatotoxicity after long-term antiretroviral treatment including nevirapine.
The Journal of infection 2005;50(3):262-4.
2005: Monique W J den Brok; Bastiaan Nuijen; Remko Harms; Josie N Buluran; Michael D Harvey; Charles K Grieshaber; Jos H Beijnen
Compatibility and stability of the novel anti-cancer agent C1311 in infusion devices and its in vitro biocompatibility.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2005;11(1):13-9.
2005: Jeany M Rademaker-Lakhai; Simon Horenblas; Wim Meinhardt; Ellen Stokvis; Theo M de Reijke; José Jimeno; Luis Lopez-Lazaro; Jose A Lopez-Martin; Jos H Beijnen; Jan H M Schellens
Phase I clinical and pharmacokinetic study of kahalalide F in patients with advanced androgen refractory prostate cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(5):1854-62.
2005: Milly E De Jonge; Alwin D R Huitema; Jan Hm Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL.
British journal of clinical pharmacology 2005;59(3):325-34.
2005: A M E Bos; Filip De Vos; E G E de Vries; Jos H Beijnen; H Rosing; Marian J E Mourits; Ate G J van der Zee; Jourik A Gietema; P H B Willemse
A phase I study of intraperitoneal topotecan in combination with intravenous carboplatin and paclitaxel in advanced ovarian cancer.
European journal of cancer (Oxford, England : 1990) 2005;41(4):539-48.
2005: Milly E De Jonge; Alwin D R Huitema; Selma M Van Dam; Sjoerd Rodenhuis; Jos H Beijnen
Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes.
Anti-cancer drugs 2005;16(3):331-6.
2005: Nadja E Schoemaker; Isa E L M Kuppens; Wim W Ten Bokkel Huinink; Patricia Lefebvre; Jos H Beijnen; Sylvie Assadourian; Ger-Jan Sanderink; Jan H M Schellens
Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours.
Cancer chemotherapy and pharmacology 2005;55(3):263-70.
2005: Bregt S Kappelhoff; Alwin D R Huitema; Kristel M L Crommentuyn; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Albert T A Mairuhu; Jos H Beijnen
Development and validation of a population pharmacokinetic model for ritonavir used as a booster or as an antiviral agent in HIV-1-infected patients.
British journal of clinical pharmacology 2005;59(2):174-82.
2005: L H H Silvertand; F Vazvaei; P Weigl; Hilde Rosing; Michel J X Hillebrand; Maria J van Maanen; Jos H Beijnen
Simultaneous quantification of fludarabine and cyclophosphamide in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2005;19(24):3673-80.
2005: Milly E De Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Clinical pharmacokinetics of cyclophosphamide.
Clinical pharmacokinetics 2005;44(11):1135-64.
2005: Isa E L M Kuppens; Pauline Breedveld; Jos H Beijnen; J H M Schellens
Modulation of oral drug bioavailability: from preclinical mechanism to therapeutic application.
Cancer investigation 2005;23(5):443-64.
2005: Bregt S Kappelhoff; Frank van Leth; Patrick A Robinson; Thomas R MacGregor; Ezio Baraldi; Francesco Montella; David E Uip; Melanie A Thompson; Darren B Russell; Joep M A Lange; Jos H Beijnen; Alwin D R Huitema
Are adverse events of nevirapine and efavirenz related to plasma concentrations?
Antiviral therapy 2005;10(4):489-98.
2005: Bregt S Kappelhoff; Alwin D R Huitema; Zeynep Yalvaç; Jan M Prins; Jan W Mulder; Pieter L Meenhorst; Jos H Beijnen
Population pharmacokinetics of efavirenz in an unselected cohort of HIV-1-infected individuals.
Clinical pharmacokinetics 2005;44(8):849-61.
2005: Natalie M G M Appels; Maria J van Maanen; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2005;19(15):2187-92.
2005: Tessa M Bosch; Linda M Kjellberg; Anja Bouwers; Bobby P C Koeleman; Jan H M Schellens; Jos H Beijnen; Paul H M Smits; Irma Meijerman
Detection of single nucleotide polymorphisms in the ABCG2 gene in a Dutch population.
American journal of pharmacogenomics : genomics-related research in drug development and clinical practice 2005;5(2):123-31.
2005: Bregt S Kappelhoff; Alwin D R Huitema; Jos H Beijnen
Should non-nucleoside reverse transcriptase inhibitors be combined?
Drugs in R&D 2005;6(2):61-9.
2005: Bregt S Kappelhoff; Frank van Leth; Thomas R MacGregor; Joep Lange; Jos H Beijnen; Alwin D R Huitema
Nevirapine and efavirenz pharmacokinetics and covariate analysis in the 2NN study.
Antiviral therapy 2005;10(1):145-55.
2005: Olaf van Tellingen; Heleen A Bardelmeijer; Tessa Buckle; Mariët Ouwehand; Jos H Beijnen; Jan H M Schellens
Cannulation of the jugular vein in mice.
Laboratory animals 2005;39(1):130.
2005: Milly E De Jonge; Alwin D R Huitema; Annemarie C Tukker; Selma M Van Dam; Sjoerd Rodenhuis; Jos H Beijnen
Accuracy, feasibility, and clinical impact of prospective Bayesian pharmacokinetically guided dosing of cyclophosphamide, thiotepa, and carboplatin in high-dose chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(1):273-83.
2005: Anthe S Zandvliet; Alwin D R Huitema; Milly E De Jonge; Rob den Hoed; Rolf W Sparidans; Vincent M Hendriks; Wim Van den Brink; Jan M Van Ree; Jos H Beijnen
Population pharmacokinetics of caffeine and its metabolites theobromine, paraxanthine and theophylline after inhalation in combination with diacetylmorphine.
Basic & clinical pharmacology & toxicology 2005;96(1):71-9.
2005: Milly E De Jonge; Alwin D R Huitema; Jan H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review.
Clinical pharmacokinetics 2005;44(2):147-73.
2005: Ellen Stokvis; Hilde Rosing; Jos H Beijnen
Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not?
Rapid communications in mass spectrometry : RCM 2005;19(3):401-7.
2005: Isa E L M Kuppens; Tessa M Bosch; Maria J van Maanen; Hilde Rosing; A Fitzpatrick; Jos H Beijnen; J H M Schellens
Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093).
Cancer chemotherapy and pharmacology 2005;55(1):72-8.
2004: Ellen Stokvis; Mariët Ouwehand; L G A H Nan; E Marleen Kemper; Olaf van Tellingen; Hilde Rosing; Jos H Beijnen
A simple and sensitive assay for the quantitative analysis of paclitaxel in human and mouse plasma and brain tumor tissue using coupled liquid chromatography and tandem mass spectrometry.
Journal of mass spectrometry : JMS 2004;39(12):1506-12.
2004: Suzanne V Frankfort; Linda R Tulner; Wilma Knol; Jos P C M van Campen; Jan H N Schellens; Jos H Beijnen
Prescription error resulting in valproic acid intoxication.
Journal of the American Geriatrics Society 2004;52(12):2142-3.
2004: Marjolein G Klous; Bastiaan Nuijen; Wim Van den Brink; Jan M Van Ree; Jos H Beijnen
Process characterisation, optimisation and validation of production of diacetylmorphine/caffeine sachets: a design of experiments approach.
International journal of pharmaceutics 2004;285(1-2):65-75.
2004: Marjolein G Klous; Bastiaan Nuijen; Wim Van den Brink; Jan M Van Ree; Jos H Beijnen
Pharmaceutical development of an intravenous dosage form of diacetylmorphine hydrochloride.
PDA journal of pharmaceutical science and technology / PDA 2004;58(6):287-95.
2004: Nadja E Schoemaker; Isa E L M Kuppens; Vladimir M Moiseyenko; B Glimelius; M Kjaer; H Starkhammer; D J Richel; Rune Smaaland; K Bertelsen; J P Poulsen; E Voznyi; J Norum; D Fennelly; Kjell Magne Tveit; A Garin; G Gruia; A Mourier; D Sibaud; Patricia Lefebvre; Jos H Beijnen; J H M Schellens; Wim W ten Bokkel Huinink
A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer.
British journal of cancer 2004;91(8):1434-41.
2004: Kristel M L Crommentuyn; Jan W Mulder; Albert T A Mairuhu; Eric C M van Gorp; Pieter L Meenhorst; Alwin D R Huitema; Jos H Beijnen
The plasma and intracellular steady-state pharmacokinetics of lopinavir/ritonavir in HIV-1-infected patients.
Antiviral therapy 2004;9(5):779-85.
2004: Ellen Stokvis; Hilde Rosing; Roger C Causon; Jan H M Schellens; Jos H Beijnen
Quantitative analysis of the P-glycoprotein inhibitor Elacridar (GF120918) in human and dog plasma using liquid chromatography with tandem mass spectrometric detection.
Journal of mass spectrometry : JMS 2004;39(10):1122-30.
2004: Pauline Breedveld; Noam Zelcer; Dick Pluim; Ozgür Sönmezer; Matthijs M Tibben; Jos H Beijnen; Alfred H Schinkel; Olaf van Tellingen; Piet Borst; Jan H M Schellens
Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
Cancer research 2004;64(16):5804-11.
2004: Marjolein G Klous; Bastiaan Nuijen; Wim Van den Brink; Jan M Van Ree; Jos H Beijnen
Development and manufacture of diacetylmorphine/caffeine sachets for inhalation via 'chasing the dragon' by heroin addicts.
Drug development and industrial pharmacy 2004;30(7):775-84.
2004: Jos H Beijnen; Jan H M Schellens
Drug interactions in oncology.
The lancet oncology 2004;5(8):489-96.
2004: Monique M R de Maat; Jeannine F J B Nellen; Alwin D R Huitema; Ferdinand W N M Wit; Jan W Mulder; Jan M Prins; Jos H Beijnen
Race is not associated with nevirapine pharmacokinetics.
Therapeutic drug monitoring 2004;26(4):456-8.
2004: E Marleen Kemper; Willem Boogerd; Ingrid Thuis; Jos H Beijnen; Olaf van Tellingen
Modulation of the blood-brain barrier in oncology: therapeutic opportunities for the treatment of brain tumours?
Cancer treatment reviews 2004;30(5):415-23.
2004: Esther F A Brandon; Rolf W Sparidans; Irma Meijerman; Ignasio Manzanares; Jos H Beijnen; Jan H M Schellens
In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug.
Investigational new drugs 2004;22(3):241-51.
2004: Heleen A Bardelmeijer; Mariët Ouwehand; Jos H Beijnen; Jan H M Schellens; Olaf van Tellingen
Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice.
Investigational new drugs 2004;22(3):219-29.
2004: Monique W J den Brok; Sabien C van der Schoot; Bastiaan Nuijen; Michel J X Hillebrand; Jos H Beijnen
2-Hydroxypropyl-beta-cyclodextrin extracts 2-phenylphenol from silicone tubing.
International journal of pharmaceutics 2004;278(2):303-9.
2004: Ellen Stokvis; Hilde Rosing; Luis López-Lázaro; Jan H M Schellens; Jos H Beijnen
A more sensitive MS detector does not obviously lead to a more sensitive assay: experiences with ES-285.
Biomedical chromatography : BMC 2004;18(6):403-7.
2004: Ellen Stokvis; Hilde Rosing; Luis López-Lázaro; J H M Schellens; Jos H Beijnen
Switching from an analogous to a stable isotopically labeled internal standard for the LC-MS/MS quantitation of the novel anticancer drug Kahalalide F significantly improves assay performance.
Biomedical chromatography : BMC 2004;18(6):400-2.
2004: Dick Pluim; Robert C A M van Waardenburg; Jos H Beijnen; Jan H M Schellens
Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines.
Cancer chemotherapy and pharmacology 2004;54(1):71-8.
2004: Godefridus J Peters; Paul Noordhuis; Cees J van Groeningen; Giuseppe Giaccone; Ulbe Holwerda; Daphne Voorn; Ad Schrijvers; Jan H Schornagel; Jos H Beijnen; Pierre Fumoleau; Jan H M Schellens
The effect of food on the pharmacokinetics of S-1 after single oral administration to patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 1):4072-6.
2004: Thomas Kerbusch; Gerard Groenewegen; Ron A A Mathôt; Virginie M M Herben; Wim W ten Bokkel Huinink; M Swart; B Ambaum; Hilde Rosing; Sindy Jansen; Emile E Voest; Jos H Beijnen; J H M Schellens
Phase I and pharmacokinetic study of the combination of topotecan and ifosfamide administered intravenously every 3 weeks.
British journal of cancer 2004;90(12):2268-77.
2004: Jeany M Rademaker-Lakhai; Desiree van den Bongard; Dick Pluim; Jos H Beijnen; Jan H M Schellens
A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(11):3717-27.
2004: Kristel M L Crommentuyn; Hilde Rosing; Michel J X Hillebrand; Alwin D R Huitema; Jos H Beijnen
Simultaneous quantification of the new HIV protease inhibitors atazanavir and tipranavir in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2004;804(2):359-67.
2004: Jeany M Rademaker-Lakhai; Catherine Terret; Stephen B Howell; Christiane M Baud; Richard F De Boer; Dick Pluim; Jos H Beijnen; Jan H M Schellens; Jean Pierre Droz
A Phase I and pharmacological study of the platinum polymer AP5280 given as an intravenous infusion once every 3 weeks in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(10):3386-95.
2004: E Marleen Kemper; Marcel Verheij; Willem Boogerd; Jos H Beijnen; Olaf van Tellingen
Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoprotein.
European journal of cancer (Oxford, England : 1990) 2004;40(8):1269-74.
2004: Kristel M L Crommentuyn; Jan W Mulder; Rolf W Sparidans; Alwin D R Huitema; Jan H M Schellens; Jos H Beijnen
Drug-drug interaction between itraconazole and the antiretroviral drug lopinavir/ritonavir in an HIV-1-infected patient with disseminated histoplasmosis.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2004;38(8):e73-5.
2004: Milly E De Jonge; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Integrated Population Pharmacokinetic Model of both cyclophosphamide and thiotepa suggesting a mutual drug-drug interaction.
Journal of pharmacokinetics and pharmacodynamics 2004;31(2):135-56.
2004: Ellen Stokvis; Hilde Rosing; Luis López-Lázaro; Jos H Beijnen
Simple and sensitive liquid chromatographic quantitative analysis of the novel marine anticancer drug Yondelis (ET-743, trabectedin) in human plasma using column switching and tandem mass spectrometric detection.
Journal of mass spectrometry : JMS 2004;39(4):431-6.
2004: Milly E De Jonge; H J G Desirée van den Bongard; Alwin D R Huitema; Ron A A Mathôt; Hilde Rosing; Paul Baas; nico van zandwijk; Jos H Beijnen; Jan H M Schellens
Bayesian pharmacokinetically guided dosing of paclitaxel in patients with non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(7):2237-44.
2004: Sanjay U C Sankatsing; Jos H Beijnen; Alfred H Schinkel; Joep M A Lange; Jan M Prins
P glycoprotein in human immunodeficiency virus type 1 infection and therapy.
Antimicrobial agents and chemotherapy 2004;48(4):1073-81.
2004: H J G Desirée van den Bongard; Rolf W Sparidans; David J P Critchley; Jos H Beijnen; Jan H M Schellens
Pharmacokinetic drug-drug interaction of the novel anticancer agent E7070 and acenocoumarol.
Investigational new drugs 2004;22(2):151-8.
2004: Isa E L M Kuppens; Henk Boot; Jos H Beijnen; Jan H M Schellens; Jerry Labadie
Capecitabine induces severe angina-like chest pain.
Annals of internal medicine 2004;140(6):494-5.
2004: Ellen Stokvis; Hilde Rosing; Mirjam Crul; M J Rieser; albert heck; J H M Schellens; Jos H Beijnen
Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry.
Journal of mass spectrometry : JMS 2004;39(3):277-88.
2004: Milly E De Jonge; Selma M Van Dam; Michel J X Hillebrand; Hilde Rosing; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Simultaneous quantification of cyclophosphamide, 4-hydroxycyclophosphamide, N,N',N"-triethylenethiophosphoramide (thiotepa) and N,N',N"-triethylenephosphoramide (tepa) in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of mass spectrometry : JMS 2004;39(3):262-71.
2004: E Marleen Kemper; Cindy Cleypool; Willem Boogerd; Jos H Beijnen; Olaf van Tellingen
The influence of the P-glycoprotein inhibitor zosuquidar trihydrochloride (LY335979) on the brain penetration of paclitaxel in mice.
Cancer chemotherapy and pharmacology 2004;53(2):173-8.
2004: Jan-Hendrik Beumer; Hilde Rosing; Michel J X Hillebrand; Lianda G A H Nan-Offeringa; Karen Foley; S Murray Yule; albert heck; Jan H M Schellens; Jos H Beijnen
Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2004;18(23):2839-48.
2004: Bregt S Kappelhoff; Kristel M L Crommentuyn; Monique M R de Maat; Jan W Mulder; Alwin D R Huitema; Jos H Beijnen
Practical guidelines to interpret plasma concentrations of antiretroviral drugs.
Clinical pharmacokinetics 2004;43(13):845-53.
2004: Sanjay U C Sankatsing; Patrick G Hoggard; Alwin D R Huitema; Rolf W Sparidans; Stephen Kewn; Kristel M L Crommentuyn; Joep M A Lange; Jos H Beijnen; David J Back; Jan M Prins
Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools.
Clinical pharmacokinetics 2004;43(12):823-32.
2004: Ellen Stokvis; Lianda G A H Nan-Offeringa; Mariët Ouwehand; Matthijs M Tibben; Hilde Rosing; Yvonne Schnaars; Martina Grigat; Peter Romeis; Jan H M Schellens; Jos H Beijnen
Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry.
Rapid communications in mass spectrometry : RCM 2004;18(13):1465-71.
2004: Rolf W Sparidans; Jan H M Schellens; Luis López-Lázaro; José Jimeno; Jos H Beijnen
Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization with trans-4'-hydrazino-2-stilbazole.
Biomedical chromatography : BMC 2004;18(1):16-20.
2004: Serge van Ruth; Ron A A Mathôt; Rolf W Sparidans; Jos H Beijnen; Vic J Verwaal; Frans A N Zoetmulder
Population pharmacokinetics and pharmacodynamics of mitomycin during intraoperative hyperthermic intraperitoneal chemotherapy.
Clinical pharmacokinetics 2004;43(2):131-43.
2004: H J G Desirée van den Bongard; E Marleen Kemper; Olaf van Tellingen; Hilde Rosing; Ron A A Mathôt; Jan H M Schellens; Jos H Beijnen
Development and validation of a method to determine the unbound paclitaxel fraction in human plasma.
Analytical biochemistry 2004;324(1):11-5.
2003: Monique W J den Brok; Bastiaan Nuijen; Elena Miranda; Pablo Floriano; Simon Munt; Ignacio Manzanares; Jos H Beijnen
Development and validation of a liquid chromatography-ultraviolet absorbance detection assay using derivatisation for the novel marine anticancer agent ES-285 x HCl [(2S,3R)-2-amino-3-octadecanol hydrochloride] and its pharmaceutical dosage form.
Journal of chromatography. A 2003;1020(2):251-8.
2003: E Marleen Kemper; Mariët Ouwehand; Jos H Beijnen; Olaf van Tellingen
Bioanalysis of zosuquidar trihydrochloride (LY335979) in small volumes of human and murine plasma by ion-pairing reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;798(1):63-8.
2003: Guy S Missotten; Jos H Beijnen; Jan E E Keunen; Johannes M G Bonfrer
Proteomics in uveal melanoma.
Melanoma research 2003;13(6):627-9.
2003: Alwin D R Huitema; Rob A J Kuiper; Pieter L Meenhorst; Jan W Mulder; Jos H Beijnen
Photophobia in a patient with high indinavir plasma concentrations.
Therapeutic drug monitoring 2003;25(6):735-7.
2003: Olaf van Tellingen; Tessa Buckle; johan jonker; Martin van der Valk; Jos H Beijnen
P-glycoprotein and Mrp1 collectively protect the bone marrow from vincristine-induced toxicity in vivo.
British journal of cancer 2003;89(9):1776-82.
2003: Monique M R de Maat; Rob ter Heine; Eric C M van Gorp; Jan W Mulder; Albert T A Mairuhu; Jos H Beijnen
Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment.
AIDS (London, England) 2003;17(15):2209-14.
2003: Marjan Bouma; Bastiaan Nuijen; Remko Harms; John R Rice; David Nowotnik; Donald R Stewart; Bart A J Jansen; Steven van Zutphen; Jan Reedijk; Mies J van Steenbergen; Herre Talsma; Auke Bult; Jos H Beijnen
Pharmaceutical development of a parenteral lyophilized formulation of the investigational polymer-conjugated platinum anticancer agent AP 5280.
Drug development and industrial pharmacy 2003;29(9):981-95.
2003: Rolf W Sparidans; Linda Silvertand; Frits Dost; Joost Rothbarth; Gerard J Mulder; Jan H M Schellens; Jos H Beijnen
Simple high-performance liquid chromatographic assay for melphalan in perfusate, rat liver and tumour tissue.
Biomedical chromatography : BMC 2003;17(7):458-64.
2003: Antonius E van Herwaarden; johan jonker; Els Wagenaar; Remco F Brinkhuis; Jan H M Schellens; Jos H Beijnen; Alfred H Schinkel
The breast cancer resistance protein (Bcrp1/Abcg2) restricts exposure to the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
Cancer research 2003;63(19):6447-52.
2003: Mirjam Crul; Nadja E Schoemaker; Dick Pluim; Marc Maliepaard; René W M Underberg; Margaret Schot; Rolf W Sparidans; Paul Baas; Jos H Beijnen; nico van zandwijk; Jan H M Schellens
Randomized phase I clinical and pharmacologic study of weekly versus twice-weekly dose-intensive cisplatin and gemcitabine in patients with advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(10 Pt 1):3526-33.
2003: Chris Twelves; K Hoekman; Adrian Bowman; Jan B Vermorken; Alan Anthoney; J Smyth; Charlotte van Kesteren; Jos H Beijnen; J Uiters; Jantien Wanders; J Gomez; C Guzmán; José Jimeno; Axel R Hanauske
Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours.
European journal of cancer (Oxford, England : 1990) 2003;39(13):1842-51.
2003: Monique M R de Maat; Rob ter Heine; Jan W Mulder; Pieter L Meenhorst; Albert T A Mairuhu; Eric C M van Gorp; Alwin D R Huitema; Jos H Beijnen
Incidence and risk factors for nevirapine-associated rash.
European journal of clinical pharmacology 2003;59(5-6):457-62.
2003: Charlotte van Kesteren; M M M de Vooght; Luis López-Lázaro; Ron A A Mathôt; J H M Schellens; José Jimeno; Jos H Beijnen
Yondelis (trabectedin, ET-743): the development of an anticancer agent of marine origin.
Anti-cancer drugs 2003;14(7):487-502.
2003: Bregt S Kappelhoff; Hilde Rosing; Alwin D R Huitema; Jos H Beijnen
Simple and rapid method for the simultaneous determination of the non-nucleoside reverse transcriptase inhibitors efavirenz and nevirapine in human plasma using liquid chromatography.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;792(2):353-62.
2003: Rolf W Sparidans; Kristel M L Crommentuyn; Jan H M Schellens; Jos H Beijnen
Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2003;791(1-2):227-33.
2003: Heleen A Bardelmeijer; Tessa Buckle; Mariët Ouwehand; Jos H Beijnen; J H M Schellens; Olaf van Tellingen
Cannulation of the jugular vein in mice: a method for serial withdrawal of blood samples.
Laboratory animals 2003;37(3):181-7.
2003: E Marleen Kemper; A Erik van Zandbergen; Cindy Cleypool; Henk A Mos; Willem Boogerd; Jos H Beijnen; Olaf van Tellingen
Increased penetration of paclitaxel into the brain by inhibition of P-Glycoprotein.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(7):2849-55.
2003: H J G D van den Bongard; Dick Pluim; R C A M van Waardenburg; Miroslav Ravic; Jos H Beijnen; J H M Schellens
In vitro pharmacokinetic study of the novel anticancer agent E7070: red blood cell and plasma protein binding in human blood.
Anti-cancer drugs 2003;14(6):405-10.
2003: Sophie Callies; Dinesh P de Alwis; Adrian Harris; Paul Vasey; Jos H Beijnen; Jan H Schellens; Michael Burgess; Leon Aarons
A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979).
British journal of clinical pharmacology 2003;56(1):46-56.
2003: Esther F A Brandon; Christiaan D Raap; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons.
Toxicology and applied pharmacology 2003;189(3):233-46.
2003: Monique M R de Maat; Alwin D R Huitema; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Albert T A Mairuhu; Jos H Beijnen
Subtherapeutic antiretroviral plasma concentrations in routine clinical outpatient HIV care.
Therapeutic drug monitoring 2003;25(3):367-73.
2003: Milly E De Jonge; Ron A A Mathôt; Selma M Van Dam; Sjoerd Rodenhuis; Jos H Beijnen
Sorption of thiotepa to polyurethane catheter causes falsely elevated plasma levels.
Therapeutic drug monitoring 2003;25(3):261-3.
2003: peter wielinga; Ingrid van der Heijden; Glen Reid; Jos H Beijnen; Jan Wijnholds; Piet Borst
Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells.
The Journal of biological chemistry 2003;278(20):17664-71.
2003: Charlotte van Kesteren; Ron A A Mathôt; Jos H Beijnen; J H M Schellens
Pharmacokinetic-pharmacodynamic guided trial design in oncology.
Investigational new drugs 2003;21(2):225-41.
2003: Marjan Bouma; Bastiaan Nuijen; Donald R Stewart; Kevin F Shannon; John V St John; John R Rice; Remko Harms; Bart A J Jansen; Steven van Zutphen; Jan Reedijk; Auke Bult; Jos H Beijnen
Pharmaceutical quality control of the investigational polymer-conjugated platinum anticancer agent AP 5280.
PDA journal of pharmaceutical science and technology / PDA 2003;57(3):198-207.
2003: Ellen Stokvis; Lianda G A H Nan-Offeringa; Hilde Rosing; Luis López-Lázaro; J L Aceña; Elena Miranda; Aleksander V. Lyubimov; B S Levine; C D'Aleo; J H M Schellens; Jos H Beijnen
Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry.
Journal of mass spectrometry : JMS 2003;38(5):548-54.
2003: Cornelis H W Koks; Alwin D R Huitema; Eugene D M B Kroon; Theshinee Chuenyam; Rolf W Sparidans; Joep M A Lange; Jos H Beijnen
Population pharmacokinetics of itraconazole in Thai HIV-1-infected persons.
Therapeutic drug monitoring 2003;25(2):229-33.
2003: Heleen A Bardelmeijer; Ingrid A M Oomen; Michel J X Hillebrand; Jos H Beijnen; Jan H M Schellens; Olaf van Tellingen
Metabolism of paclitaxel in mice.
Anti-cancer drugs 2003;14(3):203-9.
2003: Marjan Bouma; Bastiaan Nuijen; Martine T Jansen; Gianni Sava; Fabrizio Picotti; Antonella Flaibani; Auke Bult; Jos H Beijnen
Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A.
Journal of pharmaceutical and biomedical analysis 2003;31(2):215-28.
2003: Kristel M L Crommentuyn; Hilde Rosing; Lianda G A H Nan-Offeringa; Michel J X Hillebrand; Alwin D R Huitema; Jos H Beijnen
Rapid quantification of HIV protease inhibitors in human plasma by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of mass spectrometry : JMS 2003;38(2):157-66.
2003: Eelco de Bree; Hilde Rosing; Jos H Beijnen; John Romanos; John Michalakis; Vasilis Georgoulias; Dimitris D Tsiftsis
Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.p. chemotherapy for ovarian cancer.
Anti-cancer drugs 2003;14(2):103-10.
2003: C M F Kruijtzer; Henk Boot; Jos H Beijnen; H L Lochs; F X Parnis; A S T Planting; J M G Pelgrims; R Williams; Ron A A Mathôt; Hilde Rosing; Margaret Schot; Harm van Tinteren; J H M Schellens
Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(2):197-204.
2003: Nadja E Schoemaker; Hilde Rosing; Sindy Jansen; Jan H M Schellens; Jos H Beijnen
High-performance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasma.
Therapeutic drug monitoring 2003;25(1):120-4.
2003: Maarten Huisman; Johan W Smit; Hugh R Wiltshire; Jos H Beijnen; Alfred H Schinkel
Assessing safety and efficacy of directed P-glycoprotein inhibition to improve the pharmacokinetic properties of saquinavir coadministered with ritonavir.
The Journal of pharmacology and experimental therapeutics 2003;304(2):596-602.
2003: Mirjam Crul; Robert C A M van Waardenburg; Suzanne Bocxe; Monique van Eijndhoven; Dick Pluim; Jos H Beijnen; Jan H M Schellens
DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin.
Biochemical pharmacology 2003;65(2):275-82.
2003: Monique M R de Maat; Daniël M Jonker; Cornelis H W Koks; Pieter L Meenhorst; Jan W Mulder; Teun M Post; Eric C M van Gorp; Anthonius de Boer; Jos H Beijnen
Pharmacotherapy of Hospitalised HIV-Infected Patients in a General Hospital during 1990, 1997 and 2001.
Clinical drug investigation 2003;23(1):45-53.
2003: Monique M R de Maat; Alwin D R Huitema; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Albert T A Mairuhu; Jos H Beijnen
Drug Interaction of Fluvoxamine and Fluoxetine with Nevirapine in HIV-1-Infected Individuals.
Clinical drug investigation 2003;23(10):629-37.
2003: Theodora E M S de Vries-Sluijs; Jeanne P Dieleman; Dennis Arts; Alwin D R Huitema; Jos H Beijnen; Martin Schutten; Marchina E Van Der Ende
Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population.
Clinical pharmacokinetics 2003;42(6):599-605.
2003: Monique M R de Maat; G Corine Ekhart; Alwin D R Huitema; Cornelis H W Koks; Jan W Mulder; Jos H Beijnen
Drug interactions between antiretroviral drugs and comedicated agents.
Clinical pharmacokinetics 2003;42(3):223-82.
2002: Mirjam Crul; Robert C A M van Waardenburg; Jos H Beijnen; J H M Schellens
DNA-based drug interactions of cisplatin.
Cancer treatment reviews 2002;28(6):291-303.
2002: C M F Kruijtzer; J H M Schellens; J Mezger; M E Scheulen; U Keilholz; Jos H Beijnen; Hilde Rosing; Ron A A Mathôt; S Marcus; Harm van Tinteren; Paul Baas
Phase II and pharmacologic study of weekly oral paclitaxel plus cyclosporine in patients with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(23):4508-16.
2002: Nadja E Schoemaker; Ron A A Mathôt; Patrick Schöffski; Hilde Rosing; Jan H M Schellens; Jos H Beijnen
Development of an optimal pharmacokinetic sampling schedule for rubitecan administered orally in a daily times five schedule.
Cancer chemotherapy and pharmacology 2002;50(6):514-7.
2002: Mirjam Crul; Laurens V Beerepoot; Ellen Stokvis; Johannes S P Vermaat; Hilde Rosing; Jos H Beijnen; Emile E Voest; Jan H M Schellens
Clinical pharmacokinetics, pharmacodynamics and metabolism of the novel matrix metalloproteinase inhibitor ABT-518.
Cancer chemotherapy and pharmacology 2002;50(6):473-8.
2002: peter wielinga; Glen Reid; Eric E Challa; Ingrid van der Heijden; Liesbeth Van Deemter; Marcel de Haas; CA Mol; Annemieke Kuil; E Groeneveld; John D Schuetz; Connie Brouwer; Ronney A De Abreu; Jan Wijnholds; Jos H Beijnen; Piet Borst
Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells.
Molecular pharmacology 2002;62(6):1321-31.
2002: johan jonker; Marije Buitelaar; Els Wagenaar; Martin van der Valk; George L Scheffer; Rik J Scheper; Torsten Plosch; Folkert Kuipers; Ronald P J Oude Elferink; Hilde Rosing; Jos H Beijnen; Alfred H Schinkel
The breast cancer resistance protein protects against a major chlorophyll-derived dietary phototoxin and protoporphyria.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(24):15649-54.
2002: Rolf W Sparidans; Mirjam Crul; Jan H M Schellens; Jos H Beijnen
Isocratic ion-exchange chromatographic assay for the nucleotide gemcitabine triphosphate in human white blood cells.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;780(2):423-30.
2002: Maarten Huisman; Johan W Smit; Kristel M L Crommentuyn; Noam Zelcer; Hugh R Wiltshire; Jos H Beijnen; Alfred H Schinkel
Multidrug resistance protein 2 (MRP2) transports HIV protease inhibitors, and transport can be enhanced by other drugs.
AIDS (London, England) 2002;16(17):2295-301.
2002: Johan R Boelaert; Geneviève M Dom; Alwin D Huitema; Jos H Beijnen; Joep M A Lange
The boosting of didanosine by allopurinol permits a halving of the didanosine dosage.
AIDS (London, England) 2002;16(16):2221-3.
2002: Marjan Bouma; Bastiaan Nuijen; Martine T Jansen; Gianni Sava; Auke Bult; Jos H Beijnen
Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A.
Journal of pharmaceutical and biomedical analysis 2002;30(4):1287-96.
2002: Marjan Bouma; Bastiaan Nuijen; Gianni Sava; Alberto Perbellini; Antonella Flaibani; Mies J van Steenbergen; Herre Talsma; J Jantina Kettenes-van den Bosch; Auke Bult; Jos H Beijnen
Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A.
International journal of pharmaceutics 2002;248(1-2):247-59.
2002: Marjan Bouma; Bastiaan Nuijen; Martine T Jansen; Gianni Sava; Antonella Flaibani; Auke Bult; Jos H Beijnen
A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A.
International journal of pharmaceutics 2002;248(1-2):239-46.
2002: Charlotte van Kesteren; Ron A A Mathôt; Eric Raymond; Jean-Pierre Armand; Pierre Fumoleau; Cornelis J A Punt; Miroslav Ravic; Jantien Wanders; Jos H Beijnen; J H M Schellens
Development and validation of limited sampling strategies for prediction of the systemic exposure to the novel anticancer agent E7070 (N-(3-chloro-7-indolyl)-1,4-benzenedisulphonamide).
British journal of clinical pharmacology 2002;54(5):463-71.
2002: Charlotte van Kesteren; Jos H Beijnen; Jan H M Schellens
E7070: a novel synthetic sulfonamide targeting the cell cycle progression for the treatment of cancer.
Anti-cancer drugs 2002;13(10):989-97.
2002: Heleen A Bardelmeijer; Mariët Ouwehand; Tessa Buckle; Maarten Huisman; Jan H M Schellens; Jos H Beijnen; Olaf van Tellingen
Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.
Cancer research 2002;62(21):6158-64.
2002: Milly E De Jonge; Ron A A Mathôt; Otilia Dalesio; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Relationship between irreversible alopecia and exposure to cyclophosphamide, thiotepa and carboplatin (CTC) in high-dose chemotherapy.
Bone marrow transplantation 2002;30(9):593-7.
2002: Joost Rothbarth; Rolf W Sparidans; Jos H Beijnen; Leo J Schultze Kool; Hein Putter; Cornelis J H van de Velde; Gerard J Mulder
Reduced liver uptake of arterially infused melphalan during retrograde rat liver perfusion with unaffected liver tumor uptake.
The Journal of pharmacology and experimental therapeutics 2002;303(2):736-40.
2002: Marjan Bouma; Bastiaan Nuijen; Donald R Stewart; John R Rice; Bart A J Jansen; Jan Reedijk; Auke Bult; Jos H Beijnen
Stability and compatibility of the investigational polymer-conjugated platinum anticancer agent AP 5280 in infusion systems and its hemolytic potential.
Anti-cancer drugs 2002;13(9):915-24.
2002: Monique M R de Maat; Alwin D R Huitema; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Jos H Beijnen
Population pharmacokinetics of nevirapine in an unselected cohort of HIV-1-infected individuals.
British journal of clinical pharmacology 2002;54(4):378-85.
2002: Charlotte van Kesteren; Ron A A Mathôt; Eric Raymond; Jean-Pierre Armand; Christian Dittrich; Herlinde Dumez; Henri Roché; Jean Pierre Droz; Cornelis J A Punt; Miroslav Ravic; Jantien Wanders; Jos H Beijnen; Pierre Fumoleau; J H M Schellens
Population pharmacokinetics of the novel anticancer agent E7070 during four phase I studies: model building and validation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(19):4065-73.
2002: Nadja E Schoemaker; Charlotte van Kesteren; Hilde Rosing; Sindy Jansen; M Swart; J Lieverst; Daniela Fraier; Massimo Breda; Cinzia Pellizzoni; Riccardo Spinelli; M Grazia Porro; Jos H Beijnen; J H M Schellens; Wim W ten Bokkel Huinink
A phase I and pharmacokinetic study of MAG-CPT, a water-soluble polymer conjugate of camptothecin.
British journal of cancer 2002;87(6):608-14.
2002: H J G Desirée van sen Bongard; Dick Pluim; Hilde Rosing; Lianda G A H Nan-Offeringa; Margaret Schot; Miroslav Ravic; Jan H M Schellens; Jos H Beijnen
An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients.
Anti-cancer drugs 2002;13(8):807-14.
2002: Ellen Stokvis; Hilde Rosing; Luis López-Lázaro; I Rodriguez; José Jimeno; J G Supko; J H M Schellens; Jos H Beijnen
Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry.
Journal of mass spectrometry : JMS 2002;37(9):992-1000.
2002: Monique M R de Maat; Ron A A Mathôt; Agnes I Veldkamp; Aldwin D R Huitma; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Hilde Carlier; Jos H Beijnen
Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals.
Pharmacological research : the official journal of the Italian Pharmacological Society 2002;46(3):295-300.
2002: Milly E De Jonge; Ron A A Mathôt; Selma M Van Dam; Jos H Beijnen; Sjoerd Rodenhuis
Extremely high exposures in an obese patient receiving high-dose cyclophosphamide, thiotepa and carboplatin.
Cancer chemotherapy and pharmacology 2002;50(3):251-5.
2002: Eric Raymond; W W ten Bokkel Huinink; Julien Taïeb; Jos H Beijnen; Sandrine Faivre; Jantien Wanders; Miroslav Ravic; Pierre Fumoleau; Jean-Pierre Armand; J H M Schellens
Phase I and pharmacokinetic study of E7070, a novel chloroindolyl sulfonamide cell-cycle inhibitor, administered as a one-hour infusion every three weeks in patients with advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(16):3508-21.
2002: Nadja E Schoemaker; Hilde Rosing; Sindy Jansen; Patrick Schöffski; Jinee Rizzo; Jan H M Schellens; Jos H Beijnen
Determination of 9-nitrocamptothecin and its metabolite 9-aminocamptothecin in human plasma using high-performance liquid chromatography with ultraviolet and fluorescence detection.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;775(2):231-7.
2002: Cornelis H W Koks; Pieter L Meenhorst; A Bult; Jos H Beijnen
Itraconazole solution: summary of pharmacokinetic features and review of activity in the treatment of fluconazole-resistant oral candidosis in HIV-infected persons.
Pharmacological research : the official journal of the Italian Pharmacological Society 2002;46(2):195-201.
2002: Rolf P G van Heeswijk; Henriëtte J Scherpbier; Linda A de Koning; Hugo S A Heymans; Joep M A Lange; Jos H Beijnen; Richard Hoetelmans
The pharmacokinetics of nelfinavir in HIV-1-infected children.
Therapeutic drug monitoring 2002;24(4):487-91.
2002: Mirjam Crul; Hilde Rosing; GJ de Klerk; Ria Dubbelman; M Traiser; S Reichert; N G Knebel; J H M Schellens; Jos H Beijnen; Wim W ten Bokkel Huinink
Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours.
European journal of cancer (Oxford, England : 1990) 2002;38(12):1615-21.
2002: Cornelis H W Koks; Kristel M L Crommentuyn; Ron A A Mathôt; Jan W Mulder; Pieter L Meenhorst; Jos H Beijnen
Prognostic factors for the clinical effectiveness of fluconazole in the treatment of oral candidiasis in HIV-1-infected individuals.
Pharmacological research : the official journal of the Italian Pharmacological Society 2002;46(1):89-94.
2002: Virginie M M Herben; nadja E Schoemaker; Hilde Rosing; Desiree M van Zomeren; Wim W ten Bokkel Huinink; Ria Dubbelman; Solange Hearn; Jan H M Schellens; Jos H Beijnen
Urinary and fecal excretion of topotecan in patients with malignant solid tumours.
Cancer chemotherapy and pharmacology 2002;50(1):59-64.
2002: H J G Desirée van den Bongard; Ron A A Mathôt; Olaf van Tellingen; J H M Schellens; Jos H Beijnen
A population analysis of the pharmacokinetics of Cremophor EL using nonlinear mixed-effect modelling.
Cancer chemotherapy and pharmacology 2002;50(1):16-24.
2002: Matthijs M Tibben; Jeany M Rademaker-Lakhai; John R Rice; Donald R Stewart; J H M Schellens; Jos H Beijnen
Determination of total platinum in plasma and plasma ultrafiltrate, from subjects dosed with the platinum-containing N-(2-hydroxypropyl)methacrylamide copolymer AP5280, by use of graphite-furnace Zeeman atomic-absorption spectrometry.
Analytical and bioanalytical chemistry 2002;373(4-5):233-6.
2002: C M F Kruijtzer; Jos H Beijnen; Hilde Rosing; Wim W ten Bokkel Huinink; Margaret Schot; Roxanne C Jewell; Elaine M Paul; J H M Schellens
Increased oral bioavailability of topotecan in combination with the breast cancer resistance protein and P-glycoprotein inhibitor GF120918.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(13):2943-50.
2002: LS Hofstra; A M E Bos; E G E de Vries; Ate G J van der Zee; Antoon T M Willemsen; H Rosing; Jos H Beijnen; Nanno H Mulder; Jan G Aalders; P H B Willemse
Kinetic modeling and efficacy of intraperitoneal paclitaxel combined with intravenous cyclophosphamide and carboplatin as first-line treatment in ovarian cancer.
Gynecologic oncology 2002;85(3):517-23.
2002: Mirjam Crul; GJ de Klerk; M Swart; Laura J van't Veer; Daphne de Jong; Lucie Boerrigter; Peter A Palmer; CJ Bol; H Tan; G C de Gast; Jos H Beijnen; J H M Schellens
Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(11):2726-35.
2002: Mirte M Malingré; Emile A Hendrix; Jan H M Schellens; Cornelis H W Koks; Matthijs M Tibben; Eric E Challa; Jos H Beijnen
Acute poisoning after oral intake of a toluene-containing paint thinner.
European journal of pediatrics 2002;161(6):354-5.
2002: Thomas Kerbusch; Ron A A Mathôt; Hans M M B Otten; Eelco W Meesters; Hendrikus J M van Kan; Jan H M Schellens; Jos H Beijnen
Bayesian pharmacokinetics of lithium after an acute self-intoxication and subsequent haemodialysis: a case report.
Pharmacology & toxicology 2002;90(5):243-5.
2002: Diane R Mould; Nick Holford; Jan H M Schellens; Jos H Beijnen; Paul R Hutson; Hilde Rosing; Willem W ten Bokkel Huinink; Eric K Rowinsky; Joan H Schiller; Mark Russo; Graham Ross
Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.
Clinical pharmacology and therapeutics 2002;71(5):334-48.
2002: Peter Cardiello; Rolf P G van Heeswijk; Elly A M Hassink; Preeyaporn Srasuebkul; Apicha Mahanontharit; Tarika Samor; Wassana Worarien; Jos H Beijnen; Richard Hoetelmans; Kiat Ruxrungtham; David A Cooper; Joep M A Lange; Praphan Phanuphak
Simplifying protease inhibitor therapy with once-daily dosing of saquinavir soft-gelatin capsules/ritonavir (1600/100 mg): HIVNAT 001.3 study.
Journal of acquired immune deficiency syndromes (1999) 2002;29(5):464-70.
2002: Charlotte van Kesteren; Chris Twelves; Adrian Bowman; Klaas Hoekman; Luis López-Lázaro; José Jimeno; Cecilia Guzman; Ron A A Mathôt; Andrew Simpson; Jan B Vermorken; John Smyth; Jan H M Schellens; Michel J X Hillebrand; Hilde Rosing; Jos H Beijnen
Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study.
Anti-cancer drugs 2002;13(4):381-93.
2002: Mirjam Crul; Ron A A Mathôt; Giuseppe Giaccone; Cornelis A Punt; Hilde Rosing; Michel X Hillebrand; Yoshitaka Ando; Nobosuke Nishi; Hideji Tanaka; Jan M Schellens; Jos H Beijnen
Population pharmacokinetics of the novel anticancer agent KRN7000.
Cancer chemotherapy and pharmacology 2002;49(4):287-93.
2002: Alwin D R Huitema; M Spaander; R A A Mathĵt; Matthijs M Tibben; Marjo J Holtkamp; Jos H Beijnen; Sjoerd Rodenhuis
Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(3):374-84.
2002: Jetske M Meerum Terwogt; Gerard Groenewegen; Dick Pluim; Marc Maliepaard; Matthijs M Tibben; Albert Huisman; Wim W ten Bokkel Huinink; Margaret Schot; Helen Welbank; Emile E Voest; Jos H Beijnen; Jan M Schellens
Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin.
Cancer chemotherapy and pharmacology 2002;49(3):201-10.
2002: Monique M R de Maat; Suzanne V Frankfort; Ron A A Mathôt; Jan W Mulder; Pieter L Meenhorst; Eric C M van Gorp; Cornelis H W Koks; Richard Hoetelmans; Anthonius de Boer; Jos H Beijnen
Discrepancies between medical and pharmacy records for patients on anti-HIV drugs.
The Annals of pharmacotherapy 2002;36(3):410-5.
2002: Cornelis H W Koks; Rolf W Sparidans; Georgette Lucassen; Kristel M L Crommentuyn; Jos H Beijnen
Selective high-performance liquid chromatographic assay for itraconazole and hydroxyitraconazole in plasma from human immunodeficiency virus-infected patients.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 2002;767(1):103-10.
2002: Heleen A Bardelmeijer; Mariët Ouwehand; Mirte M Malingré; Jan H M Schellens; Jos H Beijnen; Olaf van Tellingen
Entrapment by Cremophor EL decreases the absorption of paclitaxel from the gut.
Cancer chemotherapy and pharmacology 2002;49(2):119-25.
2002: Rolf P G van Heeswijk; James W T Cohen Stuart; David Burger; Jos H Beijnen; Jan C C Borleffs; Richard Hoetelmans
Long-term suppression of viral replication despite low plasma saquinavir concentrations in the CHEESE Study.
British journal of clinical pharmacology 2002;53(2):211-2.
2002: C M F Kruijtzer; Jos H Beijnen; J H M Schellens
Improvement of oral drug treatment by temporary inhibition of drug transporters and/or cytochrome P450 in the gastrointestinal tract and liver: an overview.
The oncologist 2002;7(6):516-30.
2002: Mirjam Crul; GJ de Klerk; M Swart; L Weiner; Peter A Palmer; CJ Bol; Jos H Beijnen; J H M Schellens
Evaluation of the bioequivalence of tablets and capsules containing the novel anticancer agent R115777 (Zarnestra) in patients with advanced solid tumors.
European journal of drug metabolism and pharmacokinetics 2002;27(1):61-5.
2002: Nadja E Schoemaker; Virginie M M Herben; Laurina A de Jong; Robert C A M van Waardenburg; Dick Pluim; Wim W ten Bokkel Huinink; Jos H Beijnen; Jan H M Schellens
Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel-cisplatin-topotecan in a phase I study.
Anti-cancer drugs 2002;13(1):87-91.
2002: Miguel A Villalona-Calero; S Gail Eckhardt; Geoffrey Weiss; Manuel Hidalgo; Jos H Beijnen; Charlotte van Kesteren; Hilde Rosing; Elizabeth Campbell; Maura Kraynak; Luis Lopez-Lazaro; Cecilia Guzman; Daniel Von Hoff; José Jimeno; Eric K Rowinsky
A phase I and pharmacokinetic study of ecteinascidin-743 on a daily x 5 schedule in patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):75-85.
2001: Noam Zelcer; Tohru Saeki; Glen Reid; Jos H Beijnen; Piet Borst
Characterization of drug transport by the human multidrug resistance protein 3 (ABCC3).
The Journal of biological chemistry 2001;276(49):46400-7.
2001: Rolf P G van Heeswijk; Agnes I Veldkamp; Jan W Mulder; Pieter L Meenhorst; Joep M A Lange; Jos H Beijnen; Richard Hoetelmans
Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience.
Antiviral therapy 2001;6(4):201-29.
2001: Alwin D R Huitema; Ron A A Mathôt; Matthijs M Tibben; Sjoerd Rodenhuis; Jos H Beijnen
Validation of a therapeutic drug monitoring strategy for thiotepa in a high-dose chemotherapy regimen.
Therapeutic drug monitoring 2001;23(6):650-7.
2001: Agnes I Veldkamp; Rolf P G van Heeswijk; Jan W Mulder; Pieter L Meenhorst; Richard Hoetelmans; Joep M A Lange; Jos H Beijnen
Limited sampling strategies for the estimation of the systemic exposure to the HIV-1 nonnucleoside reverse transcriptase inhibitor nevirapine.
Therapeutic drug monitoring 2001;23(6):606-11.
2001: Charlotte van Kesteren; R A Mathĵt; Luis López-Lázaro; Esteban Cvitkovic; Abdelkrim Taamma; José Jimeno; Cecilia Guzman; J H M Schellens; Jean-Louis Misset; Etienne Brain; Michel J X Hillebrand; Hilde Rosing; Jos H Beijnen
A comparison of limited sampling strategies for prediction of Ecteinascidin 743 clearance when administered as a 24-h infusion.
Cancer chemotherapy and pharmacology 2001;48(6):459-66.
2001: LS Hofstra; A M E Bos; Elisabeth G E de Vries; Ate G J van der Zee; Jos H Beijnen; H Rosing; Nanno H Mulder; Jan G Aalders; P H B Willemse
A phase I and pharmacokinetic study of intraperitoneal topotecan.
British journal of cancer 2001;85(11):1627-33.
2001: Mirte M Malingré; J H M Schellens; Olaf van Tellingen; Mariët Ouwehand; Heleen A Bardelmeijer; Hilde Rosing; FJ Koopman; Margaret Schot; Wim W ten Bokkel Huinink; Jos H Beijnen
The co-solvent Cremophor EL limits absorption of orally administered paclitaxel in cancer patients.
British journal of cancer 2001;85(10):1472-7.
2001: Heleen A Bardelmeijer; Mariët Ouwehand; Jos H Beijnen; J H M Schellens; Olaf van Tellingen
Determination of cyclosporin A in human and mouse plasma by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 2001;763(1-2):201-6.
2001: Nadja E Schoemaker; Enrico Frigerio; Daniela Fraier; J H M Schellens; Hilde Rosing; Sindy Jansen; Jos H Beijnen
High-performance liquid chromatographic analysis for the determination of a novel polymer-bound camptothecin derivative (MAG-camptothecin) and free camptothecin in human plasma.
Journal of chromatography. B, Biomedical sciences and applications 2001;763(1-2):173-83.
2001: Bastiaan Nuijen; Marjan Bouma; Herre Talsma; Consuelo Manada; José Jimeno; Luis Lopez-Lazaro; Auke Bult; Jos H Beijnen
Development of a lyophilized parenteral pharmaceutical formulation of the investigational polypeptide marine anticancer agent kahalalide F.
Drug development and industrial pharmacy 2001;27(8):767-80.
2001: Thomas Kerbusch; R A Mathĵt; HJ Keizer; J Ouwerkerk; Sjoerd Rodenhuis; J H M Schellens; Jos H Beijnen
Population pharmacokinetics and exploratory pharmacodynamics of ifosfamide and metabolites after a 72-h continuous infusion in patients with soft tissue sarcoma.
European journal of clinical pharmacology 2001;57(6-7):467-77.
2001: Rolf W Sparidans; Hilde Rosing; Michel J X Hillebrand; Luis López-Lázaro; José Jimeno; Ignasio Manzanares; Charlotte van Kesteren; Esteban Cvitkovic; A T van Oosterom; J H M Schellens; Jos H Beijnen
Search for metabolites of ecteinascidin 743, a novel, marine-derived, anti-cancer agent, in man.
Anti-cancer drugs 2001;12(8):653-66.
2001: E Marleen Kemper; B Jansen; Kenneth Brouwer; J H M Schellens; Jos H Beijnen; Olaf van Tellingen
Bioanalysis and preliminary pharmacokinetics of the acridonecarboxamide derivative GF120918 in plasma of mice and humans by ion-pairing reversed-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 2001;759(1):135-43.
2001: Thomas Kerbusch; Rob L Jansen; Ron A A Mathôt; Alwin D R Huitema; M Jansen; R E van Rijswijk; Jos H Beijnen
Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
Clinical pharmacology and therapeutics 2001;70(2):132-41.
2001: Mirte M Malingré; Wim W ten Bokkel Huinink; K Duchin; J H M Schellens; Jos H Beijnen
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the oral absorption of paclitaxel.
Anti-cancer drugs 2001;12(7):591-3.
2001: Rolf W Sparidans; Ellen Stokvis; José Jimeno; Luis López-Lázaro; J H M Schellens; Jos H Beijnen
Chemical and enzymatic stability of a cyclic depsipeptide, the novel, marine-derived, anti-cancer agent kahalalide F.
Anti-cancer drugs 2001;12(7):575-82.
2001: Cornelis H W Koks; Kristel M L Crommentuyn; Richard Hoetelmans; Ron A A Mathôt; Jos H Beijnen
Can fluconazole concentrations in saliva be used for therapeutic drug monitoring?
Therapeutic drug monitoring 2001;23(4):449-53.
2001: Jan Van den Brande; VR Nannan Panday; Klaas Hoekman; H Rosing; R V Huijskes; R H Verheijen; Jos H Beijnen; Jan B Vermorken
Pharmacologic study of paclitaxel administered with or without the cytoprotective agent amifostine, and given as a single agent or in combination with epirubicin and cisplatin in patients with advanced solid tumors.
American journal of clinical oncology 2001;24(4):401-3.
2001: Agnes I Veldkamp; Rolf P G van Heeswijk; Jan W Mulder; Pieter L Meenhorst; Gerrit Schreij; Siebe van der Geest; Joep M A Lange; Jos H Beijnen; Richard Hoetelmans
Steady-state pharmacokinetics of twice-daily dosing of saquinavir plus ritonavir in HIV-1-infected individuals.
Journal of acquired immune deficiency syndromes (1999) 2001;27(4):344-9.
2001: Mirte M Malingré; Wim W ten Bokkel Huinink; M Mackay; J H M Schellens; Jos H Beijnen
Pharmacokinetics of oral cyclosporin A when co-administered to enhance the absorption of orally administered docetaxel.
European journal of clinical pharmacology 2001;57(4):305-7.
2001: JG Schrama; Joke W Baars; Marjo J Holtkamp; Jan H Schornagel; Jos H Beijnen; Sjoerd Rodenhuis
Phase II study of a multi-course high-dose chemotherapy regimen incorporating cyclophosphamide, thiotepa, and carboplatin in stage IV breast cancer.
Bone marrow transplantation 2001;28(2):173-80.
2001: Bastiaan Nuijen; Marjan Bouma; Consuelo Manada; José Jimeno; Auke Bult; Jos H Beijnen
In vitro hemolysis and buffer capacity studies with the novel marine anticancer agent kahalalide F and its reconstitution vehicle cremophor EL/ethanol.
PDA journal of pharmaceutical science and technology / PDA 2001;55(4):223-9.
2001: Thomas Kerbusch; J W vanPutten; Harry J M Groen; Alwin D R Huitema; R A Mathĵt; Jos H Beijnen
Population pharmacokinetics of ifosfamide and its 2- and 3-dechloroethylated and 4-hydroxylated metabolites in resistant small-cell lung cancer patients.
Cancer chemotherapy and pharmacology 2001;48(1):53-61.
2001: MJ van Maanen; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Urinary excretion of thioTEPA and its metabolites in patients treated with high-dose cyclophosphamide, thioTEPA and carboplatin.
Anti-cancer drugs 2001;12(6):519-24.
2001: Thomas Kerbusch; Ron A A Mathôt; HJ Keizer; GP Kaijser; J H M Schellens; Jos H Beijnen
Influence of dose and infusion duration on pharmacokinetics of ifosfamide and metabolites.
Drug metabolism and disposition: the biological fate of chemicals 2001;29(7):967-75.
2001: Agnes I Veldkamp; M Harris; J S Montaner; G Moyle; B Gazzard; M Youle; M Johnson; MO Kwakkelstein; Hilde Carlier; Remko van Leeuwen; Jos H Beijnen; Joep M A Lange; Peter Reiss; Richard Hoetelmans
The steady-state pharmacokinetics of efavirenz and nevirapine when used in combination in human immunodeficiency virus type 1-infected persons.
The Journal of infectious diseases 2001;184(1):37-42.
2001: Alwin D R Huitema; C Reinders; Matthijs M Tibben; Sjoerd Rodenhuis; Jos H Beijnen
Sensitive gas chromatographic determination of the cyclophosphamide metabolite 2-dechloroethylcyclophosphamide in human plasma.
Journal of chromatography. B, Biomedical sciences and applications 2001;757(2):349-57.
2001: Agnes I Veldkamp; Gerrit Jan Weverling; Joep M A Lange; J S Montaner; Peter Reiss; D A Cooper; STEFANO VELLA; D Hall; Jos H Beijnen; Richard Hoetelmans
High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals.
AIDS (London, England) 2001;15(9):1089-95.
2001: Alwin D R Huitema; Ron A A Mathôt; Matthijs M Tibben; Sjoerd Rodenhuis; Jos H Beijnen
A mechanism-based pharmacokinetic model for the cytochrome P450 drug-drug interaction between cyclophosphamide and thioTEPA and the autoinduction of cyclophosphamide.
Journal of pharmacokinetics and pharmacodynamics 2001;28(3):211-30.
2001: H J G Desirée van den Bongard; R A Mathĵt; Willem Boogerd; Jan H Schornagel; Marcel Soesan; J H M Schellens; Jos H Beijnen
Successful rescue with leucovorin and thymidine in a patient with high-dose methotrexate induced acute renal failure.
Cancer chemotherapy and pharmacology 2001;47(6):537-40.
2001: Cornelis H W Koks; Kristel M L Crommentuyn; Richard Hoetelmans; David Burger; P P Koopmans; Ron A A Mathôt; Jan W Mulder; Pieter L Meenhorst; Jos H Beijnen
The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals.
British journal of clinical pharmacology 2001;51(6):631-5.
2001: Mirte M Malingré; Jos H Beijnen; J H M Schellens
Oral delivery of taxanes.
Investigational new drugs 2001;19(2):155-62.
2001: Bastiaan Nuijen; Marjan Bouma; J H M Schellens; Jos H Beijnen
Progress in the development of alternative pharmaceutical formulations of taxanes.
Investigational new drugs 2001;19(2):143-53.
2001: Arjen J Witkamp; Eelco de Bree; MM Kaag; Henk Boot; Jos H Beijnen; Gooike W van Slooten; Frits van Coevorden; Frans A N Zoetmulder
Extensive cytoreductive surgery followed by intra-operative hyperthermic intraperitoneal chemotherapy with mitomycin-C in patients with peritoneal carcinomatosis of colorectal origin.
European journal of cancer (Oxford, England : 1990) 2001;37(8):979-84.
2001: Joop C M Waterval; J C Bloks; Rolf W Sparidans; Jos H Beijnen; Ignacio Rodríguez-Campos; Auke Bult; Henk Lingeman; Willy J M Underberg
Degradation kinetics of aplidine, a new marine antitumoural cyclic peptide, in aqueous solution.
Journal of chromatography. B, Biomedical sciences and applications 2001;754(1):161-8.
2001: Thomas Kerbusch; Virginie M M Herben; M J Jeuken; J Ouwerkerk; HJ Keizer; Jos H Beijnen
Distribution of ifosfamide and metabolites between plasma and erythrocytes.
Biopharmaceutics & drug disposition 2001;22(3):99-108.
2001: Mirte M Malingré; Jos H Beijnen; Hilde Rosing; FJ Koopman; Olaf van Tellingen; K Duchin; Wim W ten Bokkel Huinink; M Swart; J Lieverst; J H M Schellens
A phase I and pharmacokinetic study of bi-daily dosing of oral paclitaxel in combination with cyclosporin A.
Cancer chemotherapy and pharmacology 2001;47(4):347-54.
2001: Mirte M Malingré; Jos H Beijnen; Hilde Rosing; FJ Koopman; Olaf van Tellingen; K Duchin; Wim W ten Bokkel Huinink; M Swart; J Lieverst; J H M Schellens
The effect of different doses of cyclosporin A on the systemic exposure of orally administered paclitaxel.
Anti-cancer drugs 2001;12(4):351-8.
2001: Jetske M Meerum Terwogt; Wim W ten Bokkel Huinink; J H M Schellens; Margaret Schot; IA Mandjes; M G Zurlo; M Rocchetti; Hilde Rosing; FJ Koopman; Jos H Beijnen
Phase I clinical and pharmacokinetic study of PNU166945, a novel water-soluble polymer-conjugated prodrug of paclitaxel.
Anti-cancer drugs 2001;12(4):315-23.
2001: Marc Maliepaard; Margôt van Gastelen; A Tohgo; FREDERICK HAUSHEER; Robert C A M van Waardenburg; Laurina A de Jong; Dick Pluim; Jos H Beijnen; J H M Schellens
Circumvention of breast cancer resistance protein (BCRP)-mediated resistance to camptothecins in vitro using non-substrate drugs or the BCRP inhibitor GF120918.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(4):935-41.
2001: Maarten Huisman; Johan W Smit; Hugh R Wiltshire; Richard Hoetelmans; Jos H Beijnen; Alfred H Schinkel
P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir.
Molecular pharmacology 2001;59(4):806-13.
2001: Mirjam Crul; GJ de Klerk; Jos H Beijnen; J H M Schellens
Ras biochemistry and farnesyl transferase inhibitors: a literature survey.
Anti-cancer drugs 2001;12(3):163-84.
2001: M Crul; H J G Desirée van den Bongard; Matthijs M Tibben; Olaf van Tellingen; G Sava; J H M Schellens; Jos H Beijnen
Validated method for the determination of the novel organo-ruthenium anticancer drug NAMI-A in human biological fluids by Zeeman atomic absorption spectrometry.
Fresenius' journal of analytical chemistry 2001;369(5):442-5.
2001: Monique M R de Maat; Richard Hoetelmans; R A Math t; Eric C M van Gorp; Pieter L Meenhorst; Jan W Mulder; Jos H Beijnen
Drug interaction between St John's wort and nevirapine.
AIDS (London, England) 2001;15(3):420-1.
2001: Mirte M Malingré; Dick J Richel; Jos H Beijnen; Hilde Rosing; FJ Koopman; Wim W ten Bokkel Huinink; Margaret Schot; J H M Schellens
Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(4):1160-6.
2001: Rolf W Sparidans; Richard Hoetelmans; Jos H Beijnen
Liquid chromatographic assay for simultaneous determination of abacavir and mycophenolic acid in human plasma using dual spectrophotometric detection.
Journal of chromatography. B, Biomedical sciences and applications 2001;750(1):155-61.
2001: Mirte M Malingré; Jos H Beijnen; Hilde Rosing; FJ Koopman; Roxanne C Jewell; Elaine M Paul; Wim W ten Bokkel Huinink; J H M Schellens
Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients.
British journal of cancer 2001;84(1):42-7.
2001: Bastiaan Nuijen; Marjan Bouma; Consuelo Manada; José Jimeno; L L Lazaro; Auke Bult; Jos H Beijnen
Compatibility and stability of the investigational polypeptide marine anticancer agent kahalalide F in infusion devices.
Investigational new drugs 2001;19(4):273-81.
2001: Thomas Kerbusch; J de Kraker; HJ Keizer; J W van Putten; Harry J M Groen; Rob L Jansen; J H M Schellens; Jos H Beijnen
Clinical pharmacokinetics and pharmacodynamics of ifosfamide and its metabolites.
Clinical pharmacokinetics 2001;40(1):41-62.
2001: Alwin D R Huitema; Ron A A Mathôt; Matthijs M Tibben; J H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Population pharmacokinetics of thioTEPA and its active metabolite TEPA in patients undergoing high-dose chemotherapy.
British journal of clinical pharmacology 2001;51(1):61-70.
2000: Charlotte van Kesteren; Esteban Cvitkovic; Abdelkrim Taamma; Luis López-Lázaro; José Jimeno; Cecilia Guzman; R A Math t; J H M Schellens; Jean-Louis Misset; Etienne Brain; Michel J X Hillebrand; Hilde Rosing; Jos H Beijnen
Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(12):4725-32.
2000: J H M Schellens; Mirte M Malingré; C M F Kruijtzer; Heleen A Bardelmeijer; Olaf van Tellingen; A H Schinkel; Jos H Beijnen
Modulation of oral bioavailability of anticancer drugs: from mouse to man.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2000;12(2):103-10.
2000: Mirte M Malingré; J H M Schellens; Olaf van Tellingen; Hilde Rosing; FJ Koopman; K Duchin; Wim W Ten Bokkel Huinink; M Swart; Jos H Beijnen
Metabolism and excretion of paclitaxel after oral administration in combination with cyclosporin A and after i.v. administration.
Anti-cancer drugs 2000;11(10):813-20.
2000: Bastiaan Nuijen; Marjan Bouma; Consuelo Manada; José Jimeno; J H M Schellens; Auke Bult; Jos H Beijnen
Pharmaceutical development of anticancer agents derived from marine sources.
Anti-cancer drugs 2000;11(10):793-811.
2000: H J G Desirée van den Bongard; Ron A A Mathôt; Jos H Beijnen; J H M Schellens
Pharmacokinetically guided administration of chemotherapeutic agents.
Clinical pharmacokinetics 2000;39(5):345-67.
2000: Heleen A Bardelmeijer; Jos H Beijnen; Kenneth Brouwer; Hilde Rosing; Willem Nooijen; J H M Schellens; Olaf van Tellingen
Increased oral bioavailability of paclitaxel by GF120918 in mice through selective modulation of P-glycoprotein.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(11):4416-21.
2000: Nine van der Vange; A R van Goethem; Frans A N Zoetmulder; MM Kaag; Paul van de Vaart; Wim W ten Bokkel Huinink; Jos H Beijnen
Extensive cytoreductive surgery combined with intra-operative intraperitoneal perfusion with cisplatin under hyperthermic conditions (OVHIPEC) in patients with recurrent ovarian cancer: a feasibility pilot.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology 2000;26(7):663-8.
2000: johan jonker; Johan W Smit; Remco F Brinkhuis; Marc Maliepaard; Jos H Beijnen; J H M Schellens; Alfred H Schinkel
Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan.
Journal of the National Cancer Institute 2000;92(20):1651-6.
2000: Jetske M Meerum Terwogt; Olaf van Tellingen; VR Nannan Panday; manon huizing; J H M Schellens; Wim W ten Bokkel Huinink; M U Boschma; Giuseppe Giaccone; Cindy Veenhof; Jos H Beijnen
Cremophor EL pharmacokinetics in a phase I study of paclitaxel (Taxol) and carboplatin in non-small cell lung cancer patients.
Anti-cancer drugs 2000;11(9):687-94.
2000: Thomas Kerbusch; M J Jeuken; J Derraz; J W van Putten; Alwin D R Huitema; Jos H Beijnen
Determination of ifosfamide, 2- and 3-dechloroethyifosfamide using gas chromatography with nitrogen-phosphorus or mass spectrometry detection.
Therapeutic drug monitoring 2000;22(5):613-20.
2000: Rolf P G van Heeswijk; Agnes I Veldkamp; Jan W Mulder; Pieter L Meenhorst; Ferdinand W N M Wit; Peter Reiss; Joep M A Lange; MO Kwakkelstein; Jos H Beijnen; Richard Hoetelmans
Nevirapine plus didanosine: once or twice daily combination?
Journal of acquired immune deficiency syndromes (1999) 2000;25(1):93-5.
2000: Alwin D R Huitema; Matthijs M Tibben; Thomas Kerbusch; J Jantina Kettenes-van den Bosch; Sjoerd Rodenhuis; Jos H Beijnen
Simple and selective determination of the cyclophosphamide metabolite phosphoramide mustard in human plasma using high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 2000;745(2):345-55.
2000: Alwin D R Huitema; K D Smits; Ron A A Mathôt; J H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
The clinical pharmacology of alkylating agents in high-dose chemotherapy.
Anti-cancer drugs 2000;11(7):515-33.
2000: Heleen A Bardelmeijer; Olaf van Tellingen; J H M Schellens; Jos H Beijnen
The oral route for the administration of cytotoxic drugs: strategies to increase the efficiency and consistency of drug delivery.
Investigational new drugs 2000;18(3):231-41.
2000: Raymond Evers; Marcel de Haas; Rolf W Sparidans; Jos H Beijnen; peter wielinga; Jan Lankelma; Piet Borst
Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export.
British journal of cancer 2000;83(3):375-83.
2000: M J Maanen; C J Smeets; Jos H Beijnen
Chemistry, pharmacology and pharmacokinetics of N,N',N" -triethylenethiophosphoramide (ThioTEPA).
Cancer treatment reviews 2000;26(4):257-68.
2000: Rob A J Kuiper; Mirte M Malingré; Jos H Beijnen; J H M Schellens
Cyclosporine-induced anaphylaxis.
The Annals of pharmacotherapy 2000;34(7-8):858-61.
2000: Jan Wijnholds; CA Mol; Liesbeth Van Deemter; Marcel de Haas; George L Scheffer; F Baas; Jos H Beijnen; Rik J Scheper; S Hatse; E De Clercq; Jan Balzarini; Piet Borst
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs.
Proceedings of the National Academy of Sciences of the United States of America 2000;97(13):7476-81.
2000: Rolf P G van Heeswijk; Agnes I Veldkamp; Jan W Mulder; Pieter L Meenhorst; Joep M A Lange; Jos H Beijnen; Richard Hoetelmans
Once-daily dosing of saquinavir and low-dose ritonavir in HIV-1-infected individuals: a pharmacokinetic pilot study.
AIDS (London, England) 2000;14(9):F103-10.
2000: MJ van Maanen; K D Smits; Jos H Beijnen
Simultaneous determination of thioTEPA, TEPA and a novel, recently identified thioTEPA metabolite, monochloroTEPA, in urine using capillary gas chromatography.
Journal of chromatography. B, Biomedical sciences and applications 2000;742(2):335-43.
2000: Alwin D R Huitema; Ron A A Mathôt; Matthijs M Tibben; J H M Schellens; Sjoerd Rodenhuis; Jos H Beijnen
Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
Clinical pharmacology and therapeutics 2000;67(6):621-30.
2000: Mirte M Malingré; JM Terwogt; Jos H Beijnen; Hilde Rosing; FJ Koopman; Olaf van Tellingen; K Duchin; Wim W Ten Bokkel Huinink; M Swart; J Lieverst; J H M Schellens
Phase I and pharmacokinetic study of oral paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(12):2468-75.
2000: Thomas Kerbusch; Alwin D R Huitema; J Ouwerkerk; HJ Keizer; Ron A A Mathôt; J H M Schellens; Jos H Beijnen
Evaluation of the autoinduction of ifosfamide metabolism by a population pharmacokinetic approach using NONMEM.
British journal of clinical pharmacology 2000;49(6):555-61.
2000: Rolf W Sparidans; Richard Hoetelmans; Jos H Beijnen
Sensitive liquid chromatographic assay for amprenavir, a human immunodeficiency virus protease inhibitor, in human plasma, cerebrospinal fluid and semen.
Journal of chromatography. B, Biomedical sciences and applications 2000;742(1):185-92.
2000: Rolf P G van Heeswijk; Agnes I Veldkamp; Jan W Mulder; Pieter L Meenhorst; Ferdinand W N M Wit; Joep M A Lange; Sven A Danner; NA Foudraine; MO Kwakkelstein; Peter Reiss; Jos H Beijnen; Richard Hoetelmans
The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals.
AIDS (London, England) 2000;14(8):F77-82.
2000: MJ van Maanen; K Doesburg Smits; JM Damen; albert heck; Jos H Beijnen
Stability of thioTEPA and its metabolites, TEPA, monochloroTEPA and thioTEPA-mercapturate, in plasma and urine.
International journal of pharmaceutics 2000;200(2):187-94.
2000: Bastiaan Nuijen; Marjan Bouma; RE Henrar; Pablo Floriano; José Jimeno; Herre Talsma; J Jantina Kettenes-van den Bosch; albert heck; Auke Bult; Jos H Beijnen
Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine.
PDA journal of pharmaceutical science and technology / PDA 2000;54(3):193-208.
2000: Alexander L Vahrmeijer; Jan Hein van Dierendonck; HJ Keizer; Jos H Beijnen; R A E M Tollenaar; Milan E J Pijl; A Marinelli; Peter Kuppen; J H van Bockel; Gerard J Mulder; Cornelis J H van de Velde
Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver.
British journal of cancer 2000;82(9):1539-46.
2000: Jaap Verweij; J H M Schellens; Jos H Beijnen; L Pronk; M Bo; V Lustig; H van Tinteren; M Mackay; Wim W ten Bokkel Huinink
Docetaxel in 253 previously treated patients with progressive locally advanced or metastatic breast cancer: results of a compassionate use program in The Netherlands.
Anti-cancer drugs 2000;11(4):249-55.
2000: Sjoerd Rodenhuis; Alwin D R Huitema; Frits S A M van Dam; Elisabeth G E de Vries; Jos H Beijnen
High-dose chemotherapy with peripheral blood progenitor cell transplantation in the adjuvant treatment of breast cancer.
Cancer journal (Sudbury, Mass.) 2000;6 Suppl 2():S125-30.
2000: J van Asperen; Olaf van Tellingen; Jos H Beijnen
The role of mdr1a P-glycoprotein in the biliary and intestinal secretion of doxorubicin and vinblastine in mice.
Drug metabolism and disposition: the biological fate of chemicals 2000;28(3):264-7.
2000: RJ van Maanen; I M Tijhof; JM Damen; JW Zwikker; Jos H Beijnen
The degradation of N,N',N"-triethylenephosphoramide in aqueous solutions: a qualitative and kinetic study.
International journal of pharmaceutics 2000;196(1):85-94.
2000: Rolf W Sparidans; J den Hartig; Serge C L M Cremers; Jos H Beijnen; Pieter Vermeij
Semi-automatic liquid chromatographic analysis of olpadronate in urine and serum using derivatization with (9-fluorenylmethyl)chloroformate.
Journal of chromatography. B, Biomedical sciences and applications 2000;738(2):331-41.
2000: Jetske M Meerum Terwogt; Matthijs M Tibben; H Welbank; J H M Schellens; Jos H Beijnen
Validated method for the determination of platinum from a liposomal source (SPI-77) in human plasma using graphite furnace Zeeman atomic absorption spectrometry.
Fresenius' journal of analytical chemistry 2000;366(3):298-302.
2000: Bastiaan Nuijen; Marjan Bouma; RE Henrar; U Brauns; P Bette; Auke Bult; Jos H Beijnen
In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS.
International journal of pharmaceutics 2000;194(2):261-7.
2000: J H M Schellens; Marc Maliepaard; Rik J Scheper; George L Scheffer; johan jonker; Johan W Smit; Jos H Beijnen; Alfred H Schinkel
Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
Annals of the New York Academy of Sciences 2000;922():188-94.
2000: Alwin D R Huitema; Thomas Kerbusch; Matthijs M Tibben; Sjoerd Rodenhuis; Jos H Beijnen
Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens.
Cancer chemotherapy and pharmacology 2000;46(2):119-27.
2000: Anneke M Westermann; Ria Dubbelman; J P Baars; Wouter H Moolenaar; Jos H Beijnen; Sjoerd Rodenhuis
Feasibility and pharmacokinetics of intraperitoneal suramin in advanced malignancy.
Cancer chemotherapy and pharmacology 2000;46(1):57-62.
2000: C M F Kruijtzer; Jos H Beijnen; M Swart; J H M Schellens
Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma). A case report and review of the literature.
Cancer chemotherapy and pharmacology 2000;45(5):428-31.
2000: MA Hoitink; Jos H Beijnen; Auke Bult; J M Damen; OA van der Houwen; John A W Kruijtzer; Matthijs M Tibben; Gerard Wiese; Willy J M Underberg
Degradation of azaglycinamido residues in model tripeptides derived from goserelin.
Journal of pharmaceutical sciences 2000;89(1):108-14.
2000: Hilde Rosing; V Lustig; LJ van Warmerdam; manon huizing; Wim W ten Bokkel Huinink; J H M Schellens; Sjoerd Rodenhuis; A Bult; Jos H Beijnen
Pharmacokinetics and metabolism of docetaxel administered as a 1-h intravenous infusion.
Cancer chemotherapy and pharmacology 2000;45(3):213-8.
1999: Agnes I Veldkamp; Rolf W Sparidans; Richard Hoetelmans; Jos H Beijnen
Quantitative determination of abacavir (1592U89), a novel nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1999;736(1-2):123-8.
1999: Rolf W Sparidans; Agnes I Veldkamp; Richard Hoetelmans; Jos H Beijnen
Improved and simplified liquid chromatographic assay for adefovir, a novel antiviral drug, in human plasma using derivatization with chloroacetaldehyde.
Journal of chromatography. B, Biomedical sciences and applications 1999;736(1-2):115-21.
1999: Agnes I Veldkamp; Richard Hoetelmans; Jos H Beijnen; Jan W Mulder; Pieter L Meenhorst
Ritonavir enables combined therapy with rifampin and saquinavir.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 1999;29(6):1586.
1999: Bastiaan Nuijen; Marjan Bouma; RE Henrar; Consuelo Manada; Auke Bult; Jos H Beijnen
Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration.
Anti-cancer drugs 1999;10(10):879-87.
1999: Jetske M Meerum Terwogt; Mirte M Malingré; Jos H Beijnen; Wim W ten Bokkel Huinink; Hilde Rosing; FJ Koopman; Olaf van Tellingen; M Swart; J H M Schellens
Coadministration of oral cyclosporin A enables oral therapy with paclitaxel.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(11):3379-84.
1999: Dick Pluim; Marc Maliepaard; Robert C A M van Waardenburg; Jos H Beijnen; J H M Schellens
32P-postlabeling assay for the quantification of the major platinum-DNA adducts.
Analytical biochemistry 1999;275(1):30-8.
1999: VR Nannan Panday; LJ van Warmerdam; manon huizing; Wim W ten Bokkel Huinink; J H M Schellens; Jos H Beijnen
A limited-sampling model for the pharmacokinetics of carboplatin administered in combination with paclitaxel.
Journal of cancer research and clinical oncology 1999;125(11):615-20.
1999: Agnes I Veldkamp; Rolf P G van Heeswijk; Pieter L Meenhorst; Jan W Mulder; Joep M A Lange; Jos H Beijnen; Richard Hoetelmans
Quantitative determination of efavirenz (DMP 266), a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1999;734(1):55-61.
1999: Olaf van Tellingen; Jos H Beijnen; Jaap Verweij; E J Scherrenburg; Willem Nooijen; Alex Sparreboom
Rapid esterase-sensitive breakdown of polysorbate 80 and its impact on the plasma pharmacokinetics of docetaxel and metabolites in mice.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(10):2918-24.
1999: Miranda Verschraagen; C H Koks; J H M Schellens; Jos H Beijnen
P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil.
Pharmacological research : the official journal of the Italian Pharmacological Society 1999;40(4):301-6.
1999: Rolf P G van Heeswijk; Agnes I Veldkamp; Richard Hoetelmans; Jan W Mulder; Gerrit Schreij; A Hsu; Joep M A Lange; Jos H Beijnen; Pieter L Meenhorst
The steady-state plasma pharmacokinetics of indinavir alone and in combination with a low dose of ritonavir in twice daily dosing regimens in HIV-1-infected individuals.
AIDS (London, England) 1999;13(14):F95-9.
1999: Ardy van Helvoort; Arjan de Brouwer; Roelof Ottenhoff; Jos F Brouwers; Jan Wijnholds; Jos H Beijnen; A Rijneveld; T van der Poll; Martin van der Valk; Donné M Majoor; W Voorhout; Karel W A Wirtz; Ronald P J Oude Elferink; Piet Borst
Mice without phosphatidylcholine transfer protein have no defects in the secretion of phosphatidylcholine into bile or into lung airspaces.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(20):11501-6.
1999: MJ van Maanen; I M Tijhof; JM Damen; Cees Versluis; J J van den Bosch; albert heck; Sjoerd Rodenhuis; Jos H Beijnen
A search for new metabolites of N,N',N''-triethylenethiophosphoramide.
Cancer research 1999;59(18):4720-4.
1999: MJ van Maanen; Jos H Beijnen
Liquid chromatographic-mass spectrometric determination of the novel, recently identified thioTEPA metabolite, thioTEPA-mercapturate, in urine.
Journal of chromatography. B, Biomedical sciences and applications 1999;732(1):73-9.
1999: Olaf van Tellingen; manon huizing; VR Panday; J H M Schellens; Willem Nooijen; Jos H Beijnen
Cremophor EL causes (pseudo-) non-linear pharmacokinetics of paclitaxel in patients.
British journal of cancer 1999;81(2):330-5.
1999: Rolf W Sparidans; Babs G Taal; Jos H Beijnen
Bioanalysis of m-iodobenzylguanidine in plasma by high-performance liquid chromatography after derivatization with benzoin.
Journal of chromatography. B, Biomedical sciences and applications 1999;730(2):193-9.
1999: Judith R Kroep; Giuseppe Giaccone; Daphne Voorn; Egbert F Smit; Jos H Beijnen; H Rosing; Catharina J A Van Moorsel; Cees J van Groeningen; Pieter E Postmus; HERBERT PINEDO; Godefridus J Peters
Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(7):2190-7.
1999: Virginie M M Herben; Hilde Rosing; Wim W ten Bokkel Huinink; Desiree M van Zomeren; Diane Batchelor; E Doyle; F D Beusenberg; Jos H Beijnen; J H M Schellens
Oral topotecan: bioavailablity and effect of food co-administration.
British journal of cancer 1999;80(9):1380-6.
1999: VR Panday; Wim W ten Bokkel Huinink; Jan B Vermorken; Hilde Rosing; FJ Koopman; M Swart; J H M Schellens; Jos H Beijnen
Pharmacokinetics of paclitaxel administered as a 3-hour or 96-hour infusion.
Pharmacological research : the official journal of the Italian Pharmacological Society 1999;40(1):67-74.
1999: Rolf W Sparidans; Jan den Hartigh; Serge C L M Cremers; Jos H Beijnen; Pieter Vermeij
Semi-automatic liquid chromatographic analysis of pamidronate in urine after derivatization with 1-naphthylisothiocyanate.
Journal of chromatography. B, Biomedical sciences and applications 1999;730(1):95-9.
1999: Rolf W Sparidans; J Jantina Kettenes-van den Bosch; Olaf van Tellingen; B Nuyen; RE Henrar; José Jimeno; Glynn Faircloth; Pablo Floriano; K L Rinehart; Jos H Beijnen
Bioanalysis of aplidine, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography after derivatization with trans-4-hydrazino-2-stilbazole.
Journal of chromatography. B, Biomedical sciences and applications 1999;729(1-2):43-53.
1999: Virginie M M Herben; R van Gijn; J H M Schellens; Margaret Schot; J Lieverst; Michel J X Hillebrand; Nadja E Schoemaker; M G Porro; Jos H Beijnen; Wim W ten Bokkel Huinink
Phase I and pharmacokinetic study of a daily times 5 short intravenous infusion schedule of 9-aminocamptothecin in a colloidal dispersion formulation in patients with advanced solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1906-14.
1999: Virginie M M Herben; J H M Schellens; M Swart; G Gruia; L Vernillet; Jos H Beijnen; Wim W ten Bokkel Huinink
Phase I and pharmacokinetic study of irinotecan administered as a low-dose, continuous intravenous infusion over 14 days in patients with malignant solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(6):1897-905.
1999: J Léon; E Reubsaet; Jos H Beijnen; Wouter P van Bennekom; Auke Bult; Anne Hoekstra; E Hop; P J van Os; Jan Teeuwsen; Willy J M Underberg
Reduction of Cys36-Cys42 and Cys64-Cys74 disulfide bonds in recombinant human granulocyte colony stimulating factor.
Journal of pharmaceutical and biomedical analysis 1999;19(6):837-45.
1999: Epie Boven; WJ Jansen; Theresia M Hulscher; Jos H Beijnen; O van Tellingen
The influence of P170-glycoprotein modulators on the efficacy and the distribution of vincristine as well as on MDR1 expression in BRO/mdr1.1 human melanoma xenografts.
European journal of cancer (Oxford, England : 1990) 1999;35(5):840-9.
1999: Hilde Rosing; Desiree M van Zomeren; E Doyle; W W ten Bokkel; J H M Schellens; Auke Bult; Jos H Beijnen
Quantification of topotecan and its metabolite N-desmethyltopotecan in human plasma, urine and faeces by high-performance liquid chromatographic methods.
Journal of chromatography. B, Biomedical sciences and applications 1999;727(1-2):191-203.
1999: Agnes I Veldkamp; Rolf P G van Heeswijk; Richard Hoetelmans; Pieter L Meenhorst; Jan W Mulder; Joep M A Lange; Jos H Beijnen
Rapid quantification of delavirdine, a novel non-nucleoside reverse transcriptase inhibitor, in human plasma using isocratic reversed-phase high-performance liquid chromatography with fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1999;727(1-2):151-7.
1999: Rolf W Sparidans; RE Henrar; José Jimeno; Glynn Faircloth; Pablo Floriano; Jos H Beijnen
Bioanalysis of thiocoraline, a new marine antitumoral depsipeptide, in plasma by high-performance liquid chromatography and fluorescence detection.
Journal of chromatography. B, Biomedical sciences and applications 1999;726(1-2):255-60.
1999: JM Terwogt; J H M Schellens; Wim W Ten Bokkel Huinink; Jos H Beijnen
Clinical pharmacology of anticancer agents in relation to formulations and administration routes.
Cancer treatment reviews 1999;25(2):83-101.
1999: J van Asperen; Olaf van Tellingen; Alfred H Schinkel; Jos H Beijnen
Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein.
The Journal of pharmacology and experimental therapeutics 1999;289(1):329-33.
1999: JL Reubsaet; Jos H Beijnen; E H Belshof; M Bouyakhrichan; Auke Bult; E Hop; Y Kellekule; RJ van Maanen; Jan Teeuwsen; Willy J M Underberg
Qualitative and quantitative aspects of the degradation of several tripeptides derived from the antitumour peptide antagonist [Arg(6), D-Trp(7,9), MePhe(8)] substance P[6-11].
Journal of pharmaceutical and biomedical analysis 1999;19(3-4):277-84.
1999: JM Terwogt; IA Mandjes; H Sindermann; Jos H Beijnen; Wim W ten Bokkel Huinink
Phase II trial of topically applied miltefosine solution in patients with skin-metastasized breast cancer.
British journal of cancer 1999;79(7-8):1158-61.
1999: Virginie M M Herben; VR Panday; Dick J Richel; J H M Schellens; Nine van der Vange; Hilde Rosing; F D Beusenberg; Solange Hearn; E Doyle; Jos H Beijnen; Wim W ten Bokkel Huinink
Phase I and pharmacologic study of the combination of paclitaxel, cisplatin, and topotecan administered intravenously every 21 days as first-line therapy in patients with advanced ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(3):747-55.
1999: MJ van Maanen; A C Brandt; JM Damen; Jos H Beijnen
Degradation study of thiotepa in aqueous solutions.
International journal of pharmaceutics 1999;179(1):55-64.
1999: Annemieke Kuin; Marja Rutgers; Martin van der Valk; Jos H Beijnen; Lou A Smets
Bioavailability and toxicity after oral administration of m-iodobenzylguanidine (MIBG).
British journal of cancer 1999;79(5-6):802-6.
1999: Annemieke Kuin; Maurice C G Aalders; M Lamfers; D J van Zuidam; M Essers; Jos H Beijnen; Lou A Smets
Potentiation of anti-cancer drug activity at low intratumoral pH induced by the mitochondrial inhibitor m-iodobenzylguanidine (MIBG) and its analogue benzylguanidine (BG).
British journal of cancer 1999;79(5-6):793-801.
1999: Alwin D R Huitema; M M J Holtkamp; Matthijs M Tibben; Sjoerd Rodenhuis; Jos H Beijnen
Sampling technique from central venous catheters proves critical for pharmacokinetic studies.
Therapeutic drug monitoring 1999;21(1):102-4.
1999: R van Gijn; Olaf van Tellingen; E Haverkate; J Jantina Kettenes-van den Bosch; Auke Bult; Jos H Beijnen
Pharmacokinetics and metabolism of the staurosporine analogue CGP 41 251 in mice.
Investigational new drugs 1999;17(1):29-41.
1999: VR Nannan Panday; Ronald de Wit; Jan H Schornagel; Margaret Schot; Hilde Rosing; J Lieverst; Wim W ten Bokkel Huinink; J H M Schellens; Jos H Beijnen
Pharmacokinetics of paclitaxel administered in combination with cisplatin, etoposide and bleomycin in patients with advanced solid tumours.
Cancer chemotherapy and pharmacology 1999;44(4):349-53.
1999: Hilde Rosing; Wim W ten Bokkel Huinink; R van Gijn; R F Rombouts; Auke Bult; Jos H Beijnen
Comparative open, randomized, cross-over bioequivalence study of two intravenous dexrazoxane formulations (Cardioxane and ICRF-187) in patients with advanced breast cancer, treated with 5-fluorouracil-doxorubicin-cyclophosphamide (FDC).
European journal of drug metabolism and pharmacokinetics 1999;24(1):69-77.
1999: J van Asperen; Olaf van Tellingen; F Tijssen; Alfred H Schinkel; Jos H Beijnen
Increased accumulation of doxorubicin and doxorubicinol in cardiac tissue of mice lacking mdr1a P-glycoprotein.
British journal of cancer 1999;79(1):108-13.
1999: VR Nannan Panday; Richard Hoetelmans; Rolf P G van Heeswijk; Pieter L Meenhorst; M Inghels; Jan W Mulder; Jos H Beijnen
Paclitaxel in the treatment of human immunodeficiency virus 1-associated Kaposi's sarcoma--drug-drug interactions with protease inhibitors and a nonnucleoside reverse transcriptase inhibitor: a case report study.
Cancer chemotherapy and pharmacology 1999;43(6):516-9.
1999: R van Gijn; Wim W ten Bokkel Huinink; Sjoerd Rodenhuis; Jan B Vermorken; Olaf van Tellingen; Hilde Rosing; LJ van Warmerdam; Jos H Beijnen
Topoisomerase I/II inhibitor intoplicine administered as a 24 h infusion: phase I and pharmacologic study.
Anti-cancer drugs 1999;10(1):17-23.
1999: VR Panday; LJ van Warmerdam; manon huizing; Sjoerd Rodenhuis; J H M Schellens; Jos H Beijnen
A single 24-hour plasma sample does not predict the carboplatin AUC from carboplatin-paclitaxel combinations or from a high-dose carboplatin-thiotepa-cyclophosphamide regimen.
Cancer chemotherapy and pharmacology 1999;43(5):435-8.
1998: Richard Hoetelmans; Rolf P G van Heeswijk; M Profijt; Jan W Mulder; Pieter L Meenhorst; Joep M A Lange; Peter Reiss; Jos H Beijnen
Comparison of the plasma pharmacokinetics and renal clearance of didanosine during once and twice daily dosing in HIV-1 infected individuals.
AIDS (London, England) 1998;12(17):F211-6.
1998: Richard Hoetelmans; M Profijt; Pieter L Meenhorst; Jan W Mulder; Rolf P G van Heeswijk; Jos H Beijnen
Co-trimoxazole and stavudine interference in a high-performance liquid chromatographic analysis for didanosine in human plasma.
Therapeutic drug monitoring 1998;20(6):669-72.
1998: Olaf van Tellingen; M Kemper; F Tijssen; J van Asperen; Willem Nooijen; Jos H Beijnen
High-performance liquid chromatographic bio-analysis of PSC 833 in human and murine plasma.
Journal of chromatography. B, Biomedical sciences and applications 1998;719(1-2):251-7.
1998: Rolf P G van Heeswijk; Richard Hoetelmans; Remko Harms; Pieter L Meenhorst; Jan W Mulder; Joep M A Lange; Jos H Beijnen
Simultaneous quantitative determination of the HIV protease inhibitors amprenavir, indinavir, nelfinavir, ritonavir and saquinavir in human plasma by ion-pair high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1998;719(1-2):159-68.
1998: RJ van Maanen; Ronald D van Ooijen; JW Zwikker; Alwin D R Huitema; Sjoerd Rodenhuis; Jos H Beijnen
Determination of N,N',N"-triethylenethiophosphoramide and its active metabolite N,N',N"-triethylenephosphoramide in plasma and urine using capillary gas chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1998;719(1-2):103-12.
1998: Hilde Rosing; Michel J X Hillebrand; José Jimeno; A Gómez; Pablo Floriano; Glynn Faircloth; RE Henrar; Jan B Vermorken; Esteban Cvitkovic; Auke Bult; Jos H Beijnen
Quantitative determination of Ecteinascidin 743 in human plasma by miniaturized high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry.
Journal of mass spectrometry : JMS 1998;33(11):1134-40.
1998: Kristel M L Crommentuyn; J H M Schellens; JD Van den Berg; Jos H Beijnen
In-vitro metabolism of anti-cancer drugs, methods and applications: paclitaxel, docetaxel, tamoxifen and ifosfamide.
Cancer treatment reviews 1998;24(5):345-66.
1998: J van Asperen; Olaf van Tellingen; Martin van der Valk; M Rozenhart; Jos H Beijnen
Enhanced oral absorption and decreased elimination of paclitaxel in mice cotreated with cyclosporin A.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(10):2293-7.
1998: L M Oostweegel; Jos H Beijnen; Jan W Mulder
Hepatitis during chloroguanide prophylaxis.
The Annals of pharmacotherapy 1998;32(10):1023-5.
1998: Thomas Kerbusch; Alwin D R Huitema; J Jantina Kettenes-van den Bosch; HJ Keizer; J Ouwerkerk; J de Kraker; Jos H Beijnen
High-performance liquid chromatographic determination of stabilized 4-hydroxyifosfamide in human plasma and erythrocytes.
Journal of chromatography. B, Biomedical sciences and applications 1998;716(1-2):275-84.
1998: Alwin D R Huitema; Matthijs M Tibben; Thomas Kerbusch; JW Zwikker; Sjoerd Rodenhuis; Jos H Beijnen
Simultaneous determination of N,N',N"-triethylenethiophosphoramide, cyclophosphamide and some of their metabolites in plasma using capillary gas chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1998;716(1-2):177-86.
1998: Jan Wijnholds; G L Scheffer; Martin van der Valk; P van der Valk; Jos H Beijnen; R J Scheper; P Borst
Multidrug resistance protein 1 protects the oropharyngeal mucosal layer and the testicular tubules against drug-induced damage.
The Journal of experimental medicine 1998;188(5):797-808.
1998: JL Reubsaet; Jos H Beijnen; Auke Bult; RJ van Maanen; J A Marchal; Willy J M Underberg
Analytical techniques used to study the degradation of proteins and peptides: physical instability.
Journal of pharmaceutical and biomedical analysis 1998;17(6-7):979-84.
1998: JL Reubsaet; Jos H Beijnen; Auke Bult; RJ van Maanen; J A Marchal; Willy J M Underberg
Analytical techniques used to study the degradation of proteins and peptides: chemical instability.
Journal of pharmaceutical and biomedical analysis 1998;17(6-7):955-78.
1998: VR Panday; Wim W ten Bokkel Huinink; Hilde Rosing; FJ Koopman; Michel J X Hillebrand; Ria Dubbelman; Olaf van Tellingen; J H M Schellens; Jos H Beijnen
Phase I and pharmacologic study of weekly doxorubicin and 1 h infusional paclitaxel in patients with advanced breast cancer.
Anti-cancer drugs 1998;9(8):665-73.
1998: R van Gijn; Virginie M M Herben; Michel J X Hillebrand; Wim W ten Bokkel Huinink; Auke Bult; Jos H Beijnen
High-performance liquid chromatographic analysis of the investigational anticancer drug 9-aminocamptothecin, as the lactone form and as the total of the lactone and the hydroxycarboxylate forms, in micro-volumes of human plasma.
Journal of pharmaceutical and biomedical analysis 1998;17(8):1257-65.
1998: VR Panday; manon huizing; LJ van Warmerdam; Ria Dubbelman; IA Mandjes; J H M Schellens; Wim W Ten Bokkel Huinink; Jos H Beijnen
Pharmacologic study of 3-hour 135 mg M-2 paclitaxel in platinum pretreated patients with advanced ovarian cancer.
Pharmacological research : the official journal of the Italian Pharmacological Society 1998;38(3):231-6.
1998: MA Hoitink; Jos H Beijnen; M U Boschma; Auke Bult; OA van der Houwen; Gerard Wiese; Willy J M Underberg
Degradation kinetics of three gonadorelin analogues: developing a method for calculating epimerization parameters.
Pharmaceutical research 1998;15(9):1449-55.
1998: Rolf P G van Heeswijk; Richard Hoetelmans; Pieter L Meenhorst; Jan W Mulder; Jos H Beijnen
Rapid determination of nevirapine in human plasma by ion-pair reversed-phase high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1998;713(2):395-9.
1998: Richard Hoetelmans; M Profijt; P L Mennhorst; Jan W Mulder; Jos H Beijnen
Quantitative determination of (-)-2'-deoxy-3'-thiacytidine (lamivudine) in human plasma, saliva and cerebrospinal fluid by high-performance liquid chromatography with ultraviolet detection.
Journal of chromatography. B, Biomedical sciences and applications 1998;713(2):387-94.
1998: J van Asperen; Olaf van Tellingen; Jos H Beijnen
Determination of doxorubicin and metabolites in murine specimens by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1998;712(1-2):129-43.
1998: Hilde Rosing; Desiree M van Zomeren; E Doyle; Auke Bult; Jos H Beijnen
O-glucuronidation, a newly identified metabolic pathway for topotecan and N-desmethyl topotecan.
Anti-cancer drugs 1998;9(7):587-92.
1998: Virginie M M Herben; Wim W ten Bokkel Huinink; J H M Schellens; Jos H Beijnen
Clinical pharmacokinetics of camptothecin topoisomerase I inhibitors.
Pharmacy world & science : PWS 1998;20(4):161-72.
1998: Richard Hoetelmans; MH Reijers; Gerrit Jan Weverling; Reinier W Ten Kate; Ferdinand W N M Wit; Jan W Mulder; Hugo M Weigel; P H J Frissen; M Roos; Suzanne Jurriaans; Hanneke Schuitemaker; Frank de Wolf; Jos H Beijnen; Joep M A Lange
The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy.
AIDS (London, England) 1998;12(11):F111-5.
1998: Alwin D R Huitema; Marcel Soesan; Pieter L Meenhorst; Cornelis H W Koks; Jos H Beijnen
A dose-dependent delayed hypersensitivity reaction to acetaminophen after repeated acetaminophen intoxications.
Human & experimental toxicology 1998;17(7):406-8.
1998: Hilde Rosing; Michel J X Hillebrand; José Jimeno; A Gómez; Pablo Floriano; Glynn Faircloth; L Cameron; RE Henrar; Jan B Vermorken; Auke Bult; Jos H Beijnen
Analysis of Ecteinascidin 743, a new potent marine-derived anticancer drug, in human plasma by high-performance liquid chromatography in combination with solid-phase extraction.
Journal of chromatography. B, Biomedical sciences and applications 1998;710(1-2):183-9.
1998: J van Asperen; Olaf van Tellingen; Jos H Beijnen
The pharmacological role of P-glycoprotein in the intestinal epithelium.
Pharmacological research : the official journal of the Italian Pharmacological Society 1998;37(6):429-35.
1998: Virginie M M Herben; Wim W ten Bokkel Huinink; Margaret Schot; IR Hudson; Jos H Beijnen
Continuous infusion of low-dose topotecan: pharmacokinetics and pharmacodynamics during a phase II study in patients with small cell lung cancer.
Anti-cancer drugs 1998;9(5):411-8.
1998: JL Reubsaet; Jos H Beijnen; Auke Bult; E Hop; S D Scholten; Jan Teeuwsen; Willy J M Underberg
Oxidation of recombinant methionyl human granulocyte colony stimulating factor.
Journal of pharmaceutical and biomedical analysis 1998;17(2):283-9.
1998: Olaf van Tellingen; Willem Nooijen; L J Schaaf; Martin van der Valk; J van Asperen; RE Henrar; Jos H Beijnen
Comparative pharmacology of the novel cyclopropylpyrroloindole-prodrug carzelesin in mice, rats, and humans.
Cancer research 1998;58(11):2410-6.
1998: manon huizing; Hilde Rosing; F P Koopmans; Jos H Beijnen
Influence of Cremophor EL on the quantification of paclitaxel in plasma using high-performance liquid chromatography with solid-phase extraction as sample pretreatment.
Journal of chromatography. B, Biomedical sciences and applications 1998;709(1):161-5.
1998: GP Kaijser; J De Kraker; Auke Bult; Willy J M Underberg; Jos H Beijnen
Pharmacokinetics of ifosfamide and some metabolites in children.
Anticancer research 1998;18(3B):1941-9.
1998: Anneke M Westermann; E Havik; Friso R Postma; Jos H Beijnen; Otilia Dalesio; Wouter H Moolenaar; Sjoerd Rodenhuis
Malignant effusions contain lysophosphatidic acid (LPA)-like activity.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1998;9(4):437-42.
1998: Rolf W Sparidans; Jan den Hartigh; Jos H Beijnen; Pieter Vermeij
Semi-automatic liquid chromatographic analysis of pamidronate in serum and citrate plasma after derivatization with 1-naphthylisothiocyanate.
Journal of chromatography. B, Biomedical sciences and applications 1998;705(2):331-9.
1998: Richard Hoetelmans; M van Essenberg; M Profijt; Pieter L Meenhorst; Jan W Mulder; Jos H Beijnen
High-performance liquid chromatographic determination of ritonavir in human plasma, cerebrospinal fluid and saliva.
Journal of chromatography. B, Biomedical sciences and applications 1998;705(1):119-26.
1998: VR Nannan Panday; LJ van Warmerdam; manon huizing; Wim W ten Bokkel Huinink; Jan B Vermorken; Giuseppe Giaccone; Cindy Veenhof; J H M Schellens; Jos H Beijnen
Carboplatin dosage formulae can generate inaccurate predictions of Carboplatin exposure in carboplatin/paclitaxel combination regimens.
Clinical drug investigation 1998;15(4):327-35.
1998: J D Jonkman-de Vries; Hilde Rosing; Herre Talsma; RE Henrar; J Jantina Kettenes-van den Bosch; Auke Bult; Jos H Beijnen
Pharmaceutical development of a parenteral lyophilized formulation of the investigational antitumor neuropeptide antagonist [Arg6, D-Trp7,9, MePhe8]-Substance P [6-11].
Investigational new drugs 1998;16(2):99-111.
1998: Paul van de Vaart; Nine van der Vange; Frans A N Zoetmulder; A R van Goethem; Olaf van Tellingen; Wim W ten Bokkel Huinink; Jos H Beijnen; Harry Bartelink; Adrian C Begg
Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines.
European journal of cancer (Oxford, England : 1990) 1998;34(1):148-54.
1998: Olaf van Tellingen; Cornelis J A Punt; Ahmad Awada; D J Wagener; Martine J Piccart; Y Groot; L J Schaaf; RE Henrar; Willem Nooijen; Jos H Beijnen
A clinical pharmacokinetics study of carzelesin given by short-term intravenous infusion in a phase I study.
Cancer chemotherapy and pharmacology 1998;41(5):377-84.
1998: Rob A J Kuiper; J H M Schellens; G H Blijham; Jos H Beijnen; E E Voest
Clinical research on antiangiogenic therapy.
Pharmacological research : the official journal of the Italian Pharmacological Society 1998;37(1):1-16.
1997: U Mayer; Els Wagenaar; B Dorobek; Jos H Beijnen; Piet Borst; Alfred H Schinkel
Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833.
The Journal of clinical investigation 1997;100(10):2430-6.
1997: Jan Wijnholds; Raymond Evers; MR van Leusden; CA Mol; G J Zaman; U Mayer; Jos H Beijnen; Martin van der Valk; Paul Krimpenfort; Piet Borst
Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein.
Nature medicine 1997;3(11):1275-9.
1997: brian e davies; E A Minthorn; M J Dennis; Hilde Rosing; Jos H Beijnen
The pharmacokinetics of topotecan and its carboxylate form following separate intravenous administration to the dog.
Pharmaceutical research 1997;14(10):1461-5.
1997: RJ van Maanen; Ronald D van Ooijen; Jos H Beijnen
Determination of N,N',N"-triethylenthiophosphoramide in biological samples using capillary gas chromatography.
Journal of chromatography. B, Biomedical sciences and applications 1997;698(1-2):111-21.
1997: Mirjam Crul; J H M Schellens; Jos H Beijnen; Marc Maliepaard
Cisplatin resistance and DNA repair.
Cancer treatment reviews 1997;23(5-6):341-66.
1997: Rolf W Sparidans; Jan den Hartigh; Jos H Beijnen; Pieter Vermeij
Determination of pamidronate in urine by ion-pair liquid chromatography after derivatization with 1-naphthylisothiocyanate.
Journal of chromatography. B, Biomedical sciences and applications 1997;696(1):137-44.
1997: Hilde Rosing; V Lustig; F P Koopman; Wim W ten Bokkel Huinink; Jos H Beijnen
Bio-analysis of docetaxel and hydroxylated metabolites in human plasma by high-performance liquid chromatography and automated solid-phase extraction.
Journal of chromatography. B, Biomedical sciences and applications 1997;696(1):89-98.
1997: Anneke M Westermann; Ria Dubbelman; Wouter H Moolenaar; Jos H Beijnen; Sjoerd Rodenhuis
Successful intraperitoneal suramin treatment of peritoneal mesothelioma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(8):801-2.
1997: VR Panday; manon huizing; P H Willemse; A De Graeff; Wim W ten Bokkel Huinink; Jan B Vermorken; Jos H Beijnen
Hepatic metabolism of paclitaxel and its impact in patients with altered hepatic function.
Seminars in oncology 1997;24(4 Suppl 11):S11-34-S11-38.
1997: Richard Hoetelmans; Pieter L Meenhorst; Jan W Mulder; David Burger; Cornelis H W Koks; Jos H Beijnen
Clinical pharmacology of HIV protease inhibitors: focus on saquinavir, indinavir, and ritonavir.
Pharmacy world & science : PWS 1997;19(4):159-75.
1997: J van Asperen; U Mayer; Olaf van Tellingen; Jos H Beijnen
The functional role of P-glycoprotein in the blood-brain barrier.
Journal of pharmaceutical sciences 1997;86(8):881-4.
1997: manon huizing; LJ van Warmerdam; Hilde Rosing; M C Schaefers; A Lai; TJ Helmerhorst; Cindy Veenhof; M J Birkhofer; Sjoerd Rodenhuis; Jos H Beijnen; Wim W ten Bokkel Huinink
Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(5):1953-64.
1997: A R Wafelman; Cornelis A Hoefnagel; H J Maessen; R A Maes; Jos H Beijnen
Renal excretion of iodine-131 labelled meta-iodobenzylguanidine and metabolites after therapeutic doses in patients suffering from different neural crest-derived tumours.
European journal of nuclear medicine 1997;24(5):544-52.
1997: Wim W ten Bokkel Huinink; LJ van Warmerdam; TJ Helmerhorst; M C Schaefers; Jos H Beijnen; Sjoerd Rodenhuis
Phase II study of the combination carboplatin and paclitaxel in patients with ovarian cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(4):351-4.
1997: GP Kaijser; Jos H Beijnen; Auke Bult; HJ Keizer; Willy J M Underberg
Chromatographic analysis of the enantiomers of ifosfamide and some of its metabolites in plasma and urine.
Journal of chromatography. B, Biomedical sciences and applications 1997;690(1-2):131-8.
1997: Alex Sparreboom; J van Asperen; U Mayer; Alfred H Schinkel; J W Smit; D K Meijer; Piet Borst; Willem Nooijen; Jos H Beijnen; Olaf van Tellingen
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.
Proceedings of the National Academy of Sciences of the United States of America 1997;94(5):2031-5.
1997: Anneke M Westermann; Jos H Beijnen; Wouter H Moolenaar; Sjoerd Rodenhuis
Growth factors in human ovarian cancer.
Cancer treatment reviews 1997;23(2):113-31.
1997: JM Terwogt; Bastiaan Nuijen; Wim W Ten Bokkel Huinink; Jos H Beijnen
Alternative formulations of paclitaxel.
Cancer treatment reviews 1997;23(2):87-95.
1997: GP Kaijser; P G Ter Riet; J de Kraker; Auke Bult; Jos H Beijnen; Willy J M Underberg
Determination of 4-hydroxyifosfamide in biological matrices by high-performance liquid chromatography.
Journal of pharmaceutical and biomedical analysis 1997;15(6):773-81.
1997: J D Jonkman-de Vries; B J Van den Bemt; Wim W ten Bokkel Huinink; Willy J M Underberg; J Jantina Kettenes-van den Bosch; RE Henrar; Auke Bult; Jos H Beijnen
Pharmaceutical development of a parenteral formulation of the investigational anticancer drug clanfenur.
PDA journal of pharmaceutical science and technology / PDA 1997;51(2):89-95.
1997: LJ van Warmerdam; manon huizing; G Giaccone; P E Postmus; Wim W ten Bokkel Huinink; nico van zandwijk; M G Koolen; TJ Helmerhorst; W J van der Vijgh; Cindy Veenhof; Jos H Beijnen
Clinical pharmacology of carboplatin administered in combination with paclitaxel.
Seminars in oncology 1997;24(1 Suppl 2):S2-97-S2-104.
1997: Wim W ten Bokkel Huinink; Cindy Veenhof; manon huizing; Sjoerd Rodenhuis; TJ Helmerhorst; Ria Dubbelman; Otilia Dalesio; Jos H Beijnen; B Winograd
Carboplatin and paclitaxel in patients with advanced ovarian cancer: a dose-finding study.
Seminars in oncology 1997;24(1 Suppl 2):S2-31-S2-33.
1997: Virginie M M Herben; Wim W ten Bokkel Huinink; A C Dubbelman; IA Mandjes; Y Groot; D M van Gortel-van Zomeren; Jos H Beijnen
Phase I and pharmacological study of sequential intravenous topotecan and oral etoposide.
British journal of cancer 1997;76(11):1500-8.
1997: J van Asperen; Olaf van Tellingen; Alex Sparreboom; Alfred H Schinkel; Piet Borst; Willem Nooijen; Jos H Beijnen
Enhanced oral bioavailability of paclitaxel in mice treated with the P-glycoprotein blocker SDZ PSC 833.
British journal of cancer 1997;76(9):1181-3.
1997: Olaf van Tellingen; Willem Boogerd; Willem Nooijen; Jos H Beijnen
The vascular compartment hampers accurate determination of teniposide penetration into brain tumor tissue.
Cancer chemotherapy and pharmacology 1997;40(4):330-4.
1997: Hilde Rosing; Virginie M M Herben; D M van Gortel-van Zomeren; E Hop; J Jantina Kettenes-van den Bosch; Wim W ten Bokkel Huinink; Jos H Beijnen
Isolation and structural confirmation of N-desmethyl topotecan, a metabolite of topotecan.
Cancer chemotherapy and pharmacology 1997;39(6):498-504.
1997: G J Veldhuis; P H B Willemse; Jos H Beijnen; H Boonstra; H Piersma; Winette T A van der Graaf; Elisabeth G E de Vries
Paclitaxel, ifosfamide and cisplatin with granulocyte colony-stimulating factor or recombinant human interleukin 3 and granulocyte colony-stimulating factor in ovarian cancer: a feasibility study.
British journal of cancer 1997;75(5):703-9.
1997: manon huizing; G Giaccone; LJ van Warmerdam; Hilde Rosing; P J M Bakker; Jan B Vermorken; P E Postmus; nico van zandwijk; M G Koolen; Wim W ten Bokkel Huinink; W J van der Vijgh; F J Bierhorst; A Lai; Otilia Dalesio; HERBERT PINEDO; Cindy Veenhof; Jos H Beijnen
Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):317-29.
1996: GP Kaijser; Jos H Beijnen; E Rozendom; Auke Bult; Willy J M Underberg
Analysis of ifosforamide mustard, the active metabolite of ifosfamide, in plasma.
Journal of chromatography. B, Biomedical applications 1996;686(2):249-55.
1996: Hilde Rosing; E Doyle; Jos H Beijnen
The impact of column temperature in the high performance liquid chromatographic analysis of topotecan in rat and dog plasma.
Journal of pharmaceutical and biomedical analysis 1996;15(2):279-86.
1996: J D Vries; W G Doppenberg; RE Henrar; Auke Bult; Jos H Beijnen
Systematic study on the chemical stability of the prodrug antitumor agent carzelesin (U-80,244)
Journal of pharmaceutical sciences 1996;85(11):1227-33.
1996: U Mayer; Els Wagenaar; Jos H Beijnen; J W Smit; D K Meijer; J van Asperen; Piet Borst; Alfred H Schinkel
Substantial excretion of digoxin via the intestinal mucosa and prevention of long-term digoxin accumulation in the brain by the mdr 1a P-glycoprotein.
British journal of pharmacology 1996;119(5):1038-44.
1996: I Wolff; K Bench; Jos H Beijnen; U Bruntsch; Franco Cavalli; J de Jong; Y Groot; Olaf van Tellingen; Jantien Wanders; Cristiana Sessa
Phase I clinical and pharmacokinetic study of carzelesin (U-80244) given daily for five consecutive days.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(10):1717-23.
1996: A H Witterland; Cornelis H W Koks; Jos H Beijnen
Etoposide phosphate, the water soluble prodrug of etoposide.
Pharmacy world & science : PWS 1996;18(5):163-70.
1996: M A Hoitink; Jos H Beijnen; Auke Bult; O A van der Houwen; J Nijholt; Willy J M Underberg
Degradation kinetics of gonadorelin in aqueous solution.
Journal of pharmaceutical sciences 1996;85(10):1053-9.
1996: GP Kaijser; H J Keizer; Jos H Beijnen; Auke Bult; Willy J M Underberg
Pharmacokinetics of ifosfamide, 2- and 3-dechloroethylifosfamide in plasma and urine of cancer patients treated with a 10-day continuous infusion of ifosfamide.
Anticancer research 1996;16(5B):3247-57.
1996: ELSKEN VAN DER WALL; C C Schaake-Koning; nico van zandwijk; Joke W Baars; Jan H Schornagel; Dick J Richel; E J Th Rutgers; Jacques H Borger; Jos H Beijnen; Sjoerd Rodenhuis
The toxicity of radiotherapy following high-dose chemotherapy with peripheral blood stem cell support in high-risk breast cancer: a preliminary analysis.
European journal of cancer (Oxford, England : 1990) 1996;32A(9):1490-7.
1996: Virginie M M Herben; Wim W ten Bokkel Huinink; Jos H Beijnen
Clinical pharmacokinetics of topotecan.
Clinical pharmacokinetics 1996;31(2):85-102.
1996: Cornelis H W Koks; Pieter L Meenhorst; M J Hillebrand; A Bult; Jos H Beijnen
Pharmacokinetics of fluconazole in saliva and plasma after administration of an oral suspension and capsules.
Antimicrobial agents and chemotherapy 1996;40(8):1935-7.
1996: A R Wafelman; Cornelis A Hoefnagel; R A Maes; Jos H Beijnen
Radiochemical purity, at expiry, and radiochemical stability of iodine-131 labelled meta-iodobenzylguanidine concentrates for intravenous infusion.
Nuklearmedizin. Nuclear medicine 1996;35(4):122-5.
1996: J van Asperen; Alfred H Schinkel; Jos H Beijnen; Willem Nooijen; Piet Borst; Olaf van Tellingen
Altered pharmacokinetics of vinblastine in Mdr1a P-glycoprotein-deficient Mice.
Journal of the National Cancer Institute 1996;88(14):994-9.
1996: Ronald de Wit; Jos H Beijnen; Olaf van Tellingen; J H M Schellens; MM de Boer-Dennert; Jaap Verweij
Pharmacokinetic profile and clinical efficacy of a once-daily ondansetron suppository in cyclophosphamide-induced emesis: a double blind comparative study with ondansetron tablets.
British journal of cancer 1996;74(2):323-6.
1996: Alex Sparreboom; Olaf van Tellingen; manon huizing; Willem Nooijen; Jos H Beijnen
Determination of polyoxyethyleneglycerol triricinoleate 35 (Cremophor EL) in plasma by pre-column derivatization and reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1996;681(2):355-62.
1996: Babs G Taal; Cornelis A Hoefnagel; R A Valdes Olmos; Henk Boot; Jos H Beijnen
Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(6):1829-38.
1996: J H M Schellens; Geert-Jan Creemers; Jos H Beijnen; Hilde Rosing; MM de Boer-Dennert; M McDonald; B Davies; Jaap Verweij
Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
British journal of cancer 1996;73(10):1268-71.
1996: ELSKEN VAN DER WALL; E J Th Rutgers; M J Holtkamp; Joke W Baars; Jan H Schornagel; Johannes L Peterse; Jos H Beijnen; Sjoerd Rodenhuis
Efficacy of up-front 5-fluorouracil-epidoxorubicin-cyclophosphamide (FEC) chemotherapy with an increased dose of epidoxorubicin in high-risk breast cancer patients.
British journal of cancer 1996;73(9):1080-5.
1996: Alex Sparreboom; Olaf van Tellingen; Willem Nooijen; Jos H Beijnen
Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL.
Cancer research 1996;56(9):2112-5.
1996: Richard Hoetelmans; David Burger; Pieter L Meenhorst; Jos H Beijnen
Pharmacokinetic individualisation of zidovudine therapy. Current state of pharmacokinetic-pharmacodynamic relationships.
Clinical pharmacokinetics 1996;30(4):314-27.
1996: Richard Hoetelmans; Jan Schornagel; Wim W ten Bokkel Huinink; Jos H Beijnen
Hypersensitivity reactions to etoposide.
The Annals of pharmacotherapy 1996;30(4):367-71.
1996: LJ van Warmerdam; Sjoerd Rodenhuis; ELSKEN VAN DER WALL; R A Maes; Jos H Beijnen
Pharmacokinetics and pharmacodynamics of carboplatin administered in a high-dose combination regimen with thiotepa, cyclophosphamide and peripheral stem cell support.
British journal of cancer 1996;73(8):979-84.
1996: J D Jonkman-de Vries; J Jantina Kettenes-van den Bosch; RE Henrar; Auke Bult; Jos H Beijnen
Purity determinations in the bulk drug of the novel indoloquinone antitumor agent EO9.
Investigational new drugs 1996;14(2):181-91.
1996: Alex Sparreboom; Olaf van Tellingen; Willem Nooijen; Jos H Beijnen
Tissue distribution, metabolism and excretion of paclitaxel in mice.
Anti-cancer drugs 1996;7(1):78-86.
1996: Olaf van Tellingen; M T Kuck; L T Vlasveld; Sjoerd Rodenhuis; Willem Nooijen; Jos H Beijnen
Unchanged pharmacokinetics of etoposide given by intra-arterial hepatic infusion as compared with i.v. infusion.
Cancer chemotherapy and pharmacology 1996;38(4):387-90.
1996: LJ van Warmerdam; Geert-Jan Creemers; Sjoerd Rodenhuis; Hilde Rosing; MM de Boer-Dennert; J H M Schellens; Wim W ten Bokkel Huinink; brian e davies; R A Maes; Jaap Verweij; Jos H Beijnen
Pharmacokinetics and pharmacodynamics of topotecan given on a daily-times-five schedule in phase II clinical trials using a limited-sampling procedure.
Cancer chemotherapy and pharmacology 1996;38(3):254-60.
1996: LJ van Warmerdam; Sjoerd Rodenhuis; Wim W ten Bokkel Huinink; R A Maes; Jos H Beijnen
Evaluation of formulas using the serum creatinine level to calculate the optimal dosage of carboplatin.
Cancer chemotherapy and pharmacology 1996;37(3):266-70.
1995: manon huizing; Alex Sparreboom; Hilde Rosing; Olaf van Tellingen; HERBERT PINEDO; Jos H Beijnen
Quantification of paclitaxel metabolites in human plasma by high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;674(2):261-8.
1995: R van Gijn; E Havik; E Boven; Jan B Vermorken; Wim W ten Bokkel Huinink; Olaf van Tellingen; Jos H Beijnen
High-performance liquid chromatographic analysis of the new antitumour drug N-benzoylstaurosporine (CGP 41 251) and four potential metabolites in micro-volumes of plasma.
Journal of pharmaceutical and biomedical analysis 1995;14(1-2):165-74.
1995: JL Reubsaet; Jos H Beijnen; Auke Bult; E Hop; R Vermaas; Y Kellekule; J Jantina Kettenes-van den Bosch; Willy J M Underberg
Structural identification of the degradation products of the antitumor peptide antagonist [Arg6,D-Trp7,9,MePhe8]substance P (6-11).
Analytical chemistry 1995;67(23):4431-6.
1995: David Burger; C L Kraayeveld; Pieter L Meenhorst; Jan W Mulder; Richard Hoetelmans; Cornelis H W Koks; Jos H Beijnen
Study on didanosine concentrations in cerebrospinal fluid. Implications for the treatment and prevention of AIDS dementia complex.
Pharmacy world & science : PWS 1995;17(6):218-21.
1995: Y L Nortier; J A van de Haven; Cornelis H W Koks; Jos H Beijnen
Preparation and stability testing of a hydrogel for topical analgesia.
Pharmacy world & science : PWS 1995;17(6):214-7.
1995: J D Jonkman-De Vries; Hilde Rosing; RE Henrar; Auke Bult; Jos H Beijnen
The influence of formulation excipients on the stability of the novel antitumor agent carzelesin (U-80,244).
PDA journal of pharmaceutical science and technology / PDA 1995;49(6):283-8.
1995: David Burger; Pieter L Meenhorst; J Mulder; J Henrichs; J Frissen; F Kroon; C ten Napel; K Koks; A Bult; Jos H Beijnen
Substitution of didanosine sachets by chewable tablets: a pharmacokinetic study in patients with AIDS.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1995;10(2):163-8.
1995: manon huizing; Jan B Vermorken; Hilde Rosing; Wim W ten Bokkel Huinink; IA Mandjes; HERBERT PINEDO; Jos H Beijnen
Pharmacokinetics of paclitaxel and three major metabolites in patients with advanced breast carcinoma refractory to anthracycline therapy treated with a 3-hour paclitaxel infusion: a European Cancer Centre (ECC) trial.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(7):699-704.
1995: A R Wafelman; Y L Nortier; Hilde Rosing; H J Maessen; B G Taal; Cornelis A Hoefnagel; R A Maes; Jos H Beijnen
Renal excretion of meta-iodobenzylguanidine after therapeutic doses in cancer patients and its relation to dose and creatinine clearance.
Nuclear medicine communications 1995;16(9):767-72.
1995: G J Zaman; Jan Lankelma; Olaf van Tellingen; Jos H Beijnen; H Dekker; Coen C Paulusma; Ronald P J Oude Elferink; F Baas; Piet Borst
Role of glutathione in the export of compounds from cells by the multidrug-resistance-associated protein.
Proceedings of the National Academy of Sciences of the United States of America 1995;92(17):7690-4.
1995: Giuseppe Giaccone; manon huizing; P E Postmus; Wim W ten Bokkel Huinink; M Koolen; nico van zandwijk; Jan B Vermorken; Jos H Beijnen; Otilia Dalesio; HERBERT PINEDO
Dose-finding and sequencing study of paclitaxel and carboplatin in non-small cell lung cancer.
Seminars in oncology 1995;22(4 Suppl 9):78-82.
1995: Jan B Vermorken; Wim W ten Bokkel Huinink; I A Mandjes; Tjeerd J Postma; manon huizing; J J Heimans; Jos H Beijnen; F Bierhorst; B Winograd; HERBERT PINEDO
High-dose paclitaxel with granulocyte colony-stimulating factor in patients with advanced breast cancer refractory to anthracycline therapy: a European Cancer Center trial.
Seminars in oncology 1995;22(4 Suppl 8):16-22.
1995: LJ van Warmerdam; Wim W ten Bokkel Huinink; Sjoerd Rodenhuis; I Koier; brian e davies; Hilde Rosing; R A Maes; Jos H Beijnen
Phase I clinical and pharmacokinetic study of topotecan administered by a 24-hour continuous infusion.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(7):1768-76.
1995: Jos H Beijnen; K P Flora; G W Halbert; RE Henrar; J A Slack
CRC/EORTC/NCI Joint Formulation Working Party: experiences in the formulation of investigational cytotoxic drugs.
British journal of cancer 1995;72(1):210-8.
1995: Hilde Rosing; E Doyle; brian e davies; Jos H Beijnen
High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma.
Journal of chromatography. B, Biomedical applications 1995;668(1):107-15.
1995: JL Reubsaet; Jos H Beijnen; Auke Bult; O A van der Houwen; Jan Teeuwsen; E H Koster; Willy J M Underberg
Degradation kinetics of antagonist [Arg6, D-Trp7,9, MePhe8]-substance P [6-11] in aqueous solutions.
Analytical biochemistry 1995;227(2):334-41.
1995: R van Gijn; Olaf van Tellingen; J J de Clippeleir; Michel J X Hillebrand; E Boven; Jan B Vermorken; Wim W ten Bokkel Huinink; S Schwertz; P Graf; Jos H Beijnen
Analytical procedure for the determination of the new antitumour drug N-benzoylstaurosporine and three potential metabolites in human plasma by reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;667(2):269-76.
1995: David Burger; Pieter L Meenhorst; Jos H Beijnen
Concise overview of the clinical pharmacokinetics of dideoxynucleoside antiretroviral agents.
Pharmacy world & science : PWS 1995;17(2):25-30.
1995: ELSKEN VAN DER WALL; Jos H Beijnen; Sjoerd Rodenhuis
High-dose chemotherapy regimens for solid tumors.
Cancer treatment reviews 1995;21(2):105-32.
1995: Alex Sparreboom; Olaf van Tellingen; Willem Nooijen; Jos H Beijnen
Determination of paclitaxel and metabolites in mouse plasma, tissues, urine and faeces by semi-automated reversed-phase high-performance liquid chromatography.
Journal of chromatography. B, Biomedical applications 1995;664(2):383-91.
1995: manon huizing; Hilde Rosing; FJ Koopman; A C Keung; HERBERT PINEDO; Jos H Beijnen
High-performance liquid chromatographic procedures for the quantitative determination of paclitaxel (Taxol) in human urine.
Journal of chromatography. B, Biomedical applications 1995;664(2):373-82.
1995: Cornelis H W Koks; Hilde Rosing; Pieter L Meenhorst; A Bult; Jos H Beijnen
High-performance liquid chromatographic determination of the antifungal drug fluconazole in plasma and saliva of human immunodeficiency virus-infected patients.
Journal of chromatography. B, Biomedical applications 1995;663(2):345-51.
1995: LJ van Warmerdam; Jaap Verweij; J H M Schellens; Hilde Rosing; brian e davies; MM de Boer-Dennert; R A Maes; Jos H Beijnen
Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks.
Cancer chemotherapy and pharmacology 1995;35(3):237-45.
1995: LJ van Warmerdam; Sjoerd Rodenhuis; Wim W ten Bokkel Huinink; R A Maes; Jos H Beijnen
The use of the Calvert formula to determine the optimal carboplatin dosage.
Journal of cancer research and clinical oncology 1995;121(8):478-86.
1995: Alex Sparreboom; manon huizing; J J Boesen; Willem Nooijen; Olaf van Tellingen; Jos H Beijnen
Isolation, purification, and biological activity of mono- and dihydroxylated paclitaxel metabolites from human feces.
Cancer chemotherapy and pharmacology 1995;36(4):299-304.
1994: David Burger; Pieter L Meenhorst; C H ten Napel; Jan W Mulder; C Neef; Cornelis H W Koks; A Bult; Jos H Beijnen
Pharmacokinetic variability of zidovudine in HIV-infected individuals: subgroup analysis and drug interactions.
AIDS (London, England) 1994;8(12):1683-9.
1994: David Burger; Pieter L Meenhorst; Jan W Mulder; C L Kraaijeveld; Cornelis H W Koks; A Bult; Jos H Beijnen
Therapeutic drug monitoring of phenytoin in patients with the acquired immunodeficiency syndrome.
Therapeutic drug monitoring 1994;16(6):616-20.
1994: David Burger; Hilde Rosing; C H ten Napel; T Duyts; Pieter L Meenhorst; Jan W Mulder; Cornelis H W Koks; A Bult; Jos H Beijnen
Application of a radioimmunoassay for determination of levels of zalcitabine (ddC) in human plasma, urine, and cerebrospinal fluid.
Antimicrobial agents and chemotherapy 1994;38(12):2763-7.
1994: A R Wafelman; M C Konings; Cornelis A Hoefnagel; R A Maes; Jos H Beijnen
Synthesis, radiolabelling and stability of radioiodinated m-iodobenzylguanidine, a review.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 1994;45(10):997-107.
1994: Jos H Beijnen; manon huizing; Wim W ten Bokkel Huinink; Cindy Veenhof; Jan B Vermorken; Giuseppe Giaccone; HERBERT PINEDO
Bioanalysis, pharmacokinetics, and pharmacodynamics of the novel anticancer drug paclitaxel (Taxol).
Seminars in oncology 1994;21(5 Suppl 8):53-62.
1994: Giuseppe Giaccone; manon huizing; Wim W ten Bokkel Huinink; M Koolen; P Postmus; K van Kralingen; nico van zandwijk; Jan B Vermorken; Jos H Beijnen; Otilia Dalesio
Preliminary results of two dose-finding studies of paclitaxel (Taxol) and carboplatin in non-small cell lung and ovarian cancers: a European Cancer Centre effort.
Seminars in oncology 1994;21(5 Suppl 8):34-8.
1994: P E Pizao; E Smitskamp-Wilms; J van Ark-Otte; Jos H Beijnen; Godefridus J Peters; HERBERT PINEDO; Giuseppe Giaccone
Antiproliferative activity of the topoisomerase I inhibitors topotecan and camptothecin, on sub- and postconfluent tumor cell cultures.
Biochemical pharmacology 1994;48(6):1145-54.
1994: A R Wafelman; M C Konings; Hilde Rosing; Cornelis A Hoefnagel; B G Taal; R A Maes; Jos H Beijnen
High-performance liquid chromatographic determination of metaiodobenzylguanidine in whole blood and plasma of cancer patients.
Journal of pharmaceutical and biomedical analysis 1994;12(9):1173-9.
1994: Joost M Klaase; Bin B R Kroon; Jos H Beijnen; Gooike W van Slooten; JA van Dongen
Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb.
British journal of cancer 1994;70(1):151-3.
1994: JL Reubsaet; Jos H Beijnen; Auke Bult; Jan Teeuwsen; E H Koster; Joop C M Waterval; Willy J M Underberg